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Summary 
Malignant Pleural Mesothelioma (MPM) is an aggressive intrathoracic malignancy 
with an overall poor prognosis. MPM is associated with asbestos exposure but has 
a long latency period between exposure and disease development. Incidence of 
MPM in the UK is therefore still rising, predicted to reach a peak in 2020. The 
majority of patients with MPM present with breathlessness, frequently due to a 
pleural effusion and/or chest pain. Diagnosis of MPM can be difficult. 
Radiological detection of early stage MPM in particular can be challenging, as 
pleural tumour, nodularity or significant pleural thickening may not be evident. 
Diagnosis is further complicated by the low yield of pleural fluid cytology 
examination in MPM and pleural biopsy is therefore usually required to allow 
definitive diagnosis. This can be achieved under image guidance, at surgical 
thoracoscopy or at local anaesthetic thoracoscopy (LAT). A significant number of 
patients are either elderly or have co-morbidity precluding general anaesthesia 
and surgical thoracoscopy. Image-guided pleural biopsy is not always feasible, 
particularly in the absence of significant pleural thickening. LAT remains a 
limited resource in the UK.  
A non-invasive biomarker of MPM, which could be performed early in the 
patient’s presentation, and that could be available to most hospitals, would 
therefore be a major clinical advance, allowing clinicians to direct appropriate 
patients to specialist centres with access to LAT and specialist MDT input where 
MPM appears likely. There have been several potential blood biomarkers 
identified in the mesothelioma literature, including the most widely studied, 
Mesothelin, and more recently Fibulin-3 and SOMAscan™. Unfortunately study 
results have been variably limited by retrospective study design, inconsistent 
sampling time points, inconsistent results and lack of external validation, 
therefore despite initial promising results, none of these biomarkers have 
entered routine clinical practice for diagnosis. Similarly, utility of imaging 
biomarkers such as perfusion Computed Tomography (CT), Positron Emission 
Tomography (PET) and Dynamic Contrast Enhanced Magnetic Resonance Imaging 
(DCE-MRI) has been limited by high radiation dose, limited availability, and 
requirement for bulky (and therefore late stage) disease for assessment 
respectively. 
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In chapter 2, study design, recruitment and preliminary results of the 
DIAPHRAGM (Diagnostic and Prognostic Biomarkers in the Rational Assessment of 
Mesothelioma) study are reported. A prospective, multi-centre study was 
designed, recruiting patients with suspected pleural malignancy (SPM) at initial 
presentation to secondary care services, from a mixture of academic and more 
clinical units in the UK and Ireland, in addition to asbestos-exposed control 
subjects. In one of the largest biomarker studies in mesothelioma to date, 639 
patients with SPM and 113 asbestos-exposed control subjects were recruited 
over three years. Data cleaning is being finalised by the Cancer Research UK 
Clinical Trials Unit Glasgow at the time of writing. Preliminary results reveal 
that 26% (n=154) patients recruited to the SPM cohort were diagnosed with MPM, 
33% (n=209) had secondary pleural malignancy and 34% (n=218) were diagnosed 
with benign pleural disease. A final diagnosis is awaited in 7% (n=47) at the time 
of writing. SOMAscan™ and Fibulin-3 biomarker analyses are ongoing and 
DIAPHRAGM will definitively answer the question of diagnostic utility of these 
blood biomarkers in routine clinical practice, in a ‘real-life’ MPM population, 
relative to that of Mesothelin.  
In chapter 3, contrast-enhanced MRI was performed in patients with suspected 
MPM and a novel MRI biomarker of pleural malignancy defined (Early Contrast 
Enhancement – ECE). ECE was defined as a peak in pleural signal intensity at or 
before 4.5 minutes after intravenous Gadobutrol administration. ECE assessment 
was successfully performed in all patients who underwent contrast-enhanced 
MRI. This included patients with pleural thickening <10mm (49/58 (84%)), the 
mean pleural thickness of all patients was 5mm. ECE demonstrated good overall 
diagnostic performance for the detection of pleural malignancy (sensitivity 83% 
(95% CI 61 – 94), specificity 83% (95% CI 68 - 91%), positive predictive value 68% 
(95% CI 47 – 84%), negative predictive value 92% (95% CI 78 – 97%)), comparable 
to morphology assessment at CT morphology and MRI morphology by experienced 
thoracic radiologists. In addition, ECE demonstrated good reproducibility (inter-
observer κ = 0.864), superior to subjective morphology assessment at CT and 
MRI. Mean signal intensity gradient (MSIG), a marker of patient’s contrast 
enhancement pattern, correlated with tumour Microvessel Density (MVD) using 
Factor VII immunostain (Spearman’s rho = 0.43, p=0.02). Additionally, a high 
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MSIG (>0.533AU/s), indicative of high tumour vascularity, was associated with 
poor median overall survival (12 months vs. 20 months, p=0.047). 
Staging of MPM represents an additional challenge to clinicians. This is due to 
the complex morphology and often rind-like growth pattern of MPM. In addition, 
delineation of pleural disease from adjacent structures such as intercostal 
muscle and diaphragm can be difficult to assess, particularly at CT, which is the 
most commonly used imaging modality for diagnostic and staging assessment in 
MPM. Current clinical staging frequently underestimates extent of disease, with 
a significant proportion of patients being upstaged at time of surgery, and is 
limited by high inter-observer variability. Recent studies have reported the 
prognostic significance of CT-derived tumour volume; however, many of these 
studies have been limited by the laborious or complex nature of tumour 
segmentation, significant inter-observer variability or challenges encountered in 
separating pleural tumour from adjacent structures, which are often of similar 
density. MRI is superior to CT in the detection of invasion of the chest wall and 
diaphragm in MPM. In Chapter 4, MRI was used to quantitatively assess pleural 
tumour volume in 31 patients with MPM using novel semi-automated 
segmentation methodology. Four different segmentation methodologies, using 
Myrian® segmentation software were developed and examined. Optimum 
methodology was defined, based on the accuracy of volume estimates of an MRI 
phantom, visual-based analysis, intra-observer agreement and analysis time. 
Using the optimum methodology, there was acceptable error around the MRI 
phantom volume (3.6%), a reasonable analysis time (approximately 14 minutes), 
good intra-observer agreement (intra-class correlation coefficient (ICC) 0.875) 
and excellent inter-observer agreement (ICC 0.962). Patients with a high MRI-
estimated tumour volume (≥300cm3) had a significantly poorer median overall 
survival (8.5 months vs. 20 months) and was a statistically significant prognostic 
variable on univariate (HR 2.273 (95% CI 1.162 – 4.446), p=0.016) and multi-
variate Cox proportional hazards model (HR 2.114 (95% CI 1.046 – 4.270), 
p=0.037).
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1 Chapter 1: Introduction 
1.1 General Introduction 
Malignant Pleural Mesothelioma (MPM) is an invasive thoracic malignancy 
associated with inherent diagnostic difficulties. It frequently presents as an 
emergency admission with breathlessness associated with a pleural effusion and 
has a poor median survival of 9.5 months. Local anaesthetic thoracoscopy (LAT) 
allows examination of the pleural cavity, multiple biopsies to be taken and 
therapeutic talc poudrage pleurodesis. However, access to LAT in the UK 
remains limited and therefore referral to specialist centres providing this service 
is often needed. A non-invasive biomarker to direct appropriate patients to 
these services is urgently required. The general aim of this thesis is to examine 
the true clinical utility of existing blood biomarkers in the existing MPM 
literature and to generate novel imaging biomarkers of MPM.  
1.2 Anatomy and Physiology of the Pleural Space 
The pleura is a fibrous membrane structure consisting of a single layer of 
mesothelial cells with underlying connective tissue layers, blood vessels, nerves 
and lymphatics. (1) The pleura folds back on itself to form a double membrane 
structure lining the surface of the lung, including the interlobar fissures (visceral 
pleura) and the chest wall, diaphragm and mediastinum (parietal pleura). The 
parietal and visceral pleura are continuous at the lung hilum via the pulmonary 
ligament. (2) The visceral pleura receives its blood supply from the bronchial 
circulation and the parietal pleura receives its blood supply from the intercostal 
arteries. (3) The thin space between the parietal and visceral pleura is known as 
the pleural cavity. In healthy humans, the pleural space contains a small volume 
of pleural fluid (approximately 0.3 ml/kg body mass). (4) Pleural fluid is filtered 
from systemic capillaries to the pleural space via the parietal pleural 
interstitium down a relatively small pressure gradient. Pleural fluid circulates 
within the pleural space, where the intra-pleural pressure is subatmospheric at 
approximately -8cmH2O at end-inspiration. Pleural fluid is drained via parietal 
pleural stomata and pleural lymphatics. Pleural fluid resorption is an active 
process, mediated by pulsatile smooth muscle activity within the lymphatic walls 
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and pressure oscillations secondary to respiration. (4)  This process normally 
increases in response to an increase in pleural fluid volume, however the degree 
to which pleural lymphatic flow can increase in response to increased pleural 
fluid filtration is limited. (4) The principal function of pleural fluid in health is to 
maintain close apposition of the parietal and visceral pleural membranes during 
respiration and to provide lubrication to allow frictionless movement of the two 
pleural surfaces. (5)  
1.3 Pathophysiology of Pleural Effusion 
A pleural effusion is an excess accumulation of fluid within the pleural space. 
This can result from one of several different mechanisms interrupting the 
balance between pleural fluid filtration and pleural fluid drainage. Pleural 
effusions can be classified as a transudate or an exudate. An exudative pleural 
effusion can be distinguished from a transudate with an accuracy of 93% (6) 
using Light’s criteria, where the effusion is defined as an exudate if one or more 
of the following are true: Pleural fluid protein concentration divided by serum 
protein concentration >0.5; pleural fluid lactate dehydrogenase (LDH) 
concentration divided by serum LDH concentration >0.6; pleural fluid LDH 
concentration >2/3 upper limit of laboratory normal reference range for serum 
LDH concentration. (7) Whether a pleural effusion is a transudate or an exudate 
is a result of the mechanism of disruption between filtration and drainage of 
pleural fluid:  
1. Changes in microvascular hydrostatic or oncotic pressure (8) – resulting in a 
transudative pleural effusion, as occurs in heart failure, liver failure and 
hypoalbuminaemia, which can result from systemic illness and nephrotic 
syndrome 
2. Reduction in pleural pressure (8) – resulting in a transudative pleural 
effusion, as occurs in atelectasis, which can occur secondary to bronchial 
obstruction in lung cancer, and trapped lung 
3. Changes in mesothelial and capillary endothelial permeability (5) – resulting 
in an exudative pleural effusion as occurs in inflammatory disorders, such as 
rheumatoid pleurisy, parapneumonic effusions and effusions secondary to 
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pulmonary embolism or malignancy, where malignant infiltration of the 
pleura can increase mesothelial permeability and infiltration of blood vessels 
or tumour-mediated release of pro-inflammatory cytokines and vasoactive 
mediators can increase endothelial permeability (8,9) 
4. Impaired lymphatic drainage (8) – resulting in an exudative effusion. 
Lymphatic obstruction can result from tumour in malignancy or inflammatory 
debris in inflammatory conditions or parapneumonic effusions. Impaired 
lymphatic drainage due to malignant infiltration of mediastinal lymph nodes 
is one of the commonest mechanisms for pleural effusion in malignancy. 
(10,11) Lymphatic abnormalities, as found in yellow nail syndrome can also 
result pleural effusion via impaired lymphatic drainage 
1.4 Pleural Effusion in malignancy 
Malignancy is one of the most common causes of pleural effusion, accounting for 
approximately 30% of all pleural effusions (12) and has an estimated incidence of 
50,000 per year in the UK. (13) Lung cancer accounts for approximately 35% of 
all metastatic pleural effusions, with breast cancer (approximately 25%), 
lymphoma (approximately 10%) and ovarian cancer (approximately 5%) being the 
next most common causes of metastatic malignant pleural effusion. (11) 
Malignant pleural effusion is indicative of advanced stage malignancy and 
associated with poor survival outcomes, with a median survival of 192 days in 
breast cancer and a median survival of only 74 days in lung cancer. (14) 
However, where it will affect management, pleural metastases, defined as 
parietal pleural tumour deposits or positive effusion cytology should be 
confirmed, as pleural effusion can occur in malignancy without any evidence of 
pleural involvement. In lung cancer, pleural effusion can be parapneumonic 
secondary to bronchial obstruction, or can result from atelectasis associated 
with bronchial obstruction. (11) This is an important distinction, as patients with 
pleural effusion but no pleural metastases can still potentially be radically 
treatable and have a significantly better survival than those with malignant 
pleural effusion. (15) MPM is a primary pleural tumour in which pleural effusion 
is found in approximately 90% of cases. (13)  
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1.5 Malignant Pleural Mesothelioma 
MPM is an invasive primary pleural malignancy with 2515 mesothelioma deaths 
reported in Great Britain in 2014. (16) The main MPM histologic subtypes are  
epithelioid (associated with the best prognosis), sarcomatoid (associated with 
the worst prognosis) and biphasic (a combination of epithelioid and sarcomatoid 
features). MPM is strongly associated with asbestos exposure, (17) with a history 
of asbestos exposure elicited in approximately 80 – 85% of patients. (18,19) 
Asbestos is a group of naturally occurring silicate fibres, which can be divided 
into two major groups - serpentine asbestos, which typically have short, curly 
fibres (chrysotile) and amphibole asbestos, which is characterised by straighter 
and longer fibres (amosite, crocidolite, actinolite, anthophyllite and tremolite). 
(1) Asbestos, most commonly chrysotile, was widely used in several industries in 
the UK, particularly in the early to mid-twentieth century. (16) High risk 
occupations therefore include shipyard workers, motor industry workers, 
carpenters, plumbers, electricians and painter and decorators. (20) Low level 
non-occupational exposure to asbestos via a relative or spouse, or environmental 
exposure in the household or neighbourhood is also associated with MPM. (21) 
Several years after the initial identification of the link between asbestos 
exposure and MPM in the 1950s (22), industry regulations were put in place in 
the late 1960s, requiring employers to limit asbestos exposure and provide 
protective clothing. The importation and industrial use of amosite and 
crocidolite asbestos was banned in 1985 and chrysotile asbestos was banned 
from industrial use in 1999 in the UK. (23) However, there is a long latency 
period, with an average period of approximately 40 years between exposure and 
MPM development. (18) Predictive models therefore estimate that there will be 
approximately 2500 deaths per year ongoing until around 2020 in the UK when 
rates will begin to decline, (24) with the total number of deaths in Great Britain 
from mesothelioma predicted to be approximately 90,000 by 2050. (25) 
Unfortunately, there is an estimated 2 million tons of asbestos still being used 
globally each year, particularly in Asia and India. (26) This ongoing use of 
asbestos means that MPM will continue to be a burdensome disease for several 
decades to come. Due to its strong association with asbestos exposure, MPM is 
considered an industrial disease. Patients in the UK can therefore claim for 
compensation and all cases in the UK require reporting to the procurator fiscal 
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at time of patient death. (27) Inadequate histological confirmation of a diagnosis 
of MPM in life typically requires post-mortem confirmation at death. This can be 
stressful for the patient’s family and result in funeral delays. 
1.6 Asbestos-induced Carcinogenesis in Malignant Pleural 
Mesothelioma 
As discussed in the previous section, there is a strong association between 
asbestos exposure and MPM. There have also been reports of an association 
between ionising radiation from external beam radiotherapy, simian virus 40 
(SV40) in historic polio vaccines and a genetic predisposition with MPM. (1,28,29)  
However, by far the strongest association is asbestos exposure, with 
approximately 80 – 85% of patients with MPM having a history of asbestos. 
(18,19) Amphibole asbestos fibres are considered to be more carcinogenic than 
the shorter serpentine asbestos fibres. (30) Asbestos fibres reach the pleura 
following inhalation, either directly via alveoli and the visceral pleura or via 
lymphatic vessels. (31) The mechanism of asbestos-induced carcinogenesis in 
MPM is not entirely clear. However, previous studies have demonstrated that 
asbestos induces a chronic inflammatory reaction, with macrophage 
accumulation in the pleura, where asbestos fibres undergo frustrated 
phagocytosis by macrophages. In response, there is release of numerous 
cytokines, including Tumour Necrosis Factor-α (TNF-α), and reactive oxygen 
species (ROS) and reactive nitrogen species (RNS). Asbestos fibres can also 
directly induce human mesothelial cells to express TNF-α receptor 1 (TNF-R1) 
and to secrete TNF-α. (32) Release of ROS and RNS contribute to asbestos-
mediated deoxyribonucleic acid (DNA) damage and aneuploidy. However, instead 
of undergoing apoptosis, these cells continue to divide. This is in part mediated 
by the NF-kB pathway, which is activated by the binding of TNF- α and its 
receptor TNF-R1. (33) Activation of NF-kB results in the activation of apoptosis 
inhibitors, promoting cellular proliferation. (34) Activation of the 
phosphoinositide-3 kinase (PI3K)/Akt pathway also promotes cellular 
proliferation and inhibits apoptosis in MPM. (35) Continued division of cells with 
DNA strand breaks and chromosomal aberrations eventually results in the 
emergence of malignant cell clones. (36) In addition, numerous other cytokines 
have been implicated in the pathogenesis of MPM. Expression of vascular 
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endothelial growth factor (VEGF), a potent stimulator of tumour 
neovascularisation, necessary for tumour growth and metastasis, has been shown 
to be increased in MPM cell lines. (37) Similarly, expression of insulin-like growth 
factor (IGF), platelet-derived growth factor (PDGF), transforming-growth factor 
beta (TGF-ß), hepatocyte growth factor (HGF) and interleukins 6 and 8 is 
elevated in MPM, contributing to tumour growth, cell proliferation and 
migration, tumour neoangiogenesis and tumour invasiveness. (32,36,38) 
1.7 Current diagnostic pathway 
1.7.1 Clinical presentation 
MPM most commonly presents with breathlessness and/or chest pain as a result 
of a pleural effusion. (18) Patients may also present with weight loss, sweats or 
lethargy as a result of the systemic effects of malignancy. (18,39) Right-sided 
disease tends to predominate and bilateral disease is extremely rare (previously 
recorded in 3% of patients). (40,41) Infrequently, patients may have palpable 
lymph nodes and/or digital clubbing. Emergency presentation is common (42,43) 
and prompt initial diagnostic sampling and relief of symptomatic pleural effusion 
is often required. MPM is typically associated with an exudative pleural effusion.  
However, there are often few features to distinguish MPM from other causes of 
pleural effusion, of which there are many (see Table 1.1). Presenting symptoms 
of breathlessness and chest pain are common to many causes of pleural effusion 
other than MPM, including pulmonary thromboembolism and parapneumonic 
effusion. (44) In addition, multiple cancers can metastasise to the pleura causing 
pleural effusion and are associated with systemic features of malignancy, such 
as weight loss and sweats, which is often found in patients with MPM. A history 
of occupational exposure to asbestos in a patient presenting with pleural 
effusion always raises the possibility of MPM, however, asbestos exposure is also 
associated with benign asbestos pleural effusion (BAPE) and an increased risk of 
lung cancer. (17) Additionally, up to 12% of patients diagnosed with BAPE, based 
on the finding of fibrinous pleuritis at pleural biopsy, will prove to have MPM on 
subsequent follow-up. (45) 
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Table 1.1 Differential diagnosis of exudative pleural effusion 
   
Malignancy	 	
					Primary	pleural	malignancy	e.g.	Mesothelioma	 	
					Secondary	pleural	malignancy	 	
Infection	 	
					Parapneumonic	effusion	 	
					Tuberculosis	 	
Inflammatory	 	
					Rheumatoid	arthritis	 	
					Other	autoimmune	pleuritis	e.g.	systemic	lupus	erythematosus	 	
					Benign	asbestos	pleural	effusion	 	
					Sarcoidosis	 	
Reactive	 	
					Secondary	to	lung	collapse	 	
					Post	thoracic	surgery	e.g.	coronary	artery	bypass	graft	 	
					Post	myocardial	infarction	 	
					Pancreatitis	 	
					Pulmonary	embolism	 	
Other		 	
					Drugs	e.g.	amiodarone,	nitrofurantoin,	tyrosine	kinase	inhibitors,	dantrolene	 	
					Lymphatic	disorders	e.g.	Yellow	Nail	Syndrome	or	lymphangioleiomyomatosis	 	
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1.7.2 Initial investigations 
Current diagnostic pathways start with clinical assessment, radiographic imaging 
and ultrasound-guided pleural aspiration. (44) Appearances on chest radiography 
(CXR) that are typically found in MPM include pleural effusion, loss of 
hemithoracic volume, nodular pleural thickening, irregular fissural thickening or 
a localised mass lesion. The presence of non-calcified and calcified pleural 
plaques may alert the clinician to prior asbestos exposure, even in the absence 
of an obvious exposure history. However, pleural plaques are not specific to MPM 
and may occur after low-level asbestos exposure. (46,47) The sensitivity and 
specificity of CXR findings for MPM are unsurprisingly poor (14 – 43%) (39,48) and 
further imaging is required in all patients. 
A blood-stained appearance of fluid at initial pleural aspiration can indicate 
pleural malignancy as a potential diagnosis. (49) However, pulmonary infarction 
secondary to pulmonary thromboembolism, trauma and parapneumonic effusions 
can also cause a blood-stained pleural effusion. (49,50)   
Cytological examination of pleural fluid is diagnostic in approximately 60% of 
cases of malignancy. (44) However, the sensitivity of pleural fluid cytology in the 
diagnosis of MPM is much lower (0 – 16%). (51) While centres with expert 
cytopathology available have reported sensitivities of 73%, (52) the practice of 
diagnosing MPM on pleural fluid cytology alone remains controversial. (53,54) 
Cytological appearances can be relatively bland or resemble reactive 
mesothelial proliferation and conversely benign reactive mesothelial 
proliferation can exhibit striking cytological atypia with often many overlapping 
cytological features. (54,55) In addition, sarcomatoid MPM does not typically 
exfoliate cells into pleural fluid and a diagnosis of sarcomatoid MPM is rarely 
achievable on pleural fluid cytology. (56,57)  
Demonstration of invasion by the mesothelial cell population is therefore often 
key to making a diagnosis of MPM, (57) and this is not possible with pleural fluid 
specimens alone. Repeated pleural aspiration beyond two pleural fluid 
specimens does not significantly improve diagnostic yield (58) and should be 
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avoided to prevent extensive fibrin deposition, (59) which may preclude 
effective thoracoscopic assessment, and procedure tract metastasis, which is a 
known complication in MPM. (60) If a diagnosis is not established following 
pleural aspiration, further investigation with additional imaging and pleural 
biopsy is recommended.  Imaging is discussed further in section 1.8. 
1.7.3 Pleural Biopsy 
Pleural biopsy techniques available include blind closed needle biopsy, image-
guided percutaneous pleural biopsy, local anaesthetic thoracoscopy (LAT), 
video-assisted thoracoscopic surgery (VATS) and open pleural biopsy. Open 
pleural biopsy is rarely utilised now that thoracoscopy is available and is 
associated with intractable chest wall pain and high rates of tract metastases. 
(51)   
Blind closed needle biopsies (frequently known as Abrams biopsy) are widely 
available and can be performed under local anaesthetic. However, it frequently 
yields tissue specimens <10mm and has a poor overall sensitivity for diagnosis of 
MPM with sensitivity previously reported to be as low as 16 - 30%. (54,61) 
Asbestos fibre deposition and MPM disease distribution is heterogeneous, and at 
early stages disease is frequently concentrated in the costophrenic gutter, (62) 
not easily accessible with an Abrams biopsy needle, which may account for the 
low diagnostic yield with blind closed needle biopsy. 
Image-guided percutaneous pleural biopsy is also widely available and can be 
performed under local anaesthetic. A retrospective study of ultrasound-guided 
cutting needle biopsy in 70 patients with suspected MPM reported diagnostic 
sensitivity of 77% and negative predictive value of 57% (95% confidence intervals 
not reported). (63) Maskell et al conducted a prospective, randomised trial 
comparing Computed Tomography (CT)-guided pleural biopsy with Abram’s 
pleural biopsy in 50 patients with suspected pleural malignancy and at least one 
negative pleural cytology sample. Sensitivity of CT-guided biopsy was 
significantly higher than Abram’s pleural biopsy for the detection of pleural 
malignancy in this study (sensitivity 87% versus 47%; difference in sensitivity 47% 
(95% CI 10 – 69%), p=0.02). Results were similar in the subgroup of patients with 
MPM (CT-guided biopsy sensitivity 88% and Abram’s pleural biopsy sensitivity 
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55%). (64) Image-guided percutaneous pleural biopsy is frequently employed in 
patients with a visible pleural mass, however it does not allow for definitive 
pleural fluid management in patients with symptomatic pleural effusion and 
these patients would therefore require additional pleural intervention. In 
addition, it does not allow direct inspection of the pleural cavity. 
Adequate inspection and sampling of the pleural space is important given the 
heterogeneous disease distribution and also to allow accurate subtyping of MPM. 
There is a significant survival difference between histologic subtypes, with a 
median survival in epithelioid, biphasic and sarcomatoid MPM of 13.1, 8.4 and 4 
months respectively. (65) Inadequate sampling may result in failure to identify 
prognostically significant sarcomatoid elements, which would constitute biphasic 
disease. LAT and VATS are both techniques that allow direct visual inspection of 
the pleural cavity in addition to therapeutic drainage of pleural effusion and talc 
poudrage within a single procedure. 
VATS has excellent diagnostic sensitivity for pleural malignancy, reported to be 
95% in one retrospective case series of 182 consecutive patients (66) and 100% in 
a small prospective series, in which 23/25 patients were diagnosed with MPM. 
(67) VATS utilises dual ports, making breakdown of adhesions in a multi-
loculated pleural space more feasible to allow adequate visualisation of the 
pleural surfaces. However, VATS requires referral to a thoracic surgeon and 
fitness for general anaesthesia. It is therefore not suitable for patients with 
reduced performance status or significant co-morbidity, (44) which is frequently 
the case in patients with suspected MPM, who are often in their 7th or 8th decade 
of life given the long latency period between asbestos exposure and disease 
development. 
LAT, also known as medical thoracoscopy, does not require a general anaesthetic 
and can be performed under local anaesthetic or conscious sedation, (68) making 
it accessible to a wider population than VATS. It utilises a single port and a rigid 
or semi-rigid thoracoscope and has excellent diagnostic sensitivity for MPM, 
reported to be 96 - 98.4% in two prospective case series, (69,70) with a low 
major complication rate. (71) LAT is therefore recommended in patients who do 
not have a diagnosis following pleural aspiration as an alternative to image-
guided biopsy, particularly in patients who require talc poudrage pleurodesis. If 
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the pre-test probability of MPM is high, some centres may use LAT earlier in the 
diagnostic pathway to prevent multiple pleural interventions. (71) While the 
number of centres providing a LAT service in the UK is increasing, (71) it is 
currently limited to approximately 40 centres. Patient access to LAT therefore 
frequently requires referral to tertiary centres who offer this service. 
1.7.4 Histological findings 
There are three main histological subtypes of mesothelioma – epithelioid, 
sarcomatoid and biphasic (mixed epithelioid and sarcomatoid features). 
Epithelioid MPM accounts for approximately 60% of all mesotheliomas. 
Morphologically, it typically consists of well-formed papillary structures, 
frequently with fibrovascular cores, formed by cuboidal cells with uniform, 
round nuclei that have small to medium-sized nucleoli. These cuboidal cells can 
mimic reactive mesothelial cells. (72) Similarly, many features frequently 
demonstrated in reactive mesothelial proliferation can resemble a neoplastic 
process, including high cellularity, high mitotic activity, necrosis and formation 
of papillary groups, with entrapment of mesothelial cells within fibrosis often 
mimicking invasion. (54) Pancytokeratin staining to assess the overall 
mesothelial architecture can help to demonstrate regularity of growth and 
respect of mesothelial boundaries in reactive mesothelial proliferation to 
distinguish it from mesothelioma. (54) Immunohistochemistry can help 
distinguish epithelioid MPM from metastatic lung adenocarcinoma. A panel 
including positive mesothelial markers (e.g. Calretinin, Cytokeratin 5/6, Wilms 
Tumour-1) and negative adenocarcinoma markers (e.g. TTF1, CEA, Ber-Ep4) is 
typically demonstrated. (54,72) Sarcomatoid MPM is characterised by a 
hypercellular spindle-cell proliferation, with elongated nuclei, numerous mitotic 
figures and eosinophilic cytoplasm. Approximately 30% of sarcomatoid MPM will 
have desmoplastic features, which are predominantly hypocellular with 
scattered atypical cells among dense collagenous tissue. (73) Desmoplastic 
mesothelioma can resemble benign fibrinous pleuritis and expression of 
mesothelial markers on immunohistochemistry can be inconsistent or absent. 
(73) Recently, studies have highlighted potential clinical utility of p16 
chromosomal deletion detected using Fluroescence in situ hybridisation (FISH). 
One study demonstrated hemi- or homozygous deletion in 67% of epithelioid, 
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87.5% of biphasic, 100% of sarcomatoid MPM and no cases of benign fibrinous 
pleurisy. (74) Demonstration of invasion into submesothelial tissue or underlying 
fat, skeletal muscle, rib or lung is however still considered key in the diagnosis 
of MPM. (54) Clinical history and imaging findings should also be reviewed in 
conjunction with pathologic findings before confirming a diagnosis of MPM.  
1.8 Imaging 
Detection of Malignant Pleural Mesothelioma 
Imaging plays a major role in the assessment of all patients with pleural disease. 
Imaging in pleural malignancy and in particular early stage MPM can be difficult 
as morphological features of pleural malignancy and pleural thickening may be 
minimal or absent. There are also often few features that differentiate MPM 
from secondary pleural malignancy, which can often be diagnosed without the 
need for LAT.  
1.8.1 Computed Tomography (CT) 
CT imaging is established as the key imaging test in patients with MPM and is 
recommended in all patients with suspected pleural malignancy and in patients 
with an undiagnosed exudative pleural effusion. (44) Optimal CT assessment of 
the pleura requires post-contrast imaging at an interval of 60 – 90 seconds. (75) 
The imaged volume should include the thorax and abdomen to allow accurate 
assessment of disease extent and stage, including the most inferior borders of 
the costophrenic sulci. CT features of pleural malignancy have been widely 
reported and include pleural enhancement, infiltration of the chest wall, 
mediastinum or diaphragm, nodular or mediastinal pleural thickening and 
interlobar fissural nodularity (see Figure 1.1 for an example). (76,77) The 
detection of one or more of these features on CT was associated with a 
sensitivity of 96% and specificity of 80% for malignancy (although not MPM 
specifically). (77)  
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Figure 1.1 Axial contrast-enhanced CT images of a patient with MPM, taken at 
the Queen Elizabeth University Hospital 2015, demonstrating enhancing pleural 
mass lesions, nodular pleural thickening and mediastinal pleural thickening 
(Panels A and B) and infiltration of the diaphragm (Panel C).  
Pleural effusion and pleural thickening are common but non-specific features, 
and are frequently demonstrated in benign pleural disease, including BAPE. (78) 
The concomitant presence of pleural calcification has been reported as more 
commonly associated with benign pleural disease, (76) but pleural plaques are 
frequently visualised in MPM (in up to 53% of patients). (40) No CT features 
reliably differentiate MPM from metastatic pleural malignancy, although 
enhancement of the interlobar fissures was reported more frequently in MPM in 
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a single study (39% in MPM versus 0% in other malignancies) (79). Moreover, CT 
cannot reliably distinguish between histological MPM subtypes, although 
ipsilateral volume loss, interlobar fissural involvement and mediastinal pleural 
involvement are reported more frequently in patients with sarcomatoid disease. 
(40,80) Metintas et al reported circumferential pleural thickening in 70% of MPM 
patients but only 15% of patients with metastatic pleural malignancy, resulting 
in a MPM sensitivity, specificity and odds ratio of 70%, 85%, and 3.17 (95% CI 1.67 
– 6.01). (81) The same study reported mediastinal pleural involvement more 
frequently in MPM than metastatic pleural malignancy (85% versus 33% 
respectively), resulting in an MPM sensitivity of 85% and specificity of 67% for 
this feature. (81) In this study, the stage of the patients included was not 
reported, but it is important to note that features such as circumferential 
pleural thickening are frequently absent in early stage disease. In addition, CT 
imaging can grossly underestimate macroscopic disease visible at thoracoscopy 
and can occasionally fail to identify nodular pleural thickening what is often 
diffuse at thoracoscopy (see Figure 1.2). It is also important to note that all of 
the above features are subjective and therefore operator dependent. This is 
perhaps reflected in the heterogeneity in reported overall diagnostic 
performance of CT for pleural malignancy in the literature. While previous 
research have reported sensitivities of 70 – 93% and specificity of 87 – 96%, 
(77,81) Hallifax et al reported lower diagnostic performance (sensitivity 68% 
(95% CI 62 – 75%) and specificity 78% (95% CI 72 – 84%) in a retrospective review 
of 370 patients referred for LAT. (82) Similarly, our own research group has 
reported sensitivity of 58% (95% CI 51 – 65%) and specificity of 80% (95% CI 72 – 
87%), resulting in a positive predictive value (PPV) of 83% (95% CI 75 – 89%) and a 
negative predictive value (NPV) of 54% (95% CI 46 – 61%), in 315 patients 
presenting with suspected pleural malignancy, reflecting the lower diagnostic 
performance of CT in ‘real-life’ clinical practice. (83) This is clearly an 
important difference, research studies typically adhere to strict imaging 
protocols, with optimised contrast timings, and utilise study specific reporting 
with thoracic specialty radiologists. In our study, 50% of patients presented as an 
emergency to secondary care services and almost 1 in 5 of these patients had a 
CT pulmonary angiogram (CTPA) performed to exclude concomitant pulmonary 
thromboembolism. In these patients, the diagnostic sensitivity of CTPA for 
detecting pleural malignancy was significantly lower than those who had venous 
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phase CT performed (sensitivity 27% (95% CI 9 – 53%) versus 61% (95% CI 53 – 68%) 
respectively, p=0.0056). In addition, only 37% of the scans performed in this 
study were reported by a thoracic radiologist (defined as radiologists with a 
primary subspecialty interest in chest imaging, including involvement in a 
thoracic oncology multidisciplinary team). CT scans that were reported by a non-
thoracic radiologist had lower diagnostic sensitivity (53% (95% CI 44 – 62%)) than 
those reported by a thoracic radiologist (69% (95% CI 55 – 79%) p=0.0488), 
reflecting the subjectivity of CT assessment. (83) 
 
Figure 1.2 Axial contrast-enhanced CT images of a patient with Malignant Pleural 
Mesothelioma demonstrating a large left sided pleural effusion but little in the 
way of pleural thickening or nodularity (Panels A and B). Thoracoscopic findings 
in the same patient (Panels C and D) demonstrate diffuse nodular pleural tumour 
affecting the costal pleura, aorta (Ao), left lower lobe (LLL) and left 
hemidaphragm (LHD) despite lack of obvious tumour at CT imaging. Reproduced 
with permission. (84)  
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1.8.2 PET-CT 
Positron Emission Tomography (PET) exploits increased uptake of radioactive 
metabolic tracers (e.g. 18Fluoro-Deoxy-Glucose (FDG)) by cancer cells. 
Integrated PET-CT overcomes the poor spatial resolution of PET by combining 
metabolic PET data with high resolution CT data. Patients are typically fasted 
for 4 - 6 hours before injection of 3.5 – 5.2 MBq/kg of 18FDG 60 – 120 minutes 
prior to scanning. 
 
In pleural malignancy, increased FDG uptake is typically visualised at sites of 
pleural tumour, lymph node involvement and distant metastases (see Figure 
1.3). SUV values are typically higher in MPM (reported mean SUVmax 6.5 +/- SD 
3.4) than in benign pleural disease (reported mean SUVmax 0.8 +/- SD 0.6), 
however some overlap in these values has been demonstrated in previous single-
centre prospective case series. (85) (86) An SUVmax threshold of >2.0 has been 
found to reliably differentiate MPM from benign pleural disease with a sensitivity 
of 88 - 97% and specificity of 88 - 100%, based on single-centre prospective 
studies. (85-87) Importantly, SUV values are influenced by patient 
characteristics, including weight, blood glucose levels and respiratory motion, as 
well as technical factors such as scanner variability and parameter variability 
including field of view. (88) Additionally, SUV values are calculated over 
identified Regions of Interest and may not reflect the overall biology of the 
pleura or disease, particularly in MPM where disease distribution can be 
markedly heterogeneous. Visual-based assessment is therefore recommended in 
combination with SUV values when assessing patients. False negatives have been 
reported in patients with small lesions or a low proliferative index, which may 
be found in patients with early stage MPM. Additionally, false positives in 
patients with inflammatory disorders, such as rheumatoid pleuritis and 
tuberculous pleurisy, and in patients with prior talc pleurodesis has been well 
reported. (89-91). This is highlighted by the low specificity (35%) reported in one 
study that included patients with prior talc pleurodesis. (90) Recent meta-
analyses regarding FDG-PET are somewhat contradictory, reporting differing 
pooled sensitivities/specificities in differentiating MPM from benign pleural 
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disease. Treglia reported a sensitivity of 95% (95% CI 92 – 97%) and specificity of 
82% (95% CI 76 – 88%) (89), while Porcel et al reported a sensitivity of only 81% 
(95% CI 66 – 91%) and a specificity of 74% (95% CI 58 – 85%) for semi-quantitative 
interpretation using PET-CT. (92) There are no specific PET-CT features that 
differentiate MPM from other causes of pleural malignancy. One single centre 
study demonstrated a tendency for epithelioid MPM to have a lower SUV value to 
sarcomatoid MPM (mean SUV 3.78 versus 6.16), however this was not statistically 
significant. (86) In general PET-CT is not routinely used for imaging detection of 
MPM but may be useful in identifying suitable targets for image-guided pleural 
biopsy. This is currently being examined in a UK multi-centre randomised 
controlled trial (TARGET trial, ISRCTN 14024829). (93) 
 
Dual time point FDG-PET imaging has been evaluated as a means of improving 
the specificity of PET-CT. The technique involves imaging at two separate time 
points following a single administration of 18FDG. Previous studies reported rising 
SUV values in malignant tumours for several hours post-administration in 
contrast to inflammatory disorders. (94,95) Mavi et al demonstrated a 
significantly higher SUVmax at both time points (early and delayed) in patients 
with MPM in comparison to patients with benign pleural disease. In addition, 
they observed increasing SUVmax values in patients with MPM in contrast to 
static or decreasing SUVmax values in patients with benign disease. (94) 
Similarly, Yamamoto et al demonstrated increased FDG uptake between early 
and delayed phased FDG-PET in patients with MPM but no increase in patients 
with benign pleural disease. (95) However, dual time point imaging clearly 
requires longer scan times and therefore expense and availability may limit its 
clinical utility. 
 
More recently, novel PET tracers targeting tumour hypoxia and angiogenesis 
have recently been developed. 18F-fluoromisonidazole (FMISO) is one example of 
a PET tracer that can be used to assess tumour hypoxia, and has recently been 
examined multiple solid tumours, including NSCLC, prostate cancer and head 
and neck cancer. (96) (97) Similarly, 18F-fluciclatide is a novel angiogenesis PET 
tracer, which is targeted to integrin αvβ3 and has been studied in NSCLC, 
colorectal cancer and breast cancer. (97) (98) 
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Figure 1.3 Axial 18FDG-PET-CT image of a patient with Malignant Pleural 
Mesothelioma, taken at the West of Scotland PET centre 2013, demonstrating 
intense 18FDG uptake within pleural tumour 
 
1.8.3 Magnetic Resonance Imaging (MRI) 
Magnetic Resonance Imaging (MRI) utilises resistive electromagnets to generate a 
magnetic field, with modern MRI systems having the ability to generate field 
strengths of up to 7-Tesla. Current clinical systems typically operate at 1.5 to 3-
Tesla. MRI has advantages of not utilising ionising radiation and provides 
excellent contrast and spatial resolution for anatomic information in addition to 
functional information that can provide insight into underlying disease biology. 
Basic magnetic resonance theory is discussed here before discussing the role of 
MRI in the detection and differentiation of MPM. 
 
1.9 Basic Magnetic Resonance Theory 
1.9.1 Nuclear Magnetic Resonance 
Magnetic resonance (MR) images are constructed from the dissipation of energy 
absorbed by the nuclei of Hydrogen atoms in response to a radiofrequency (RF) 
pulse, when a patient is placed in a magnetic field. Hydrogen consists of a single 
proton nucleus, orbited by one electron and is the most abundant element in the 
human body. For simplicity, the Hydrogen atom can be referred to as a proton.  
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Each proton spins around its own axis in a random orientation. When a magnetic 
field (B0) is applied, the protons align with the magnetic field, either in parallel 
or in anti-parallel, and ‘precess’ at the Larmour frequency. The Larmour or 
precessional frequency is dependent on the strength of the magnetic field and 
the gyromagnetic ratio, which is constant for any given nucleus (42.57 
MHz/Tesla for H+). More protons are aligned parallel (low energy state) with BØ 
than anti-parallel (high energy state), resulting in a net longitudinal 
magnetisation in the direction of the magnetic field (Z axis, see figure 1.4). In 
response to an excitatory RF pulse, protons spinning at the same precessional 
frequency as the frequency of the RF pulse will ‘flip’, rotating the net 
magnetisation into the transverse plane (X-Y, see figure 1.4). The degree that 
net magnetisation rotates into the transverse plane (flip angle) is dependent on 
the amplitude and duration of the RF pulse. 
Once the excitatory RF pulse ends, the protons begin to relax back to their 
original state (equilibrium), resulting in rotation of the net magnetisation back 
from the transverse plane to the longitudinal axis. Relaxation depends on 
protons releasing the absorbed energy from the RF pulse, resulting in an MR 
signal. Relaxation can be divided into two independent but simultaneous 
processes, T1 relaxation and T2 relaxation. 
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Figure 1.4 Schematic representation of net magnetisation vector of tissue 
protons orientated in the same plane as the main magnetic field (BØ) 
(longitudinal/Z axis) and tipping of net magnetisation into the transverse plane 
(X-Y axis) in response to a 90º excitatory radiofrequency (RF) pulse. Reproduced 
with the permission of Dr Kevin Blyth  
1.9.2 T1 Relaxation (Spin-Lattice relaxation) 
T1 relaxation describes the recovery of the longitudinal net magnetisation at the 
end of the RF pulse, with release of energy into the surrounding tissues (lattice). 
The T1 relaxation time is defined as the time it takes for the longitudinal 
magnetisation to recover to 63% of its original magnetisation at equilibrium. This 
T1 relaxation time is different for different tissues, depending on the proton’s 
surrounding environment. 
1.9.3 T2 Relaxation (Spin-Spin relaxation) 
T2 relaxation describes the decay of transverse magnetisation produced by an 
excitatory RF pulse. Each individual proton spins around its own axis with no 
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phase coherence (out-of-phase). In response to a RF pulse, the protons start 
spinning in the same direction (in-phase). When the RF pulse is switched off, the 
protons will start to de-phase, resulting in decay of transverse magnetisation 
and release of energy amongst individual protons. T2 relaxation time is defined 
as the time it takes for the spins to de-phase to 37% of the original value. T2 
relaxation is also tissue dependent and occurs much faster than T1 relaxation.  
Contrast between tissues in MRI is a result of different T1 and T2 characteristics 
of adjacent tissues. Alterations in MRI pulse sequences can be made to optimise 
contrast between adjacent tissues of interest, producing T1- or T2-weighted 
images. T1-weighted images can be produced by reducing the time in between 
repeated excitatory RF pulses (the Repetition Time (TR)). T2-weighted images 
can be produced by increasing TR and increasing the Echo Time (TE). Echo time 
is the time from the RF pulse to the resulting MR signal (the echo).   
1.9.4 Spatial Localisation of Tissue 
Gradient coils are embedded in the inner core of the main electromagnet in the 
MRI scanner. They are arranged in sagittal, coronal and axial planes to the main 
magnetic field (BØ), creating additional small magnetic fields in their own plane. 
These gradient coils are used to create a Slice Encoding Gradient, a Phase 
Encoding Gradient, and a Frequency Encoding Gradient, which allows MR signal 
to be localised to an individual voxel within an individual block of tissue. 
1.9.5 K-space 
K-space is made up of the raw, unprocessed MRI signals. Low frequency signals 
are arranged in the centre of k-space, containing information about signal and 
tissue contrast. High frequency signals are arranged around the periphery of k-
space and contains information about spatial resolution. The unprocessed MRI 
signals within k-space are transformed into interpretable images by the 
computer using a mathematical process known as Fourier Transformation.  
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1.10 MRI in the detection and differentiation of MPM 
Pleural fluid appears dark on T1-weighted images due to the slower T1 
relaxation of free water solutions in comparison to tissue such as fat (which has 
a fast T1 relaxation and therefore appears bright), see Figure 1.5. This effect is 
enhanced using paramagnetic contrast agents such as gadolinium. On T2-
weighted imaging, free fluid such as pleural effusion appears bright, in contrast 
to lung and muscle. T2-weighted imaging can be useful for detecting septations 
within pleural fluid (which can also be identified using thoracic ultrasound). This 
is important when considering patients for local anaesthetic thoracoscopy, 
where significant loculation can preclude effective examination of the pleural 
cavity (see Figure 1.6).  
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Figure 1.5 T1-weighted axial (Panel A) and coronal (Panel B) fat-saturated VIBE 
images of a patient with pleural effusion, taken post-contrast using a 3T Siemens 
Magnetom PRISMA® MR scanner at the Glasgow Clinical Research Imaging 
Facility, QEUH 
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Figure 1.6 T2-weighted axial (Panels A and B) and coronal (Panel C) HASTE 
images of a patient with pleural effusion, taken pre-contrast using a 3T Siemens 
Magnetom PRISMA® MR scanner at the Glasgow Clinical Research Imaging 
Facility, QEUH. Panels B and C clearly demonstrate multiple septations 
(appearing dark) within pleural fluid (bright) 
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Features of malignancy previously described such as nodular pleural thickening, 
mediastinal pleural involvement and infiltration of the chest wall or diaphragm 
are all demonstrable on MRI (see Figure 1.7). The presence of these features at 
MRI resulted in a sensitivity of 96% and specificity of 80% for pleural malignancy 
in one retrospective series (95% confidence intervals not reported). (77) The 
same study reported findings of increased signal intensity of malignant pleural 
lesions in comparison to intercostal muscles at both T2-weighted and contrast-
enhanced T1-weighted imaging, with a resulting sensitivity of 91% and 93% and 
specificity of 80% and 73% respectively (95% confidence intervals not reported). 
When combining this signal intensity data with the described morphological 
findings, the authors reported an overall sensitivity of 100% and specificity of 
93% for pleural malignancy (95% confidence intervals not reported). (77)  
Boraschi et al reported increased signal intensity at T1 and T2-weighted imaging 
in patients with MPM and low signal intensity within benign pleural plaques. (99) 
Similarly, Falaschi et al reported pleural hyperintensity in comparison to 
intercostal muscle at T1-weighted imaging, differentiating between malignant 
and benign pleural lesions with a sensitivity of 100% and specificity of 60% (95% 
confidence interval not reported). Patients with TB pleuritis demonstrated 
falsely elevated pleural hyperintensity on both T1 and T2-weighted imaging in 
this study. (100) 
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Figure 1.7 T1-weighted axial (Panel A) and coronal (Panel B) fat-saturated VIBE 
images of two patients with Malignant Pleural Mesothelioma, taken post-contrast 
using a 3T Siemens Magnetom Verio® MR scanner at the BHF Glasgow 
Cardiovascular Imaging Facility (Panel A) and a 3T Siemens Magnetom PRISMA® 
MR scanner at the Glasgow Clinical Research Imaging Facility, QEUH (Panel B). 
Panel A demonstrates enhancing pleural tumour and Panel B demonstrates 
nodular pleural thickening with chest wall invasion 
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MRI examination of patients with pleural malignancy using diffusion-weighted 
MRI (DWI-MRI) has also been described. DWI-MRI is based on the random motion 
of water protons within tissue. (101) The Apparent Diffusion Co-efficient (ADC), 
measured at DWI-MRI is a quantitative measure of the diffusion of water 
molecules, and can provide information about tissue such as tissue cellularity 
(increased cellularity resulting in a lower ADC) and oedema (associated with a 
higher ADC). (102) DWI-MRI is well established in neuro-imaging, in particular 
assessment of acute cerebral ischaemia (103) and has also been used to assess 
renal lesions (104) and prostate cancer. (105)  Changes in MPM at DWI-MRI have 
previously been reported by Gill et al, who reported lower ADC levels in MPM in 
comparison to patients with benign pleural disease, indicating increased 
cellularity causing restricted water diffusion. (106) In addition, it has been 
reported that patients with epithelioid subtype exhibit significantly higher ADC 
values than patients with sarcomatoid MPM. (107,108) However, Gill et al were 
unable to compute ADC values for 12% (n=7) of the patients included in their 
study as a result of significant image distortion. (106) Coolen et al also 
demonstrated significantly lower ADC values at DWI-MRI in patients with MPM in 
comparison to patients with benign disease and reported a sensitivity of 71% and 
specificity of 100% at an optimum ADC cut-off of 1.52 x 10-3mm2/sec (95% 
confidence intervals not reported). (90) Pleural pointillism is a more recently 
described visual analogue of ADC at DWI-MRI, which does not require software 
calculation of a quantitative value. This describes inhomogeneous pleural 
hyperintensity at high b value imaging (b value 1000 sec/mm2) representing 
areas of low diffusion. In a single-centre, prospective study of 100 consecutive 
patients with suspected MPM, the presence of pleural pointillism was detectable 
in patients with pleural malignancy with a sensitivity of 92.5% (95% CI 83.7 – 
96.8%) and specificity of 78.8% (95% CI 62.2 – 89.3%). (109)  
 
Dynamic-Contrast Enhanced MRI (DCE-MRI) is based on assessment of tissue 
microvasculature and vascular permeability. Sequential MR images are acquired 
in the first few seconds after contrast injection (typically intravenous 
gadolinium), imaging the temporal passage of contrast material through tissue 
and thus providing information about tissue perfusion. (110) Utilising DCE-MRI, 
pharmacokinetic parameters characterising perfusion (redistribution rate 
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constant (Kel)) and microvascular permeability (elimination rate constant (Kep)) 
can be calculated. Kel is a measure of the rate of Gadolinium transfer between 
the extracellular space and the vascular space. Kep is a measure of the rate of 
Gadolinium elimination from the intravascular space. DCE-MRI has previously 
been studied in multiple tumour types, including breast (111-113), 
hepatocellular (114) and prostate cancer. (115,116) In addition, DCE-MRI has 
previously been studied in MPM. Giesel et al performed DCE-MRI in 19 patients 
with predominantly stage IV MPM, measuring pharmacokinetic parameters 
(amplitude, redistribution rate constant (kep) and elimination rate constant 
(kel)) following intravenous Gadolinium contrast administration. They 
demonstrated areas of intense contrast enhancement within pleural tumour 
(high amplitude) in addition to a rapid washout pattern (positive kel) within ‘hot 
spots’ of the tumour and slow contrast elimination (negative kel) within the 
remaining tumour. (117) The same authors went on to report a moderate 
correlation (r=0.5) between total tumour Amplitude (increase of signal intensity 
post-contrast relative to pre-contrast signal intensity) and Microvessel Density 
measured in formalin-fixed, paraffin-embedded pleural tumour, using CD34 
immunostain. (118)  
 
Coolen et al subsequently corroborated these findings, performing DCE-MRI in 
addition to DWI-MRI in a small prospective cohort study with a combined 
sensitivity of 93% and specificity 94% (95% confidence intervals not reported) for 
pleural malignancy. (90) These studies highlight the potential of DCE-MRI for 
detection of MPM, however, successful measurement of pharmacokinetic 
parameters is difficult to achieve in patients who do not have bulky (and 
therefore typically advanced) tumour. In addition, DCE-MRI is limited by the 
compromise between spatial resolution and temporal resolution (119), which is 
significant in a morphologically complex disease such as MPM. A limited number 
of slices and therefore volume can be included in DCE-MRI, due to the limited 
acquisition time, resulting in localised, ‘hot-spot’ sampling rather than acquiring 
information about the entire volume of pleura. This results in a risk of sampling 
error, where the region sampled is not representative of the entire tumour, 
(120) which is significant in MPM, which has a heterogeneous and often 
widespread disease distribution. This limits clinical utility as a diagnostic 
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biomarker, particularly in early stage detection of MPM but highlights its 
potential as a predictive biomarker of anti-angiogenic chemotherapy response.  
 
1.11 Staging of MPM 
Staging of MPM is difficult due to its unusual rind-like growth pattern, different 
to the expansile mass growth of most other tumours. Until recently, the 
International Mesothelioma Interest Group (IMIG) recommended Tumour Node 
Metastasis (TNM) 7th edition staging system was the mostly widely accepted 
current staging system for MPM (see Table 1.2). (121) However, these 
recommendations were based largely on expert consensus and data from small 
retrospective surgical series. In addition, Tumour (T) staging reflected 
anatomical surfaces involved or invaded into, rather than the size of the primary 
tumour, and these judgements were best made at time of surgery, rather than 
on imaging. It was therefore difficult to use in clinical practice, where the 
majority of patients do not undergo surgery. In addition, nodal (N) staging was 
based on the N descriptors in Non-Small Cell Lung Cancer (NSCLC) staging. The 
lymphatic drainage of the pleura differs from that of the lung, with evidence of 
direct mediastinal drainage in previous studies. (122) (123) As a result, patterns 
of nodal spread in MPM almost certainly differ to those in lung cancer. (124)  
The International Association for the Study of Lung Cancer (IASLC) Mesothelioma 
database, was established as part of the Mesothelioma Staging Project in 2011. 
This incorporated retrospective data, from multiple (largely surgical) centres, 
including data from patients diagnosed between 1995 to 2009. Initial review of 
3101 patients, 3017 (97%) of whom were surgical, included in the database 
highlighted inadequacies in the current staging system. In particular, there were 
discrepancies between clinical and pathological staging, with frequent upstaging 
following surgery, and no statistically significant difference in survival between 
T1 versus T2 patients nor between N1 versus N2 patients. (125) The Prospective 
Staging Project in Malignant Pleural Mesothelioma was therefore initiated by the 
IASLC in 2010. Subsequent review of a database of 3519 MPM cases (1566 
prospectively collected and 1953 retrospectively collected) from 29 centres 
across four continents has informed the 8th edition of TNM staging, (see Table 
1.3) and includes a larger number of non-surgical patients. (126) (127) (128) 
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Review of T staging in 1987/3519 MPM cases demonstrated poor discrimination in 
survival between clinically staged T1a and T1b categories (HR 0.99, p=0.95). 
(126) Furthermore, review of N staging in 2173/3519 MPM cases demonstrated 
poor discrimination in survival between pathologically staged N1 and N2 
categories (HR 0.99, p=0.99). (127) Updated 8th edition T-staging therefore 
collapses 7th edition T1a and T1b into a single T1 category. (126) Similarly, 
updated 8th edition N-staging collapses 7th edition N1 and N2 into a single N1 
category, comprising ipsilateral, intrathoracic nodal metastases, with the 7th 
edition N3 now being reclassified as N2. (127) 
At the time of recruitment of patients to the studies outlined in this thesis, the 
previous edition of TNM staging was being used and therefore all staging 
reported in the following chapters is done so according to the 7th edition TNM 
staging system. Review of the mesothelioma database has demonstrated a 
survival disadvantage with increasing maximal pleural thickness (patients with a 
maximal pleural thickness <5.1mm had a 24-month survival of 51% versus 39% for 
patients with a maximal pleural thickness ≥5.1mm) and increasing total pleural 
thickness (patients with a total pleural thickness <13mm, 13 – 60mm and ≥60mm 
had a 24-month survival of 55%, 40% and 30% respectively). Increasing pleural 
thickness was also associated with an increased rate of nodal involvement. (126) 
Quantifying disease using pleural thickness measurements or volumetric 
assessment therefore has the potential to be used in the future as an alternative 
or addition to T staging. The need for this has been highlighted by the significant 
difficulty in accurate clinical staging in MPM using current imaging modalities, 
with 80.8% of stage I and 69.5% of stage II patients being upstaged following 
surgical staging. (125) Here I discuss the current roles of CT, PET-CT and MRI in 
the staging of MPM.
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Table 1.2 IMIG/TNM 7th Edition staging system for Malignant Pleural 
Mesothelioma 
Primary	Tumour	(T)	 	      
Tx	 Not	assessable	 	     
T0	 No	evidence	of	primary	tumour	 	    
T1a	 Tumour	limited	to	the	ipsilateral	parietal	pleura,	including	mediastinal	and	
diaphragmatic	pleura,	no	involvement	of	visceral	pleura	
	
 
T1b	 Tumour	involving	ipsilateral	parietal	and	visceral	pleura	 	
T2	 Invasion	of	tumour	into	the	underlying	lung	or	involvement	of	the	diaphragmatic	
muscle	
	
 
T3	 Locally	advanced	but	potentially	resectable	tumour	 	
 Invasion	of	tumour	into	endothoracic	fascia	or	mediastinal	fat	 	
 Solitary	focus	of	tumour	invading	chest	wall	 	
 Non-transmural	pericardial	involvement	 	
T4	 Locally	advanced,	technically	unresectable	tumour	 	
 Diffuse	or	multi-focal	chest	wall	involvement,	with	or	without	rib	destruction	
	 Trans-diaphragmatic	extension	of	tumour	into	peritoneum	 	
 Extension	of	tumour	to	the	contralateral	pleura,	spine	or	one	or	more	
mediastinal	organs,	including	transmural	pericardial	involvement,	with	or	
without	pericardial	effusion,	or	tumour	involving	the	myocardium	
	
  
  
Regional	Lymph	Nodes	(N)	 	     
Nx	 Not	assessable	 	
N0	 No	regional	lymph	node	metastases	 	
N1	 Ipsilateral	intrapulmonary	or	hilar	lymph	node	metastases	 	
N2	 Ipsilateral	mediasitinal	lymph	node	metastases,	including	ipsilateral	internal	
mammary	or	para-aortic	lymph	node	metastases	
	
 
N3	 Contralateral	intrapulmonary,	hilar	or	mediastinal	lymph	node	metastases,	or	
any	(ipsilateral	or	contralateral)	supraclavicular	lymph	node	metastases	
	
 
Distant	Metastasis	(M)	 	      
MX	 Not	assessable	 	
M0	 No	distant	metastasis	 	
M1	 Distant	metastasis	present	 	
 
 
61 
 
Table 1.3 TNM 8th Edition staging system for Malignant Pleural Mesothelioma 
Primary	Tumour	(T)	 	      
Tx	 Not	assessable	 	     
T0	 No	evidence	of	primary	tumour	 	    
T1	 Tumour	limited	to	parietal	(including	mediastinal	and	diaphragmatic	pleura)	+/-	
involvement	of	the	visceral	pleura	
	
 
T2	 Invasion	of	tumour	into	the	underlying	lung	or	involvement	of	the		
diaphragmatic	muscle	
	
 
T3	 Locally	advanced	but	potentially	resectable	tumour	 	
 Invasion	of	tumour	into	endothoracic	fascia	or	mediastinal	fat	 	
 Solitary	focus	of	tumour	invading	chest	wall	 	
 Non-transmural	pericardial	involvement	 	
T4	 Locally	advanced,	technically	unresectable	tumour	 	
 Diffuse	or	multi-focal	chest	wall	involvement,	with	or	without	rib	destruction	 	
 Trans-diaphragmatic	extension	of	tumour	into	peritoneum	 	
 Extension	of	tumour	to	the	contralateral	pleura,	spine	or	one	or	more		
mediastinal	organs,	including	transmural	pericardial	involvement,	with	or	without	
pericardial	effusion,	or	tumour	involving	the	myocardium	
	
  
  
Regional	Lymph	Nodes	(N)	 	      
Nx	 Not	assessable	 	
N0	 No	regional	lymph	node	metastases	 	
N1	 Ipsilateral	intrapulmonary,	hilar	or	mediastinal	lymph	node	metastases,	including		
ipsilateral	internal	mammary	or	para-cardiac	lymph	nodes	
	
 
N2	 Contralateral	intrapulmonary,	hilar	or	mediastinal	lymph	node	metastases,	or	any	
(ipsilateral	or	contralateral)	supraclavicular	lymph	node	metastases	
	
 
Distant	Metastasis	(M)	 	      
MX	 Not	assessable	 	
M0	 No	distant	metastasis	 	
M1	 Distant	metastasis	present	 	
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1.11.1 CT  
Despite its widespread use in clinical practice for the detection of pleural 
malignancy and MPM, CT performs poorly as a staging tool in comparison to 
alternative imaging techniques such as PET-CT and MRI.  
CT features that suggest disease is not technically resectable include: invasion of 
extrapleural fat, infiltration or displacement of ribs by tumour, bony destruction 
and invasion or tumour encasement of the diaphragm. (110) However, CT has 
limitations in the assessment of infiltration of the chest wall and diaphragm, 
(129,130) with one study reporting 75% of cases with chest wall infiltration 
precluding surgical resection not being identified on preceding CT imaging. (131) 
The sensitivity of CT for nodal metastases has previously been reported as 56% 
with a specificity of 39% (95% confidence intervals not reported). (130) This is 
insufficient, particularly given the significant survival differences between 
patients with N0 versus N1 and N2 disease (HR 1.26, p=0.0071 and HR 1.40, p 
<0.0001 respectively). (125) Distant metastases, including pulmonary metastases 
can be identified on CT (132) However, previous studies have demonstrated 
frequent up-staging of disease following further evaluation with PET-CT. One 
study reported up-staging in 37% of patients who underwent CT and PET-CT, 
with 77% of cases reflecting distant metastases identified on PET-CT that were 
not identified on CT. (133) 
 
Volumetric assessment of tumour burden has previously been studied utilising CT 
for prognostic and treatment response purposes. Pass et al assessed pre-
operative tumour volumes in 48 MPM patients undergoing extrapleural 
pneumonectomy or pleurectomy/decortication. They reported a significant 
difference in survival based on pre-operative CT-based tumour volumes. Patients 
with tumour volumes <100cm3 had a median overall survival of 22 months, 
compared to 9 months in patients with tumour volumes >100cm3. In addition, 
progressively higher post-operative IMIG stage was associated with higher 
median pre-operative CT tumour volume in this study. (134) Similarly, Gill et al 
retrospectively measured pre-operative CT-based tumour volume in 88 patients 
with epithelioid MPM undergoing extrapleural pneumonectomy. The median 
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tumour volume was 319cm3 in this study and increasing tumour volume was 
associated with worse survival (tumour volume ≤500cm3 had a median overall 
survival of 24.4 months versus a median overall survival of 12 months for tumour 
volume >500cm3). (135) While CT volumetry appears to be a promising technique 
of assessing tumour burden, its application in clinical practice is currently still 
limited, principally due to the time consuming nature of free-hand volumetric 
measurements. Studies have utilised a semi-automated method of measuring 
tumour volume to overcome this, based on differential Hounsfield Units (HU). 
(136) (137) (138) However, MPM is morphologically complex, with an unusual 
growth pattern and delineation of pleural tumour from adjacent structures, such 
as intercostal muscle and pleural fluid, with a similar density represents a 
significant challenge in this regard. 
 
1.11.2 PET-CT 
Based on prior data, integrated PET-CT should be utilised rather than isolated 
PET since the sensitivity of the latter for N2 disease has previously been 
reported as 11% in patients undergoing surgical resection with lymph node 
dissection, whereas the sensitivity and specificity of integrated PET-CT for 
predicting N2 disease has been reported as 60% and 80% respectively. (139) 
Plathow et al assessed the accuracy of CT, PET-CT and MRI for the selection of 
patients with potentially-operable disease (earlier than Stage III) by acquiring all 
scans prior to surgery in 54 patients (52 of whom subsequently underwent 
surgery). They concluded that PET-CT offered the highest diagnostic accuracy, 
for example in stage III disease, diagnostic accuracy rates for CT, MRI and PET-
CT were 75% (sensitivity 75%, specificity 100%), 90% (sensitivity 91%, specificity 
100%) and 100% (sensitivity 100%, specificity 100%), respectively. (140) This 
performance largely reflected better detection of nodal and extra-thoracic 
metastases. However, PET-CT has been shown to underestimate T staging in up 
to 29% of patients in previous studies, largely due to under-identification of 
chest wall and diaphragmatic invasion. (141) PET-CT provided accurate T staging 
in only 14/24 (63%) of patients in comparison to pathological staging in patients 
enrolled in a single-centre, prospective feasibility study of EPP followed by 
intensity-modulated radiation therapy. (141) In one other small study, 24% (n=7) 
of patients had extra-thoracic metastases demonstrated on PET-CT not 
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previously identified utilizing conventional CT. (141) (142) Although integrated 
PET-CT is the best imaging modality for detecting nodal and extra-thoracic 
metastases, (143) its limitations in MPM should also be appreciated, particularly 
in the assessment of locally invasive T4 disease. (141) Therefore, PET-CT has 
important limitations but definite utility in the staging of patients who are being 
considered for radical therapies or trials. 
 
1.11.3 MRI 
In previous studies, MRI has been shown to be superior to CT in detecting 
invasion of chest wall, diaphragm and bony structures, which was best visualised 
on T1-weighted images, and important for both detection and staging of MPM. 
(79,144) Stewart et al performed contrast-enhanced 1.5-Tesla MRI scans on 69 
patients with apparently resectable MPM following contrast-enhanced CT 
scanning. MRI detected the presence of technically non-resectable disease in 
17/69 (22%) of these patients not previously demonstrated on CT. This included 
mediastinal involvement, diaphragmatic invasion, chest wall infiltration and 
contralateral pleural disease. (145) Therefore MRI has clinical utility in MPM 
staging and assessment of the presence of infiltrative disease that would 
preclude surgical resection. 
1.12 Blood Biomarkers 
A diagnostic biomarker is a quantifiable substance, involving measurements on 
biological material, such as blood, or on imaging that can be used to accurately, 
reproducibly and objectively differentiate a pathological state from an 
alternative controlled state (such as a normal biological state). (146,147) An 
ideal diagnostic biomarker in oncology would be measurable non-invasively and 
detectable at an early disease stage. In MPM, biomarkers are most frequently 
measured in blood and pleural fluid. Previously published data regarding the 
most widely studied and/or promising blood biomarkers are summarised below.  
1.12.1 Mesothelin 
Mesothelin is a cell-adhesion glycoprotein that is over-expressed in MPM (in 
addition to pancreatic and ovarian cancer). (148,149) Serum mesothelin levels 
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(also known as serum mesothelin related protein (SMRP)) are elevated in 
patients with MPM in comparison to asbestos-exposed controls. (150,151) In a 
meta-analysis, Hollevoet et al performed a ROC regression analysis on serum 
mesothelin levels in MPM patients versus controls and reported that the highest 
AUC was obtained when differentiating patients with advanced stage (III/IV) 
epithelioid MPM (AUC 0.84) and the lowest AUC was demonstrated in patients 
with early stage (I/II) sarcomatoid MPM (AUC 0.56). (152) Previous authors have 
reported sensitivities for MPM ranging from 56-77% at 95% specificity. (149-151) 
However the meta-analysis by Hollevoet et al, incorporating data from 4491 
individuals (1026 with MPM) reported substantial between-study heterogeneity in 
results, with sensitivity ranging between 19 – 68% and specificity ranging 
between 88 – 100%. The summary estimate of sensitivity was only 47% (95% 
prediction interval 26 – 70%) and specificity 96% (95% prediction interval 85 – 
99%). (152) This is insufficient for diagnostic purposes and Mesothelin is not 
currently part of assessment algorithms. (44) (143) 
1.12.2 Megakaryocyte Potentiating Factor 
Megakaryocyte Potentiating Factor (MPF) is a cleavage product of the Mesothelin 
Precursor Protein, the other being Mesothelin/SMRP. Increased serum levels 
have been reported in MPM cases, relative to asbestos-exposed controls and 
patients with pleural plaques and/or asbestosis. (150) Creaney et al reported a 
sensitivity of 34% at 95% specificity in a study involving 66 MPM patients and 
inferior performance compared to serum Mesothelin in the same cohort. (150) 
Hollevoet et al later reported a MPF sensitivity of 64% at 95% specificity, which 
was equivalent to Mesothelin (68% at 95% specificity) in a larger prospective 
study, which included 85 MPM patients.  (153) MPF therefore offers no advantage 
over Mesothelin.  
1.12.3 Osteopontin 
Osteopontin is a glycoprotein overexpressed in several cancers, including MPM, 
lung cancer, ovarian cancer and malignant melanoma. Pass et al reported higher 
serum Osteopontin levels in 76 MPM patients relative to asbestos-exposed normal 
controls, with a MPM sensitivity of 78% at 86% specificity. Diagnostic accuracy 
was similar in patients with early and late stage MPM, leading the authors to 
66 
 
propose a potential future role as an early detection marker in asbestos-exposed 
individuals. (154) However, these results were not validated externally, with a 
sensitivity of 47% at 95% specificity subsequently reported by Creaney et al 
(150), possibly related to protein instability due to thrombin cleavage. 
Osteopontin therefore has no current clinical role as a MPM biomarker. 
1.12.4  HMGB-1 
High Mobility Group Box-1 (HMGB-1) is secreted by active 
monocytes/macrophages and passively released by cells undergoing necrosis. 
(155) It is pro-inflammatory and overexpressed in a number of different tumour 
cells including colorectal cancer, melanoma, breast cancer and pancreatic 
cancer. (156) In human mesothelial cells, asbestos exposure results in necrosis 
and release of HMGB-1 (non-acetylated isoform) into the extracellular space, 
triggering activation and accumulation of macrophages and resultant active 
secretion of pro-inflammatory mediators, including HMGB-1 (hyper-acetylated 
isoform) and Tumour Necrosis Factor (TNFα). (157,158) In a retrospective series, 
Tabata et al reported increased serum HMGB-1 (isoform not specified) in 
patients with MPM (n=61) relative to patients with pleural plaques and asbestosis 
(n=26) and healthy asbestos-exposed controls (n=19). Between these groups they 
reported a sensitivity of 34% (at 100% specificity), however they found no 
difference in HMGB1 levels between MPM cases and 11 additional patients with 
secondary pleural malignancy (159). This greatly limits the clinical applicability 
of these findings. More recently, Napolitano et al reported increased serum 
levels of hyper-acetylated HMGB-1 in patients with MPM (n=22) in comparison to 
asbestos-exposed (n=20) and healthy controls (n=20). A cut-point of 2.0ng/ml 
differentiated these groups perfectly (sensitivity 100%, specificity 100% (AUC 
1.000). Serum HMGB-1 performed less well in the differentiation of MPM from 
benign effusions (n=13) or non-mesothelioma malignant effusions (n=25, AUC 
0.86 for total HMGB-1 and AUC 0.84 for hyper-acetylated HMGB-1). (158) These 
results are promising and should be prospectively validated in external 
populations in future studies. 
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1.12.5 SOMAscan™ Proteomic Classifier 
SOMAscan™ is a 13-protein classifier developed by SomaLogic Inc. (Boulder, 
Colorado, USA), using a novel proteomics-based biomarker detection technique 
based on SOMAmers™ (Slow Off-rate Modified Aptamers). (160) Proteomics is the 
study of the whole complement of proteins produced by an organism in order to 
gain better understanding of its underlying biology. The SOMAscan™ assay has 
the capability of measuring >1000 proteins from a small biological sample such 
as serum. (161) SOMAmers™ are polyanion-single-stranded DNA molecules 
(aptamers) (162) that have been chemically modified with the addition of 
protein-like functional groups, allowing them to bind to an increased number of 
proteins and peptides with high specificity. SOMAmers™ with slow dissociation 
rates (half-life >30 minutes) are selected to further improve specificity, where 
non-specific protein binding interactions have faster dissociation kinetics (half-
life of a few minutes or less) following challenging by an anionic competitor, 
e.g. dextran sulfate. (160,161)  
Ostroff et al measured over 800 candidate proteins using the Somascan™ 
proteomic assay in the serum of 117 MPM patients and 142 asbestos-exposed 
controls. The study was retrospective, using archived serum and all samples 
were drawn at surgical MPM centres in the US between 1996 and 2011. They 
identified 64 candidate biomarkers, which were ranked by their Gini importance 
and constructed a 13-protein random forest classifier model containing the 
highest ranked markers. Using a cut-off classifier score of 0.5, the 13-protein 
classifier was able to differentiate MPM from controls with an overall sensitivity 
(in combined training, verification and validation cohorts) of 93.2% (95% CI 88.6 – 
97.7%) at a specificity of 90.8% (95% CI 86.1 – 95.6%). (163). Sensitivity of the 
classifier for detecting stage I/II disease was 88%. However, MPM specificity was 
lower in patients with non-MPM pleural effusion, with 30/32 patients with non-
MPM pleural effusion having false positive results (specificity 6%). (163) 
The 13 proteins that comprise the Somascan™ classifier are either up-regulated 
(n=9) or down-regulated (n=4) in MPM vs. asbestos-exposed control (see Table 
1.4). The up-regulated proteins include: C9, encoded by C9, CKbeta8-1, encoded 
by CCL23, Cyclin-dependent kinase-5 (CDK5), encoded by CDK5/CDK5R1, B-
lymphocyte chemoattractant (BLC) encoded by CXCL13, Coagulation factor 
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encoded by F1, Ficolin-2 (FCN2), encoded by FCN2, Soluble Intercellular 
Adhesion Molecule-2 (sICAM-2), encoded by ICAM2, Midkine, encoded by MDK and 
CD30, encoded by TNFRSF8. The down-regulated proteins include: 
Apolipoprotein A-1 (Apo A-1), encoded by APOA1, Fibronectin encoded by FN1, 
Stem Cell Factor soluble receptor (SCF-sR), encoded by KIT and Kallistatin, 
encoded by SERPINA4.(163) These proteins are principally involved in 
inflammation and regulation of cellular proliferation. (163) The roles of these 13 
proteins are discussed briefly here.
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Table 1.4. 13 proteins that comprise the SOMAscan assay, which are either up-regulated or down-regulated in Malignant Pleural 
Mesothelioma (MPM) relative to Asbestos-exposed controls (AEC)  
Protein	Target	
Encoding	
Gene	 Function	
MPM	vs.	
AEC*	
Previously	
identified	
in	MPM	 	
Complement	9	 C9	 Adaptive	immune	response	 Up	 No	 	
Ck-!8-1	 CCL23	 Cellular	ion	homeostasis,	inflammatory	response	 Up	 No	 	
Cyclin-dependent	kinase5/p35	 CDK5	 Cell	morphogenesis	 Up	 No	 	
B-lymphocyte	chemoattractant	 CXCL13	 Immune	system	development	 Up	 No	 	
Coagulation	Factor	IX	 F9	 Coagulation	cascade	 Up	 No	 	
Ficolin-3	 FCN2	 Immune	effector	 Up	 No	 	
Intecellular	Adhesion	Molecule-2	 ICAM2	 Cell	adhesion	 Up	 No	 	
Midkine	 MDK	 Regulation	of	cell	division	 Up	 No	 	
CD30	 TNFRSF8	 Regulation	of	cytokines	&	cell	proliferation	 Up	 Yes	 	
Fibronectin	 FN1	 Cell	morphogenesis	 Down	 Yes	 	
Stem	Cell	Factor	 KIT	 Immune	system	development,	receptor	tyrosine	kinase	 Down	 Yes	 	
Kallistatin	 SERPINA4	 Serine	protease	inhibitor	 Down	 No	 	
Apolipoprotein-A1	 APOA1	 Lipd	transport	 Down	 No	 	
MPM;	Malignant	Pleural	Mesothelioma,	AEC;	Asbestos-exposed	control	 	   
*Up	or	down-regulated	in	MPM	relative	to	AECs	 	    
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CD30 is a member of the Tumour Necrosis Factor (TNF)-receptor family, it is a 
type 1 transmembrane glycosylated protein. (164) It is expressed in activated T 
cells and activated B cells producing Th2-type cytokines (165) and Hodgkin’s and 
Reed-Sternberg cells. (164) Elevated serum levels of soluble CD30 is found in 
autoimmune conditions, including systemic lupus erythematosus and mixed 
connective tissue disease, (166) viral infections including Human 
Immunodeficiency Virus (HIV) and Epstein-Barr Virus (EBV) infection and 
malignancy, including Hodgkin’s disease and anaplastic large cell lymphoma. 
(167-169) Cross-linking of CD30, mediated by TNFR-associated factor (TRAF) 
proteins, results in activation of NF-kappa B, resulting in induction of IL-2, IL-6 
and TNF-alpha. (167) CD30 positive immunohistochemistry staining has also 
previously been demonstrated in MPM. (170) 
CKbeta8-1/CCL23 is a chemokine which interacts with CCR1 receptor, which is 
expressed on monocytes, dendritic cells, lymphocytes and endothelial cells. 
(171) It augments endothelial cell migration and differentiation (172) and 
mediates monocyte chemotaxis. (173) Serum levels of CKbeta8-1 have been 
reported to be elevated in inflammatory disorders such as Systemic Sclerosis. 
(174) 
Cyclin-dependent kinase-5 (CDK5) is a widely expressed enzyme, found in 
pancreatic cells and lens epithelial cells. It is principally expressed in neuronal 
tissues where it regulates neuronal migration and axonal growth in the 
developing central nervous system. (175) Dysregulation of CDK5 has been 
implicated in neurodegenerative disorders including Alzheimer’s disease and 
Motor Neuron Disease and it is upregulated in nociceptive neurons during 
peripheral inflammation. (175) CDK5 is activated by p35 in response to 
inflammation and this has been shown to be regulated by TNF alpha-induced NF 
kappa B signalling pathways. (176) 
B-lymphocyte chemoattractant (BLC) is a chemokine that mediates B-cell 
migration to lymphoid follicles and the spleen. (177) Induction of BLC is 
regulated by NF-kappa B signalling pathways (178,179) and its expression has 
been shown to be upregulated in breast cancer. (180) This is associated with 
increased serum levels of BLC in patients with metastatic breast cancer.(180) 
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Complement 9 (C9) is a part of the complement system that forms a membrane 
attack complex (MAC) along with complement proteins C5b, C6, C7 and C8 (C5b-
9 complex). The MAC interacts with the cell membrane, forming pores which 
ultimately result in cell lysis. However, if insufficient channels are formed in the 
cell membrane, the C5b-9 complex can induce cellular proliferation instead of 
lysis (181) by activating signal transduction pathways and transcription factors. 
(182,183) Resistance to complement-dependent cell death is also mediated by 
the NF-kappa B pathway. (184) C5b-9 expression has previously been shown to 
be upregulated in gastric adenocarcinoma (185) and breast cancer. (186) 
Ficolin-2 (FCN2) is a protein synthesised in the liver and found in serum. (187) It 
can activate complement via the lectin pathway (188) and binds to and 
opsonises a number of microbial pathogens including Streptococcus pneumoniae 
and Pseudomonas aeruginosa. (187) 
Intercellular Adhesion Molecule-2 (ICAM2) is a transmembrane glycoprotein that 
is a member of the immunoglobulin superfamily. It is expressed on resting 
lymphocytes, vascular endothelial cells and haematopoietic progenitor cells 
(189) and has roles in lymphocyte trafficking, and neutrophil migration. 
(190,191) ICAM-2 has previously been reported to inhibit cancer cell migration, 
limiting the metastatic potential of neuroblastoma cells. (192) 
Midkine is a heparin-binding growth factor which has roles in migration of 
inflammatory cells, angiogenesis, cell growth and carcinogenesis (193) There is 
Increased expression of midkine in a number of malignancies, (194) including 
gastric cancer, (195) hepatocellular carcinoma, (196) oesophageal cancer, 
pancreatic cancer, lung cancer (197), breast cancer (198) and neuroblastoma. 
(199) This is increased expression is associated with increased circulating levels 
of midkine. (194) Cell-free midkine mRNA levels have also been demonstrated to 
be elevated in malignant effusions from lung cancer patients, (200) however 
there has been no previously reported association between midkine levels and 
MPM. 
Apolipoprotein A-1 (Apo A-1) is the major protein component of human plasma 
high density lipoprotein (HDL), synthesised in the liver and small intestine. (201) 
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It has roles in the transportation of cholesterol to the liver and intestine and is 
involved in the uptake of lipoproteins by tissues. (202) It has also been reported 
to inhibit inflammation, tumour growth and metastasis. (203) Low levels of Apo 
A-1 have been shown to be associated with increased risk of lung cancer, (204) 
oesophageal cancer (205) and breast cancer, (206) and is associated with a 
poorer prognosis in lung cancer.(206) 
Fibronectin is an extracellular matrix (ECM) glycoprotein synthesised in the liver 
with roles in cell adhesion, cell migration and wound healing through ECM 
remodelling. (207) In cancer, alternatively spliced fibronectin is up-regulated 
within tumour stroma and is associated with epithelial-mesenchymal transition 
of cancer cells, enhanced neoangiogenesis and tumour invasion and a stiffened 
ECM. (208) Low fibronectin expression in multiple mesothelioma cell lines in 
vitro has been reported. (209) However, high plasma and pleural fluid 
fibronectin levels have previously been demonstrated in MPM, metastatic lung 
cancer and tuberculous effusions. (210,211) 
Stem Cell Factor (SCF), also known as kit ligand or mast cell growth factor, is a 
cytokine that exists in soluble and transmembrane forms. It is the ligand for the 
tyrosine kinase receptor c-kit and has roles in haematopoiesis, germ cell 
maturation, melanocyte development and mast cell proliferation. (212) SCF-
deficient mutant mice exhibit increased sensitivity to lethal irradiation, (213) 
highlighting the potential role of SCF in inhibiting apoptosis and stimulating cell 
cycle progression. (212,214) Upregulation of c-kit receptor and SCF has 
previously been reported in chemoresistant mesothelioma cell lines in vitro. 
(215) 
Kallistatin is a serine protease inhibitor initially identified in human lung 
fibrolasts as a kallikrein-binding protein. (216) Kallikrein enzymatically releases 
kinin from kinogen. Kinin is a vasoactive peptide that mediates smooth muscle 
contractility, vasodilation and vascular permeability. (216) Kallistatin as 
additional roles in regulation of blood pressure and inhibition of angiogenesis, 
inflammation and tumour growth. (217,218) Kallistatin suppression of tumour 
angiogenesis has been reported to be via inhibition of TNF alpha-induced NF 
kappaB pathways and reduced expression of VEGF. (219) 
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Many of the proteins that make up this SOMAscan™ signature have not previously 
been associated with MPM and may lead to novel drug or diagnostic targets. 
Importantly, several of these proteins are inflammatory mediators and their 
relationships with talc pleurodesis, which is known to produce an acute systemic 
inflammatory response, (220,221) and prognostically important inflammatory 
biomarkers, including neutrophil-to-lymphocyte ratio and the modified Glasgow 
Prognostic Score (mGPS) (222,223) need to be assessed. 
1.12.6 Fibulin-3 
Structure and Function 
Fibulin-3 is a secreted extracellular glycoprotein encoded by the gene EFEMP1 
(EGF-containing fibulin-like extracellular matrix protein 1) located on 
chromosome 2p16. (224,225) It is a short fibulin, with a molecular mass of 
55kDA, (225) characterised by 6 repeated calcium-binding epidermal growth 
factor (EGF)-like modules followed by a fibulin-type module at the C terminal 
region. (224,226) Fibulin-3 is expressed in human fibroblasts and is up-regulated 
in senescent fibroblasts. (224,227) In adult humans, it is widely distributed 
including to cartilage, bone, subretinal pigment epithelium, skin and capillaries, 
(226) localised to the basement membrane in epithelial and endothelial cells. 
(225) Fibulin-3 binds to the elastin precursor, tropoelastin. Elastic fibres, 
consisting of elastin and microfibrils, together with collagen fibres, contribute to 
the integrity of the basement membrane in connective tissues. (228-230) EFEMP1 
knockdown mice exhibit premature aging and atrophy of fat and muscle, with 
loss of body mass, formation of hernias and a reduced lifespan. (231) In contrast, 
mice transfected with EFEMP1, demonstrate an upregulation of vascular 
endothelial growth factor (VEGF) expression and an accumulation of Fibulin-3 
protein in the endoplasmic reticulum of retinal pigment epithelial cells, 
resulting in vision loss similar to age-related macular degeneration. (232) 
Fibulin-3 in malignancy 
The level of Fibulin-3 expression varies between solid tumours. It is down-
regulated in breast, (233,234) colorectal, (235) non-small cell lung cancer 
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(NSCLC), (236,237) nasopharyngeal, (238) and hepatocellular carcinoma, (239) 
where it has been reported to function as a tumour suppressor. Paradoxically, it 
has been found to be up-regulated in glioma, (240,241) cervical cancer (242) and 
pancreatic cancer, (232) where it has been reported to promote tumour growth 
and invasion. 
Fibulin-3 has been shown to inhibit the expression and activity of matrix 
metalloproteinase (MMP)-2, MMP-3 and MMP-9, and increase the expression and 
activity of MMP antagonists – tissue inhibitor of metalloproteinase (TIMP)-1 and 
TIMP-3. (225,243) This results in inhibition of cell migration, cell growth, 
endothelial cell proliferation, angiogenesis and invasion in vitro and inhibits 
tumour angiogenesis in vivo, demonstrated in a fibrosarcoma mouse model. 
(228,238,243) 
In breast cancer, EFEMP1 has been reported to be down-regulated in 
approximately 60% of breast cancer tissues (233) and this has been found to be 
more exaggerated in advanced stage (IV) breast cancer. (234) Fibulin-3 
expression has also been shown to be downregulated in hepatocellular 
carcinoma cell lines and colorectal carcinoma tissue in comparison to normal 
colonic tissue and colonic adenomatous tissue as a result of epigenetic silencing 
through hypermethylation in the promotor region of Fibulin-3. (228,235,239) 
Comparable to previous studies in breast cancer, (234) Tong et al, demonstrated 
that Fibulin-3 down-regulation was more marked in advanced stage (III/IV) 
tumours. (235) Similarly, there was a significantly higher rate of EFEMP1 
promotor methylation in aggressive NSCLC cell lines in comparison to less 
invasive NSCLC cell lines (244) and in NSCLC tumour tissue samples in 
comparison to non-tumour tissue samples. (236) This was reported to be 
associated with poor tumour differentiation, advanced tumour stage and lymph 
node metastasis. (236,237) 
In contrast, EFEMP1 was found to be up-regulated in aggressive, pro-angiogenic 
pancreatic carcinoma cell lines in comparison to non-aggressive pancreatic 
tumour cell lines, in addition to human pancreatic ductal carcinoma tissue 
specimens. (232) It has been reported that EFEMP1 expression indirectly 
stimulates tumour growth through activation of epidermal growth factor 
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receptor (EGFR) (245) and tumour angiogenesis by increasing vascular 
endothelial growth factor (VEGF) secretion. (232) 
Similarly, Fibulin-3 expression is up-regulated in glioma cells, where it is 
associated with a more aggressive, metastatic phenotype, (240) with increased 
cancer cell adhesion and migration in vitro and increased tumour invasion in vivo 
in a glioma mouse model. Fibulin-3 expression was shown to promote tumour 
invasion and survival in glioblastoma cells. (240) These tumours also 
demonstrated increased expression of MMP-2 and MMP-9, (241) in direct contrast 
to the findings in other cancers. (225,243) 
Cervical carcinoma cells have also been reported to show higher levels of 
Fibulin-3 expression in comparison to normal cervical squamous epithelium. This 
was associated with lymph node metastasis and vascular invasion, with a positive 
correlation between EFEMP1 expression and microvessel density, a surrogate 
marker of tumour vascularity, measured using CD34 immunostaining of tumour 
tissue. (242) 
Fibulin-3 as a Blood Biomarker in Mesothelioma 
Davidson et al initially reported increased EFEMP1 gene expression in a small 
study, which included 5 patients with Malignant Peritoneal Mesothelioma. (246) 
Fibulin-3 was subsequently first highlighted as a potential biomarker in Malignant 
Pleural Mesothelioma by Pass et al. In this retrospective study, Fibulin-3 was 
measured by a Fibulin-3 ELISA (USCN Life Science Inc., Houston, Texas, USA) on 
archived plasma and pleural fluid samples from patients with MPM, asbestos-
exposed controls and patients with non-MPM pleural effusions in two cohorts 
(Detroit and New York) and a blinded external validation set (Toronto cohort). 
Mean plasma Fibulin-3 levels were significantly higher in patients with MPM in 
comparison to asbestos-exposed controls and patients with non-MPM pleural 
effusion (112.9 ± 7.6ng/ml, 24.3 ± 1.4ng/ml, 44.7 ± 3.4ng/ml respectively, p 
<0.001) in the New York cohort. At an optimum Fibulin-3 threshold of 52 ng/ml, 
sensitivity was 97% (at 95% specificity) for distinguishing MPM from all other 
controls (AUC 0.99 (95% CI 0.974 – 0.997). However, in the blinded external 
validation set, measured plasma Fibulin-3 levels in patients with MPM was lower 
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(mean 66.4 ± 7.2ng/ml) and sensitivity was below 40% (at 95% specificity), AUC 
0.87 (95% CI 0.805 – 0.921). (247)  
Creaney et al subsequently reported lower plasma Fibulin-3 levels (median 
28.0ng/ml (interquartile range (IQR) 20 – 47) in patients with MPM, a lower 
optimum threshold of 29ng/ml and overall inferior diagnostic performance 
(sensitivity 21% at 95% specificity, AUC 0.671) than previously reported by Pass 
et al. They found that the diagnostic performance of Fibulin-3 was inferior to 
that of Mesothelin measured in the same cohort of patients. (151) This study was 
performed using archived samples that were drawn within 1 month of diagnosis 
and this is therefore likely to include patients who have had significant pleural 
intervention, including thoracoscopic biopsy and talc pleurodesis. This is 
significant as talc pleurodesis has previously been reported to be associated with 
increased Fibroblast Growth Factor-beta (FGFb) levels with resultant stimulation 
of fibroblast proliferation. (248) It is therefore likely that talc pleurodesis would 
result in elevated Fibulin-3 levels, even in non-MPM effusions.   
A small Italian study subsequently found no difference in Fibulin-3 levels 
between patients with MPM (mean 25.2 ± 1.8ng/ml) and asbestos-exposed 
controls (mean 20.7 ± 1.3), p value not reported. However, this study utilised 
serum rather than plasma and the asbestos-exposed control group had asbestosis 
rather than benign asbestos-related pleural disease. (249) Serum levels have 
previously been demonstrated to be significantly lower than plasma levels (mean 
87.3 ± 17.6ng.ml vs. 110.8 ± 21.1ng/ml, p=0.006). (247) Following this, in a 
small Egyptian study using an unspecified Fibulin-3 assay and internally defined 
cut-points, Agha et al reported 100% sensitivity and 78% specificity in 
differentiating MPM (n=25) from non-malignant pleural disease (n=9), and 88% 
sensitivity at 82% specificity in differentiating MPM from secondary pleural 
malignancies (n=11). (250) No combined sensitivity was reported and the study 
was limited by small patient numbers. Demir et al also assessed serum Fibulin-3 
levels in patients with MPM, asbestos-exposed controls and healthy controls. 
They reported significantly higher levels in MPM (mean 168.1 ± 165.1ng/ml) in 
comparison to healthy controls (mean 76.4 ± 39.6ng/ml) and asbestos-exposed 
controls, which consisted largely of patients with pleural plaques (mean 87.4 
±.53.5ng/ml), p=0.001. They defined an optimum Fibulin-3 cut-off of 51.41ng/ 
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providing a sensitivity of 88.1%, specificity 66.7%.(251) Similarly, Kaya et al 
reported significantly higher serum Fibulin-3 levels in patients with MPM (n=43) 
compared to healthy controls with no known asbestos exposure (n=40) (mean 
90.3 ±42.1 ng/ml vs. 17.8 ± 12.7 ng/ml respectively, p <0.001). Overall 
diagnostic performance for serum Fibulin-3 in this study was high, with an AUC 
0.976 and an optimum cut-off point of 26.6ng/ml providing a sensitivity of 93% 
at 90% specificity, confidence intervals were not reported. (252) However, this 
study did not include asbestos-exposed subjects or patients with pleural disease 
as controls and its clinical relevance is therefore limited. 
Finally, Kirschner et al measured Fibulin-3 expression and secretion in vitro using 
cell-conditioned medium collected from several human MPM cell lines (including 
H28, H226, H2452 and MSTO) and benign mesothelial cells lines (LP9 and MeT-
5A) and in vivo in MPM mouse models utilising using a Fibulin-3 ELISA (USCN Life 
Science Inc.). In vitro, both MPM cell lines and benign mesothelial cell lines 
expressed Fibulin-3 with no significant difference between the two groups 
(p=0.093) and there was a strong correlation between cellular Fibulin-3 
expression and Fibulin-3 protein secretion (Spearman’s rho=0.78, p=0.017). In 
vivo, Fibulin-3 was measurable in plasma (but not serum) samples from H226 and 
MSTO-xenografts. (253) The same group then assessed Fibulin-3 levels in 
archived blood taken from patients with MPM prior to diagnostic video-assisted 
thoracoscopic surgical biopsy (VATS) or extrapleural pneumonectomy. Blood 
samples from patients with benign pleural disease (pleural plaques and 
pleuritis), non-MPM malignancy (lung, breast, endometrial, colonic 
adenocarcinoma) and patients with coronary artery disease (CAD) undergoing 
cardiac surgery were also used as control samples. Archived pleural fluid 
samples from patients with and without MPM were also assessed for fibulin-3 
levels. This was done in two separate cohorts (Sydney, which included 37 
patients with MPM and 32 non-MPM controls, and Vienna, which included 47 MPM 
and 24 non-MPM). Fibulin-3 levels in patients with MPM was significantly higher 
in patients with MPM than patients with pleural plaques or CAD in the Sydney 
cohort (mean level 16.10 ± 1.87ng/ml vs. 10.92 ± 1.54ng/ml, p=0.039) but not in 
the Vienna cohort (mean level 11.51 ± 1.73ng/ml vs. 11.97 ± 3.56ng/ml, 
p=0.897). AUC was 0.63 (95% CI 0.50 – 0.76) and 0.56 (95% CI 0.47 - 0.71) for the 
Sydney and Vienna cohorts respectively, (253) significantly lower than originally 
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reported by Pass et al (AUC 0.99). (247) Confidence intervals were wide, 
reflecting the low patient number included in this study. This study was also 
limited by its retrospective nature and utilisation of blood samples from patients 
with CAD as a major contributor to the control arm, who did not have evidence 
of asbestos exposure or pleural disease.  
Results from these previous studies are summarised in Table 1.5. 
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Table 1.5.   Summary of previous studies of Fibulin-3 in Malignant Pleural Mesothelioma 
Author	 Patient	Cohort	 Sample	
type	
Fibulin-3	
Assay	
Fibulin-3	level	(ng/ml)	 Cut-off	
(ng/ml)	
Sensitivity	
(95%	CI)	
Specificity	
(95%	CI)	
AUC	(95%	CI)	
	
Pass	et	al	
(247)	
Detroit	
Plasma	
ELISA	
(USCN	Life	
Science	
Inc.)	
Mean	105	±	71	
32.9	 100%	(90.5	-	100%)	
100%	(91.4	-	
100%)	 1	(NR)	
	
MPM	 n=78	 	
AEC	 n=41	 Mean	13.9	±	1.2*	 	
non-MPM	effusion	 n=53	 Not	measured	 	
New	York	
Plasma	
ELISA	
(USCN	Life	
Science	
Inc.)	
Mean	112.9	±	7.6	 52.8	 94.6%	(84.9	-	98.9%)	
95.7%	(89.6	-	
98.8%)	 0.99	(NR)	
	
MPM	 n=64	 	
AEC	 n=95	 Mean	24.3	±	1.4*	 	
non-MPM	effusion	 n=40	 Mean	44.7	±	3.4**	 	
Toronto	(blinded	external	
validation)	
Plasma	
ELISA	
(USCN	Life	
Science	
Inc.)	
Mean	66.4	±	7.2	 28.96	 72.9%	(NR)	 88.5%	(NR)	
0.87	(0.805	-	
0.921)	
	
MPM	 n=48	 	
AEC	 n=96	 Mean	13.9	±	2.1*	 	
Creaney	et	
al	(254)	 MPM	 n=82	
Plasma	
ELISA	
(USCN	Life	
Science	
Inc.)	
Median	28.0	(IQR	20	-	
47)	
29	 48%	(NR)	 71%	(NR)	 0.671	(0.606	-	0.732)	
	
AEC	 n=49	 Median	29.3	(IQR	21	-	41)	 	
non-MPM	effusion	
(benign)	 n=35	
Median	17.4	(IQR	12	-	
22)*	 	
non-MPM	effusion	
(malignant)	 n=36	
Median	17.1	(IQR	12	-	
21)*	 	
Kirschner	
et	al	(253)	
Sydney	
Plasma	
ELISA	
(USCN	Life	
Science	
Inc.)	
Mean	16.1	±	1.87	 29	 13.5%	(NR)	 96.9%	(NR)	 0.63	(0.51	-	0.76)	
	
MPM	 n=37	 	
non-MPM	 n=32	 Mean	10.92	±	1.54†		 	
Vienna	 Plasma	 Mean	11.51	±	1.73	 29	 12.7%	(NR)	 87.5%	(NR)	 	
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MPM	 n=47	 ELISA	
(USCN	Life	
Science	
Inc.)	
0.56	(0.41	-	
0.71)	
	
non-MPM	 n=24	 Mean	11.97	±	3.56	
	
Agha	et	al	
(250)	
MPM	 n=25	
Serum	
ELISA	
(specific	
assay	NR)	
Mean	96.64	±	32.64	 18††	 100%	(NR)††	 77.8%	(NR)††	 0.897	(NR)††	 	
non-MPM	(malignant)	 n=11	 Mean	58.45	±	27.01‡	 66.5‡‡	 88%	(NR)‡‡	 81.8%	(NR)‡‡	 0.776	(NR)‡‡	 	
non-MPM	(benign)	 n=9	 Mean	30.11	±	33.72§	 		 		 		 		 	
Corradi	et	
al	(249)	
MPM	 n=14	
Serum	
ELISA	
(USCN	Life	
Science	
Inc.)	
Mean	25.2	±	1.8	
NR	 NR	 NR	 NR	
	
Asbestosis	 n=14	 Mean	20.7	±	1.3	 	
NSCLC	 n=23	 Mean	13.2	±	1.5§§	 	
Controls	 n=23	 Mean	16.7	±	1.5¶	 	
Demir	et	
al	(251)	
MPM	 n=42	
Serum	
ELISA	
(Shanghai	
Sunred	
BioTech	
Co.,	Ltd.)	
Mean	168.1	±	165.1	
51.4	 88.1%	(NR)	 66.7%	(NR)	 NR	
	
AEC	 n=48	 Mean	87.4	±	53.5*	 	
Heatlhy	control	 n=41	 Mean	76.4	±	39.6¶¶	
	
Kaya	et	al	
(252)	
MPM	 n=43	
Serum	
ELISA	
(specific	
assay	NR)	
Mean	90.3	±	42.1	
36.6	 93%	(NR)	 90%	(NR)	 0.976	(NR)	
	
Healthy	control	 n=40	 Mean	17.8	±	12.7¶¶	
	
Hooper	et	
al	(255)	
MPM	 n=73	 Plasma	 	NR	 Median	21.17		 NR	 NR	 NR	 NR	 	(IQR	13.46	-	34.41)	 	
95%	CI;	95%	Confidence	Interval,	MPM;	Malignant	Pleural	Mesothelioma,	AEC;	Asbestos	Exposed	Control,	non-MPM,	non-Malignant	Pleural	Mesothelioma	
diagnosis,	ELISA;	Enzyme	Linked	Immunosorbent	Assay,	IQR;	Interquartile	Range,	SD;	Standard	Deviation,	NR;	Not	reported,*	p	<0.001	for	the	comparison	between	
MPM	and	AEC	groups,	**	p	<0.001	for	the	comparison	between	MPM	and	non-MPM	effusion	groups,	†	p	<0.05	for	the	comparison	between	MPM	and	non-MPM	
groups,	‡	p	<	0.001	for	the	comparison	between	MPM	and	non-MPM	(malignant)	groups,	§	p	<	0.001	for	the	comparison	between	MPM	and	non-MPM	(benign)	
groups,	††	for	differentiation	between	MPM	and	benign	cases,	‡‡	for	differentiation	between	MPM	and	non-MPM	(malignant)	cases,	§§	p	<	0.01	for	the	
comparison	between	MPM	and	NSCLC	groups,	¶	p	<0.05	for	the	comparison	between	MPM	and	control	groups,	¶¶	p	<	0.001	for	the	comparison	between	MPM	
and	healthy	control	groups		
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1.13 Biomarker Reproducibility 
One of the major challenges with biomarker development in cancer is 
reproducibility. A multitude of factors can affect biomarker reproducibility and 
this would need to be assessed before applicability to routine clinical practice 
can be determined. Human specimens are often subject to marked variations in 
pre-analytical factors such as specimen collection, processing and storage that 
can significantly alter their molecular composition and consistency, which can in 
turn affect assay outcomes and reproducibility. (256) It is therefore vital that 
these variables are recorded and their effect on experimental outcomes 
assessed. (256) 
1.13.1 Patient and Specimen Factors 
Experimental assessment of any biomarker should reflect its intended purpose. 
(146) Timing of specimen collection from patients within biomarker research 
studies should be uniform and replicate when it would be used in clinical 
practice. In MPM, there are significant diagnostic challenges, and patients should 
ideally be referred to a specialist centre with access to appropriate diagnostics 
including local anaesthetic thoracoscopy early in their journey. This would avoid 
unnecessary repeated pleural aspirations or blind pleural biopsies, which is 
associated with a risk of tumour seeding along intervention tracts and undue 
delays in diagnosis of MPM, which can preclude access to important clinical 
trials. A diagnostic biomarker for MPM would therefore be best placed as early as 
possible in the patient journey, such as at presentation. 
Many previous biomarker studies in MPM have been limited by their retrospective 
nature or recruitment from surgical centres. Patients have frequently had 
specimens taken for biomarkers after a diagnosis of MPM has been made and 
therefore by definition after pleural biopsy and often pleurodesis has been 
performed. In addition, many archived samples taken from surgical centres that 
have been used in previous biomarker studies have been taken post-operatively, 
and in some cases after chemotherapy has been initiated. As a result, it is 
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difficult to quantify the effect of pleural biopsy, surgery, chemotherapy and 
pleurodesis on measured biomarkers from the current literature. In addition, 
other patient factors such as body weight, age, co-morbidities, concomitant 
medications, renal function and liver function are all potential confounders that 
may alter the measurement of a biomarker. (147) The magnitude of the effect of 
these factors need to be known to allow appropriate interpretation of results in 
clinical practice. 
1.13.2  Specimen processing and storage 
As MPM is a relatively rare malignancy, many biomarker studies in MPM utilise 
archived biological samples. Specimens are therefore likely to have been subject 
to different processing and storage procedures to that of the assay 
manufacturer’s instructions. Longterm biomarker stability in plasma or serum is 
critical when using stored samples in biomarker studies. (147) 
To be valuable in routine clinical practice, where specimens will often be taken 
in an outpatient clinical setting, biomarker levels need to remain stable at room 
temperature, as it would be difficult to achieve immediate transportation and 
processing, especially at low temperatures (such as 2-8°C as is required in the 
Fibulin-3 assay kit manufacturer’s instructions), to the laboratory in ‘real life’ 
clinical practice. 
1.13.3 Assay performance and validation 
Analytical factors can also affect biomarker reproducibility, it is therefore vital 
to examine the analytic performance of any assay being used in a biomarker 
study. Precision, reproducibility, linearity and analytic sensitivity and specificity 
are all important assessments of an assay’s performance. Given the significant 
variation in measured Fibulin-3 levels and diagnostic performance of Fibulin-3 
previously reported in MPM studies, rigorous internal validation of the FBLN3 
assay kit (Cloud-Clone Corp., formerly ISCN Life Science, Houston, Texas, USA) 
was performed as part of the DIAPHRAGM study.  
83 
 
 
1.14 Summary 
Malignant Pleural Mesothelioma is a rare invasive thoracic malignancy with a 
poor median overall survival of 9.5 months, and one-year survival rate of 41% 
and three-year survival rate of 12%. (65) Patients can therefore spend a 
significant amount of their remaining time following initial presentation in 
hospital. This is due to the symptomatic burden of pleural effusion frequently 
resulting in emergency presentation requiring hospital admission, followed by 
the potential requirement for multiple investigations and pleural procedures due 
to the much poorer sensitivity of investigations such as pleural aspiration in 
comparison to other pleural malignancies. This is associated with the potential 
for deterioration in the patient’s performance status, which can then preclude 
them from treatment, risk of procedural complications, such as tract metastases 
and emotional distress of the patient and their family resulting from diagnostic 
uncertainty. In addition, some patients are unable to have a diagnosis of MPM 
confirmed during life, which results in the requirement for a post-mortem 
examination due to medicolegal implications of the diagnosis.  
The variable and often subtle imaging abnormalities typical of early stage MPM 
result in significant challenges in detection and staging. In particular, 
differentiating early stage MPM from BAPE, where pleural effusion and minimal 
pleural thickening may be the only visible change on imaging. Similarly 
differentiating MPM from secondary pleural malignancy such as lung cancer can 
be difficult. The rind like spread of MPM and heterogeneous disease distribution 
makes assessment of volume of disease challenging, and this is reflected in the 
limitations of current staging systems and frequent finding of underestimation of 
clinical disease stage in published literature. Despite advances in imaging 
technology, there remains significant limitations in the non-invasive assessment 
of MPM in current clinical practice. 
Due to the inherent difficulties surrounding MPM diagnostics, non-invasive 
biomarkers are urgently required to direct appropriate patients to specialist 
centres offering timely diagnostic investigations, such as LAT, and access to 
specialist mesothelioma MDTs, where diagnosis and staging can be reviewed and 
an up to date clinical trials portfolio is maintained. 
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Ideally, biomarkers would offer sufficient sensitivity at high specificity 
(mandatory given the relative rarity of MPM) to improve diagnostic accuracy in 
patients presenting with possible MPM. A positive biomarker test could then 
direct specialist referral to a thoracoscopy centre, ensuring that diagnostic 
delays and unnecessary repeated pleural interventions are avoided.  
Despite promising results in discovery studies no MPM biomarker has been 
sufficiently validated. Studies to date have been limited by their retrospective 
design and use of selected MPM cohorts (e.g. late stage patients referred to 
tertiary centres rather than unselected patients at first presentation). Many 
studies have also used control subjects with little or no relevance to the 
significant current clinical challenges health professionals face when managing a 
patient with potential MPM. In particular, the evidence surrounding the utility of 
Fibulin-3 as a diagnostic biomarker in MPM is conflicting, with 3 studies reporting 
diagnostic performance >80% sensitivity and >80% specificity (250,252,257) and 3 
studies concluding insufficient diagnostic performance of Fibulin-3 to be used in 
routine clinical practice. (151,251,253) In addition, there appears to be variation 
in the levels of Fibulin-3 measured in plasma from patients with MPM between 
studies, (mean levels ranging from 11.51ng/ml to 112.9ng/ml), despite the vast 
majority of studies using ELISA assay kits from the same manufacturer (USCN Life 
Science, Houston, Texas, USA).  
As highlighted by studies of Fibulin-3, there are frequently inconsistent sampling 
protocols, assay methodology and optimum thresholds reported between studies. 
It is therefore important to consider factors that may have affected 
reproducibility of the original results, including patient factors and analytical 
factors. An appropriately designed prospective trial and a robust assay validation 
process are both pertinent.
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1.15  Aim of thesis and hypotheses tested 
The overall aim of this thesis is to examine the diagnostic performance, 
reproducibility and prognostic value of blood and novel Magnetic Resonance 
Imaging biomarkers in Malignant Pleural Mesothelioma. To address this aim, I 
have undertaken three separate studies in a large and well-characterised patient 
cohort, and tested three specific hypotheses.  
Chapter 2: ‘DIAPHRAGM – Diagnostic and Prognostic Biomarkers in the 
Rational Assessment of Mesothelioma’ 
SOMAscan™ and Fibulin-3 are blood biomarkers that have initially shown promise 
as diagnostic biomarkers of MPM. However, studies have been retrospective in 
nature, utilising archived specimens, largely from patients at surgical centres, 
and frequently from patients who already had a confirmed diagnosis of MPM (and 
therefore were post-biopsy +/ pleurodesis) and therefore not in the population 
where a novel biomarker is most urgently required (i.e. at presentation). The 
principal hypothesis of this study was that SOMAscan™ and Fibulin-3 provide 
clinically useful diagnostic and prognostic information related to MPM in an 
intention to diagnose population. 
Chapter 3: ‘Early Contrast Enhancement as a non-invasive imaging biomarker 
of pleural malignancy’ 
Novel, non-invasive imaging biomarkers of pleural malignancy and MPM are 
urgently required. Ideally, these should not rely on anatomical/morphological 
features of malignancy, since these are frequently minimal or absent in early 
stages of disease. Previous MRI studies have utilised DWI-MRI and DCE-MRI to 
detect changes in the tumour microenvironment (tumour cellularity with DWI-
MRI and tumour vascularity with DCE-MRI). However, these techniques have been 
limited due to issues with image distortion (DWI-MRI) or applicability in early 
stage patients without bulky imaging abnormalities (DCE-MRI). The principal 
hypothesis of this study was that a novel contrast-enhanced MRI protocol, 
exploiting neo-vascularisation in the pleural tumour micro-environment, could 
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distinguish benign from malignant pleural disease with sufficient diagnostic 
accuracy to be of utility in clinical practice, including in patients with early 
stage MPM and minimal pleural thickening. 
Chapter 4: ‘Volumetric assessment of Malignant Pleural Mesothelioma’ 
The need for better non-invasive techniques to accurately assess disease burden 
in MPM is clear. Volumetric assessment of MPM has previously been studied 
utilising CT. However, MRI may provide a more accurate assessment of disease 
burden due to its inherent advantages over CT in terms of contrast resolution 
and therefore tumour boundary delineation. The principal hypothesis of this 
study was that primary tumour volume can be accurately, reproducibly and 
practically assessed in patients with MPM using novel, semi-automated 
methodology at contrast-enhanced MRI.
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CHAPTER 2: DIAPHRAGM
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2 Chapter 2: DIAPHRAGM – Diagnostic and 
Prognostic Biomarkers for the Rational 
Assessment of Mesothelioma 
2.1 INTRODUCTION 
As previously discussed in Chapter 1, a reliable, non-invasive diagnostic 
biomarker for MPM would be a major clinical advance. This would allow 
clinicians to reliably differentiate likely MPM from secondary pleural 
malignancies (e.g. lung or breast cancer), which may present with similar 
clinical and imaging features but require less evolved diagnostic pathways. This 
reflects the improved sensitivity of pleural cytology in these diseases and the 
frequent option of alternative sites for tissue biopsy. A positive MPM biomarker 
test could facilitate early referral to a thoracoscopy centre and avoid 
unnecessary diagnostic delay (e.g. due to repeated pleural aspirations), 
minimising the risk of subsequent needle-tract metastases and maximizing 
opportunity for clinical trial enrolment.  
Biomarker results should correlate with disease extent, which is difficult in MPM 
given the previously described difficulties in MPM disease quantification and 
staging, and have defined relationships with potential confounders including the 
effect of pleural interventions. This is important because the precedent has 
been established in prostate and breast cancer, that recent sampling, resection 
or peri-tumoural inflammation may affect biomarker expression. This is 
particularly relevant to MPM where biopsies are frequently large and often 
combined with pleurodesis.  
Previously studied biomarkers are not currently used in routine clinical practice 
as a diagnostic tool, largely due to insufficient diagnostic performance in early 
stage MPM. Two recently reported blood biomarkers, SOMAscan™ (163) and 
Fibulin-3 (247) show promise as diagnostic biomarkers of MPM, but studies have 
been limited by their retrospective nature, inconsistent (and often late) 
sampling time-points, and in the case of Fibulin-3 inconsistent results. 
(151,250,253) 
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This chapter examines the design and set-up of the DIAPHRAGM study, clinical 
activity and recruitment of patients to the study and my laboratory activity in 
the study.   
2.2 AIM AND OBJECTIVES 
The aim of the DIAPHRAGM study was to prospectively evaluate the diagnostic 
and prognostic performance of the SOMAscan™ classifier and Fibulin-3 in an 
intention to diagnose population. A robust Fibulin-3 assay validation process was 
incorporated given previously discussed inconsistent results between studies. 
The principal hypothesis was that with an adequate sample size and appropriate 
clinical trial design, the diagnostic performance of SOMAscan™ and/or Fibulin-3 
would have sufficiently high sensitivity (>90% and >80% respectively) at high 
specificity (>90% for both) to be of routine clinical value in the diagnosis of MPM.  
Study objectives and their related outcome measures are presented in Table 2.1.
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Table 2.1 Research objectives and related outcome measures of the DIAPHRAGM 
study 
Research Objective Outcome Measures 
Primary 
To determine whether SOMAscan™ 
results and/or Fibulin-3 levels in blood 
at presentation can differentiate MPM 
from asbestos-exposed controls and 
patients with other causes of pleural 
effusion with a sufficient degree of 
sensitivity and specificity to be of 
routine clinical value 
 
Serum SOMAscan™ 
Plasma Fibulin-3 
Final diagnosis reached 
Secondary 
To determine whether: 
1. SOMAscan™ results and/or 
Fibulin-3 levels at presentation 
provide clinically useful prognostic 
information in MPM patients 
 
 
2. early changes in Fibulin-3 levels 
after diagnosis (at 3 months) are 
associated with a poorer prognosis 
in MPM 
 
 
Serum SOMAscan™ & plasma 
Fibulin-3 at presentation  
Survival (from registration) 
 
 
 
Plasma Fibulin-3 at presentation 
and 3 months post-diagnosis 
Survival (from registration) 
 
Exploratory 
To determine whether: 
1. there is a correlation between 
SOMAscan™ and/or Fibulin-3 
levels in blood and tumour volume, 
defined by MRI 
 
 
 
2. there is a correlation between 
SOMAscan™ and/or Fibulin-3 
levels in blood and tumour 
angiogenesis (as defined by 
perfusion-based MRI biomarkers) 
 
 
 
3. there is a correlation between 
SOMAscan™ and/or Fibulin-3 
levels in blood and pleural fluid at 
presentation in patients with MPM 
 
 
Serum SOMAscan™ 
Plasma Fibulin-3 
MPM tumour volume at MRI, 
defined using Myrian intrasense™ 
software 
 
 
Serum SOMAscan™ 
Plasma Fibulin-3 
MRI Early Contrast Enhancement 
 
 
 
 
 
SOMAscan™ and Fibulin-3 at 
presentation and at 1 month post-
biopsy +/- drainage and 
pleurodesis 
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2.3 METHODS 
DIAPHRAGM was funded by the Chief Scientist Office (CSO) Scotland (ETM/285) 
in March 2013. At the time of grant application, I was a full-time trainee in 
Respiratory and General Internal Medicine, working with Dr Kevin Blyth, who was 
the principal grant applicant. While I was not involved in writing the grant 
application, I was involved in discussions regarding the study protocol and 
logistics of recruiting to the study with Dr Blyth during the grant application 
process. When DIAPHRAGM was funded in March 2013, I applied for a 3-year 
period ‘out-of-programme for research’ to the Postgraduate Dean. This was 
approved from September 2013 and I commenced my time as a Clinical Research 
Fellow in November 2013, the first 2 years of which was funded through the 
DIAPHRAGM study grant award. 
2.3.1 Ethical Approval  
The study was approved by the West of Scotland Research Ethics Committee on 
26th November 2013 (Ref: 13/WS/0240). NHS Greater Glasgow & Clyde acted as 
the study sponsor. 
2.3.2 Study design and setting 
DIAPHRAGM was a prospective, multi-centre observational study. It included a 
Suspected Pleural Malignancy (SPM) group and an asbestos-exposed control (AEC) 
group. Overall study design for the SPM cohort is summarised in Figure 2.1. 
Overall study design for the AEC cohort is summarised in Figure 2.2. The 
biomarker sampling windows were designed to replicate when the biomarker 
would be used in routine clinical practice, i.e. at initial presentation with 
suspected pleural malignancy, and were therefore drawn prior to a diagnosis of 
MPM being made. In addition to better replicating the future use of these 
potential biomarkers, this avoided the potential confounding effect of pleural 
biopsy and/or pleurodesis on biomarker results. In order to maximise the 
potential population of SPM patients, the study design allowed for biomarkers to 
be drawn after simple diagnostic pleural aspiration had been performed. 
However, exact timing of the biomarker draw relative to pleural aspiration was 
recorded in every case to assess any confounding effect this intervention may 
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have on biomarker results. Identical processing and storage protocols were used 
in both SPM and AEC cohorts. Potential additional confounders including renal 
function, inflammatory indices and drugs was also recorded. An exploratory, 
cross-sectional MRI sub-study was performed to determine whether there was 
any correlation between blood biomarker levels and MPM tumour volume. 
Tumour volume was measured at contrast-enhanced MRI, which is described in 
detail in Chapter 4.  
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Figure 2.1 Study flowchart for participants recruited to Suspected Pleural 
Malignancy cohort of the DIAPHRAGM study 
 
Figure 2.2 Study flowchart for participants recruited to the Asbestos-exposed 
Control cohort of the DIAPHRAGM study 
2.3.3 Study Set-Up 
2.3.3.1 Overall 
A trial management group (TMG), which included the study Chief Investigator (Dr 
Kevin Blyth), the CRUK Clinical Trials Unit Glasgow team (project manager, 
clinical trial co-ordinator, trial statistician and trial monitor) and myself (as 
Clinical Research Fellow) was formed. TMG responsibilities included study site 
selection and set up, development of study documentation, monitoring of trial 
94 
 
  
activities and communication with sites. Importantly, the TMG met on a monthly 
basis to review recruitment, including overall recruitment numbers, recruitment 
at each site, site screening logs and mesothelioma numbers. Study 
documentation, including patient information sheets and case report forms were 
drafted by me and approved by Dr Blyth and the other members of the 
DIAPHRAGM TMG. DIAPHRAGM newsletters were sent to each recruiting site with 
the aim of providing recruitment updates, reminders about protocol updates and 
gratitude and encouragement for ongoing study participation.  
The study was supported by the National Cancer Research Institute (NCRI) and is 
registered on the ISRCTN registry (ISRCTN10079972), a searchable clinical trial 
registry. In addition, details of the study were made available on the Cancer 
Research UK website, the Experimental Cancer Medicine Centre (ECMC) website 
and the Mesothelioma UK website and newsletters. The study was also 
highlighted at the ‘British Thoracic Oncology Group (BTOG)/Mesothelioma UK 
Managing Mesothelioma in the UK’ Meeting in 2014, in order to promote national 
and international awareness of the study and encourage potential recruiting 
centres to approach the TMG if interested in contributing.   
2.3.3.2 Site Selection 
The SPM group was recruited from 22 centres in the U.K. and Republic of 
Ireland. Recruiting centres were deliberately a mixture of academic and more 
clinically-orientated units, making results of the study generalisable to patients 
presenting with SPM to acute hospital services. 11/22 (50%) of these centres 
were concentrated in a geographical location with a MPM standardised mortality 
ratio (SMR) >100. (258) 
 Sites interested in participating as a recruiting centre were asked to complete a 
site ‘Confirmation of Interest and Feasibility’ form (see Appendix 1). All 
principal investigators had a declared interest in pleural disease and each centre 
had sufficiently evolved pleural diagnostic services to deliver a reliable 
diagnosis. Specifically, access to on-site thoracoscopy (ideally including LAT) and 
a regional mesothelioma multi-disciplinary team (MDT) meeting (for diagnostic 
review and staging) was required. In addition, all centres were required to have 
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access to research nurses, a centrifuge and a -80ºC freezer, and most centres 
had a history of successful multi-centre research collaboration.  
Centres opened to recruitment in a staggered fashion over a period of 2.5 years. 
All centres completed standard procedures before opening to recruitment (see 
Figure 2.3). The Queen Elizabeth University Hospital (QEUH) opened in June 
2015 merging 3 individual sites, which closed at that point to form the QEUH, 
these being the Southern General Hospital, Victoria Infirmary and Gartnavel 
General Hospital. While outpatient clinics continued to be based at the original 
hospitals, all in-patient services were moved to QEUH. These centres will be 
referred to as West of Scotland (WoS) centres for the remainder of this thesis. 
The AEC group and the MRI sub-study cohort were recruited from West of 
Scotland centres only. 
Site training was done myself, either remotely (utilising PowerPoint slides, e-
mail correspondence +/- telephone conference) or in person at a site visit. On-
site initiation visits were conducted at all WoS centres, Aberdeen Royal 
Infirmary, Southmead Hospital (Bristol), University Hospital of South Manchester, 
Northern General Hospital (Sheffield), Royal Alexandra Hospital (Paisley), Forth 
Valley Royal Hospital (Falkirk), Inverclyde Royal Hospital (Greenock) and 
University Hospital Galway. 
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 Figure 2.3 Recruiting centre opening process
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2.3.4 Study Population 
2.3.4.1 Suspected Pleural Malignancy Cohort 
Patients with suspected PM were identified on presentation to a Respiratory out-
patient clinic or acute hospital admissions unit. Eligibility criteria for the SPM 
cohort were as follows: 
Inclusion Criteria 
1. Suspected pleural malignancy, defined by a unilateral pleural effusion or 
pleural mass lesion 
2. Sufficient fitness for diagnostic sampling (site investigator’s clinical 
judgment)  
3. Informed written consent 
Exclusion Criteria 
1. Insufficient fitness (based on site investigator’s clinical judgement) 
2. Intercostal chest drain in-situ 
3. Intercostal chest drain inserted within the previous 3 months 
2.3.4.2 Asbestos-exposed Control Cohort 
Eligibility for the asbestos-exposed control cohort were as follows: 
Inclusion Criteria: 
1. Documented history of asbestos exposure and associated radiological 
evidence of asbestos exposure, e.g. pleural plaques, asbestosis or diffuse 
pleural thickening 
2. Willing and able to travel to a research clinic interview in Glasgow 
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3. Informed written consent 
Exclusion Criteria: 
1. Known Malignant Pleural Mesothelioma 
2. Known or suspected other thoracic malignancy under investigation 
3. Known pleural effusion of any cause 
2.3.4.3 Cross-sectional MRI sub-study Cohort 
In order to address the study’s exploratory objectives, a cross-sectional MRI sub-
study was performed. Eligibility for the MRI sub-study were as follows: 
Inclusion Criteria: 
1. Pleural histological sampling (by LAT/image-guided biopsy) indicated to 
investigate suspected pleural malignancy following a non-diagnostic pleural 
aspiration 
2. Recruited in a West of Scotland centre 
Exclusion Criteria: 
1. Unable to undergo MRI (due to claustrophobia or known contraindications 
such as pacemaker, ferrous metal implants or metallic foreign body) 
2. Allergy to Gadolinium contrast 
3. Renal impairment (eGFR <30ml/min) 
4. Pregnancy 
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2.3.5 Glasgow Recruitment 
Suspected Pleural Malignancy Cohort   
Patients in WoS centres (n=4) were identified, screened and recruited by myself. 
Patients in the Royal Alexandra Hospital (RAH) and Inverclyde Royal Hospital 
(IRH) were identified and screened by myself and recruited by a research nurse 
based at the Glasgow Clinical Research Facility. At these centres, potential 
patients were identified by myself using an electronic Healthcare Information 
System (Trakcare®, InterSystems Corporation, Massachusetts, USA). This system 
is used by NHS Greater Glasgow & Clyde health board (which incorporates all of 
the WoS centres, RAH and IRH) and includes details of all hospital out-patient 
appointments and in-patient admissions, which can be sorted by individual 
hospital consultants or services and in-patient wards. I could review patients’ 
electronic case records as a member of the clinical team. Previous electronic 
case records (including referral letters, clinic letters, discharge letters and 
previous laboratory results) are available via Trakcare®. In addition, patients’ 
images (including chest radiographs and CT scans) were accessible using an 
electronic picture archiving and communication system (PACS v11.4, Carestream 
Health, NY, USA).  
Utilising these systems, I identified potential study participants by reviewing all 
new out-patient referrals to all of the respiratory consultants (n=30) at each 
hospital. This included review of the referral letter and any available previous 
clinic letters and radiology. In addition, I screened all new patient admissions to 
the acute medical receiving units and respiratory inpatient wards on a daily 
basis, reviewing any available investigations and radiology. After initial 
identification using this methodology, potential participants were further 
assessed for their eligibility based on history and examination, attained via 
personal review and/or communication with the patient’s responsible 
consultant. Any potentially eligible patients were provided with the study 
Patient Information Sheet (PIS), see Appendix 2, by myself or the patient’s 
responsible consultant and given sufficient time to read and consider it and ask 
any questions prior to providing informed written consent. Respiratory 
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consultants in WoS centres were provided with a diagnostic pleural aspiration 
service by myself so that any patients with suspected PM not identified at the 
time of Trakcare® review had a second opportunity to be identified and 
screened, when they attended for their diagnostic pleural aspiration. In the vast 
majority of cases, patients were consented and blood biomarkers were drawn on 
the same date as their diagnostic pleural aspiration. 
Asbestos-Exposed Control Cohort 
AEC subjects were initially recruited via invitations sent by Clydeside Action on 
Asbestos (CAA), an advocacy body based in Glasgow with a database of over 600 
clients, see Appendix 3. An additional population of potential AEC subjects was 
identified via respiratory outpatient clinics at WoS centres from 17th October 
2014 to study completion.  
Subjects invited by CAA were asked to contact either myself or a research nurse 
based at the Glasgow Clinical Research Facility if they were interested in taking 
part. If eligible, an AEC PIS (see Appendix 4) was posted out to the subject and 
telephone contact made the following week to confirm ongoing interest in 
participation and a single research clinic visit scheduled.   
Potential subjects were identified from respiratory outpatient clinics by myself 
in a similar fashion to the method described in section 2.3.5. I reviewed clinic 
letters and any available recent imaging of all new and returning patients 
attending respiratory out-patient clinics at WoS centres. If potentially eligible, a 
research nurse would aim to attend the clinic, provide the patient with the AEC 
PIS and recruit the patient if confirmed as eligible. If this was not possible, 
either due to research nurse availability or if the patient did not have sufficient 
time to consider the PIS, they were invited to attend a separate single research 
clinic visit at a later date. Transportation from the subject’s home to the 
research clinic at the Glasgow Clinical Research Facility was provided if required 
in an attempt to minimise participant burden. All participants were given 
sufficient time to read and consider the PIS and ask any questions prior to 
providing informed written consent 
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Cross-sectional MRI sub-study Cohort 
All patients included in the MRI sub-study were recruited by myself from WoS 
centres. Patients were identified by reviewing the results of their pleural 
aspiration, MDT discussion and referral for further investigation. Patients were 
approached at the clinical visit where the non-diagnostic pleural aspiration 
results, and the need for further investigation (e.g. thoracoscopy or image-
guided biopsy), were discussed. Subjects were provided with a separate MRI sub-
study PIS (see Appendix 5) and given sufficient time to read and consider it and 
given the opportunity to ask questions. If willing, they were asked to provide 
additional informed written consent when they attended for the MRI scan.  
All MRI scans were performed at the Glasgow Clinical Research Imaging Facility. 
This was initially based at the British Heart Foundation (BHF) Glasgow 
Cardiovascular Imaging Facility, University Avenue, University of Glasgow, which 
was located separate to the WoS recruiting hospitals. Return transportation from 
the subject’s home was provided if required in order to minimise patient 
burden. From August 2015, the Glasgow Clinical Research Imaging Facility was 
based at the QEUH. Following this, patients were generally consented and 
underwent MRI examination on the same date that they were electively 
admitted for LAT or image-guided biopsy (both of which were performed at 
QEUH).  
2.3.6 Study Procedures 
The schedule of assessments for each SPM subject recruited to the DIAPHRAGM 
study is presented in Table 2.2. The schedule of assessments for each AEC 
subject recruited to the DIAPHRAGM study (depending on whether they were 
invited by CAA or identified via respiratory out-patient clinics) is presented in 
Table 2.3 and Table 2.4 respectively. 
2.3.6.1 Patient Registration 
All patients were registered to the study and provided with a unique study 
identification number by the Clinical Trials Unit Glasgow following confirmation 
of eligibility.
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Table 2.2 Schedule of assessments for participants recruited to the Suspected Pleural Malignancy cohort of the DIAPHRAGM study  
DIAGNOSTIC TESTING &  BASELINE BIOMARKER RECORDING 
FOLLOW-UP & 
REPEAT 
BIOMARKERS 
OUTCOME &         
DIAGNOSIS UPDATES 
Visit Number/Name 1 2 3(1) 3(a) 4 5 6 7 Outcome Diagnosis 
Approximate timing Day 0 Day 3 Day 9 
Day 
15 
(+/- 4 
days)  
MRI 
only 
Day 
18 
(+/- 4 
days) 
Day 
28 
(+/- 4 
days) 
Final 
Dx plus 
31 
days 
(+/- 7 
days)     
MRI 
only 
Final Dx 
plus 92 
days 
(+/- 14 
days) 
MPM 
only 
Final Dx 
plus 5 
months 
(+/- 14 
days) 
MPM 
only 
When new 
Dx made 
or Final Dx 
+ 1 year 
(+/- 14 
days) Non-
MPM (non-
path Dx) 
only 
  
Clinical visits will vary depending on local 
pathways 
1 
month 
Post-
Dx 
3 
months 
Post-Dx 
Every 2 
months As above 
Clinical Activity 
History, examination +/- imaging X                   
Diagnostic pleural aspiration X X*                 
Clinical Review with pleural aspiration 
results     X               
Pleural biopsy +/- pleurodesis         X           
Clinical review with biopsy results           X         
Clinical review +/- imaging             X X     
Core Study Activity 
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Review eligibility criteria X X*                 
Introduce study if eligible X X*                 
Provide with PIS X X*                 
Discussion and informed consent   X X*               
Register patient with CTU   X X*               
Complete asbestos questionnaire   X X*               
Record clinical history   X X*               
Clinical examination   X X*         X     
Record all diagnostic test results (including 
any repeats)   X X*     X         
Record concomitant medications   X X*         X     
Blood draw   X X*         X     
Research pleural fluid draw (MRI sub-study 
only)   X                 
Update relevant imaging results               X     
Outcome assessment               X X   
Diagnosis update                   X 
MRI Sub-study Activity 
Review eligibility criteria     X               
Introduce study if eligible     X               
Provide separate sub-study PIS     X               
X-ray orbits if indicated     X               
MRI safety questionnaire     X X*             
Discussion and informed consent       X             
Register patient with CTU       X             
Pleural MRI scan       X             
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Retain or discard research pleural fluid 
sample       X             
Blood draw             X       
Clinical examination             X       
Record relevant imaging results             X       
Record concomitant medications             X       
*If not previously done, Dx; Diagnosis 
 
(1) At visit 3, where the results of the diagnostic pleural aspiration are reviewed, there are 3 possible outcomes: 
I. If any non-MPM diagnosis is made: subject will exit study. No further blood draws or follow-up visits are required but a Diagnosis 
Review 1 year from the date of Final Diagnosis will be required in patients with a non-pathological diagnosis. This will include all 
patients diagnosed with a non-MPM illness after a pleural aspiration alone, EXCEPT those with a cytological diagnosis of non-MPM 
malignancy 
II. If no diagnosis is made: a pleural biopsy will be arranged, if clinically indicated (e.g. Thoracoscopy or image-guided pleural biopsy). If 
a West of Scotland patient, these patients may be considered for the MRI sub-study 
III. If diagnosis is confirmed as MPM (unlikely based on cytology): subject will enter follow-up with a 3 month blood draw 
*If not previously done 
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Table 2.3 Schedule of assessments for participants recruited to the asbestos-
exposed control cohort of the DIAPHRAGM study via invitation by Clydeside 
Action on Asbestos (CAA) 
CAA identified patients 
Visit Number Screening Visit 1 Visit 2 
Approximate Day* 0 7-14 14-28 
Postal Invitation X   
Post PIS X X  
(if not already 
done) 
 
Telephone contact  X  
Eligibility 
screening 
 X  
Discussion & 
Informed consent 
  X 
Register subject 
with CTU 
  X 
Record medical 
history 
  X 
Record Medications   X 
Asbestos exposure 
history 
questionnaire 
  X 
Blood draw   X 
*The exact dates will depend on when/if each study participant 
responds to the postal invitation and when they can attend for interview 
and blood draw
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Table 2.4 Schedule of assessments for participants recruited to the Asbestos-
exposed control cohort of the DIAPHRAGM study after identification at 
respiratory outpatient clinic 
Hospital Identified Patients 
Visit Number Screening Visit 1 
(Telephone 
contact if 
eligibility 
screening not 
performed at 
screening visit) 
Visit 2 
Approximate Day* 0 1-7 7-28 
Introduce Study X   
Eligibility 
screening 
X 
 
X 
(if not previously 
performed) 
 
Provide PIS X X 
(will be posted out 
if not provided at 
screening) 
 
Opportunity for 
discussion 
X X X 
Discussion & 
Informed consent 
  X 
Register subject 
with CTU 
  X 
Record medical 
history 
  X 
Record Medications   X 
Asbestos exposure 
history 
questionnaire 
  X 
Blood draw   X 
*The exact dates will depend on when in the hospital encounter each study 
participant is given the PIS and when they can attend for interview and blood 
draw
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2.3.6.2 Case Report Forms 
Suspected Pleural Malignancy Cohort 
All patients in the SPM cohort had a Baseline Information Form (see Appendix 6) 
completed. Patients who had a final diagnosis of MPM had a Follow-up Visit Form 
(see Appendix 7) completed at 3 months after diagnosis and a Long Term Follow-
up Form (see Appendix 8) completed at 2 monthly intervals post-diagnosis.  
Patients without a cytological or histological diagnosis, and patients with a 
benign diagnosis (even if histologically confirmed, e.g. BAPE based on benign 
fibrinous pleurisy at pleural biopsy) had a Diagnostic Review Form (see Appendix 
9) completed at the 12-month anniversary of the original diagnosis, or as soon as 
a new pleural diagnosis was made. The purpose of this was to capture any false 
negative diagnostic tests from the initial pathway, acknowledging the major 
diagnostic challenges posed by pleural malignancies, particularly MPM, which is 
associated with a false negative pleural biopsy rate of up to 12% reported in 
previous case series. (45)  
Asbestos-Exposed Control Cohort 
All participants in the AEC cohort had an Asbestos-Exposed Controls Case Report 
Form (CRF) (see Appendix 10) completed. This form included a review of any 
unexplained breathlessness, chest wall pain or breathlessness experienced 
within the preceding 6 months reported by the subject at the research visit. The 
purpose of this was to ensure that any recent development of concerning clinical 
features that may indicate new, undiagnosed pleural malignancy would be 
detected. If this was the case, then the subject was referred for clinical 
investigation as appropriate and excluded from the AEC cohort. The subject’s 
available imaging was also reviewed and recorded.    
2.3.6.3 Asbestos Exposure Questionnaire 
Detailed asbestos exposure histories were taken from all participants in both the 
SPM cohort and the AEC cohort using an asbestos exposure questionnaire derived 
108 
 
  
from the Health and Safety Executive asbestos survey (259) (see Appendix 11). 
This questionnaire included recording of the nature of occupational exposure(s), 
which can be correlated to likely fibre exposure. The duration and first year of 
exposure was also recorded. Non-occupational sources of exposure were also 
recorded (e.g. the washing of an occupationally exposed spouse’s work clothes 
or environmental exposure from the household or surrounding environment).  
2.3.7 Statistical Analysis 
2.3.7.1 Sample Size Calculation  
SOMAscan™ assay 
Sample size calculations were performed by the Cancer Research UK (CRUK) 
Clinical Trials Unit Glasgow statisticians based on the previously published 
sensitivity of 93.2% (95% CI 88.6 – 97.7%) and specificity of 90.8% (95% CI 86.1 – 
95.6%) for SOMAscan™. (163) As MPM is a relatively rare disease, it would be 
clinically important for the biomarker test to have high sensitivity at high 
specificity. With an MPM sample size of 120, the study will be able to distinguish 
a sensitivity of <80% from a sensitivity >90% with 93% power, at the 5% one-sided 
level of significance. Initial projected incidence of MPM in the target population 
of patients presenting with suspected PM was 20%. The target overall sample 
size was therefore 600 patients with suspected pleural malignancy. However, as 
the study was designed to recruit patients at presentation with suspected PM, 
the final number of patients included in the study with a final diagnosis of MPM 
will not be known until study completion. The precision around the reported 
sensitivity from this study will therefore depend on the final number of MPM 
patients included but the standard error in the estimated sensitivity will be <5%, 
provided at least 120 MPM cases are recruited and their samples are available for 
analyses.  
109 asbestos-exposed control subjects will distinguish a specificity of <80% from 
a specificity of >90% with 88% power, at the 5% one-sided level of significance. 
The standard error in the estimated specificity will be <5%.   
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The study data will be used to estimate the AUC for SOMAscan™ for 
distinguishing patients with MPM from non-MPM patients in the suspected pleural 
malignancy cohort. Assuming 120 patients in the MPM group and 120 in the non-
MPM group, the AUC can be estimated with a 95% CI width of 0.120 – 0.168 
(assuming a cut-point exists with a reasonable sensitivity of 80% and a modest 
specificity of 40%). if more sensitive/specific cut-points exist, the width of the 
95% CI will be much reduced.  
Fibulin-3 
With a MPM sample size of 120, the study will be able to distinguish a sensitivity 
of >80% from a sensitivity of <70% with 80% power, at the 5% one-sided level of 
statistical significance. The precision around the reported sensitivity will depend 
on the final number of MPM patients included but the standard error in the 
estimated sensitivity will be <5%.  
In order to achieve 90% power to distinguish a specificity of >90% from a 
specificity <85%, at the 5% one-sided level of statistical significance, a random 
sample of 378 non-MPM samples will analysed. The standard error in the 
estimated specificity will be <2.3%.  
2.3.7.2 Primary analysis plan 
Statistical analysis will be performed by the CRUK Clinical Trials Unit Glasgow 
statisticians. Sensitivity and specificity at pre-specified cut-offs (0.5 for 
SOMAscan™ and 52ng/ml for Fibulin-3) will be estimated using 2 x 2 contingency 
tables. The overall diagnostic performance of each biomarker will be assessed 
using ROC curves. Logistic regression will be used to estimate a diagnostic model 
using biomarker results and clinical or radiological variables. Cross-validation 
will be used to provide robust estimates of AUC and specificity at fixed 
sensitivity rates of 80%, 90% and 95%.  
2.3.7.3 Secondary analysis plan 
A prognostic model will be developed using Cox proportional hazard techniques. 
The modelling process will incorporate biomarker measurements at presentation 
(both biomarkers) and at 3 months (Fibulin-3 only due to cost restraints 
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associated with SOMAscan™ analyses) and other known prognostic features. This 
will include performance status and tumour histology.  
2.3.7.4 Exploratory analysis plan 
The association between SOMAscan™ results and Fibulin-3 in blood and tumour 
volume/measures of tumour angiogenesis will be estimated by Pearson or 
Spearman correlation, depending on the normality of the distribution of the 
data. The same methods will be used to test the association between Fibulin-3 
in blood and pleural fluid. Changes in Fibulin-3 levels before and after 
histological sampling will be compared using a paired t-test or Wilcoxon signed 
rank-sum test, depending on the normality of the distribution of the data.  
2.3.8 Biomarker Sampling, Processing and Storage 
2.3.8.1 Biomarker Sampling  
Materials for blood sampling 
• Tourniquet 
• Alcohol wipe 
• 21-gauge needle (BD Medical, UK) 
• 20 ml syringe (BD Medical, UK) 
• 2 x 5 ml vacutainer tube containing SST clot activator (Greiner Bio-One)  
• 1 x 9 ml (or 2 x 4 ml) vacutainer tube containing EDTA (Greiner Bio-One)   
Materials for pleural fluid sampling 
• Sterile gloves and gown 
• Antiseptic solution 
• Dressing pack with sterile drape 
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• 1% lidocaine 
• Occlusive dressing 
• 2 x 21-gauge needle (BD Medical, UK) 
• 1 x 25-gauge needle (BD Medical, UK) 
• 1 x 10 ml syringe (BD Medical, UK) 
• 1 x 60 ml syringe (BD Medical, UK) 
• 1 x 20 ml universal container (ThermoFisher Scientific)  
Methods for biomarker sampling 
Blood samples were taken from participants by a competent member of the 
study team. Sufficient blood was collected to allow duplicate samples of serum 
and plasma to be collected for all measurements at all visits, ensuring 
redundancy in case of loss or damage to samples during transportation. 9 ml of 
venous blood was collected first into a vacutainer tube containing SST clot 
activator. A further 9 ml of venous blood was then collected into a second 
vacutainer tube containing EDTA.   
In WoS centres, 20 ml pleural fluid was collected by myself at the time of initial 
diagnostic or therapeutic aspiration into a plain universal container. All pleural 
aspirations were performed under ultrasound guidance and aseptic technique, 
following consent. If pleural fluid was not collected at this initial time, then a 
further opportunity was allowed immediately prior to thoracoscopy if the patient 
was registered in the MRI sub-study. 
2.3.8.2 Sample Processing and Storage 
Materials for sample processing and storage 
• 500 µL cryovials (ThermoFisher Scientific) 
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• 1 ml pipette  
• Centrifuge 
• Cryolabels 
• Cryobox  
• -80ºC freezer 
Methods for sample processing and storage 
Serum samples (collected in the vacutainer tube containing SST clot activator) 
was allowed to clot for 30 minutes before centrifugation. Plasma samples 
(collected in the vacutainer tube containing EDTA) and pleural fluid samples 
could be centrifuged immediately. All samples were centrifuged at 2200g for 15 
minutes at room temperature. These were the processing instructions provided 
by SOMAlogic® at study commencement.   
For all samples, the supernatant was withdrawn by pipette immediately 
following centrifugation and aliquoted into a minimum of 4 cryovials of at least 
250µL volume, labelled with the patient’s study ID, sample details (i.e. serum, 
plasma or pleural fluid) and the sampling date, before being placed in a cryobox 
and into a -80ºC freezer within 2 hours of initial blood draw.  
2.3.9 Biomarker Analyses 
The diagnostic performance of SOMAscan™ and Fibulin-3 will be assessed using 
cut-points determined in the relevant original studies (SOMAscan™ classifier cut-
off score of >0.5 and Fibulin-3 cut-off of 52ng/ml) and compared to the 
currently best studied MPM biomarker, Mesothelin using the MESOMARK® ELISA 
(Fujirebio Diagnostics Inc, PA, USA). 
SomaLogic® are performing all SOMAscan™ analyses, utilising SOMAmer™ reagents 
to specifically bind to protein targets in serum as discussed in Chapter 1. Fibulin-
3 and Mesothelin levels are being measured by the Translational Pharmacology 
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Unit (Wolfson Wohl Cancer Research Centre, UK) according to GCP guidelines.  
Fibulin-3 levels in plasma and pleural fluid is being measured using the 
commercially available ELISA (Cloud-Clone Corp., formerly USCN Life Science 
Inc, Houston, Texas, USA) as in the original study. (247) Mesothelin is being 
measured using the MESOMARK® ELISA (Fujirebio Diagnostics, Inc, PA, USA).   
2.3.10 Data Storage 
All data for the DIAPHRAGM study was recorded on paper Case Report Forms. 
This data was then entered into a password encrypted electronic database by 
the CRUK Clinical Trials Unit Glasgow team (ORACLE database version 11g, 
Oracle Corporation, California, USA). 
2.3.11  Laboratory Activity - Fibulin-3 assay validation 
Pre-validation testing of the most widely used Fibulin-3 assay (FBLN3 assay, 
Cloud-Clone Corporation, Houston, Texas, USA) was undertaken by the 
Translational Pharmacology Laboratory, formerly Analytical Services Unit 
(University of Glasgow, UK). These tests highlighted possible manufacturing 
inconsistencies between batches of the FBLN3 assay kit (Cloud-Clone Corp., 
Houston, Texas, USA). Initial standard curves from lot number L141204141 were 
successful, with coefficient of variation (CV%) <20%. However, the quality 
control sample provided by the manufacturer did not produce a result within the 
range of the standard curve. on two separate occasions. This experiment was 
repeated using lot number L150714373. However, the standard curve failed on 4 
separate occasions (with CV% of up to 119%). It was then noticed that the 
standard diluent and assay diluent A appeared cloudy. Further kits from the 
original lot number (L141204141) were therefore ordered from the 
manufacturer. Unfortunately, further quality control samples could not be 
provided by the kit manufacturer. In order to validate the assay, we therefore 
had to establish alternative positive and negative control samples. This was done 
by myself under the direct supervision of Caroline McCormick (Research 
Assistant) and Fiona Thomson (Director/Senior Research Fellow) at the 
Translational Pharmacology Laboratory (TPL), Wolfson Wohl Cancer Research 
Centre, Institute of Cancer Sciences, University of Glasgow. The establishment 
of these positive and negative control samples is summarised in Sections 
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2.3.11.1 – 2.3.11.2. Subsequent assay validation was not performed by me and is 
not described here; this was completed by the TPL.   
2.3.11.1 Materials 
Cell lines 
Mesothelioma cell lines HP1 and H2595, and the benign mesothelial cell line LP9, 
were sourced from Dr Harvey Pass at NYU Langone Medical Center by Dr Kevin 
Blyth. Mesothelioma cell line H226 was sourced from the Beatson Institute for 
Cancer Research by Dr Kevin Blyth. 
Culture medium 
• Dulbecco’s Modified Eagle Medium (DMEM) (ThermoFisher Scientific, 
Massachusetts, USA) 
• Penicillin (10,000 units/ml) and Streptomycin (10,000 micrograms/ml) 
(Gibco, Life Technologies, UK) 
• Heat-activated Foetal Bovine Serum (FBS) (Gibco, Life Technologies, UK) 
Equipment 
Fibulin-3 assay kit was purchased from Cloud-Clone Corporation, formerly USCN 
Life Science, Houston, Texas, USA. Materials included in the kit were: 
• Pre-coated 96-well strip plate 
• Plate sealer for 96 wells 
• Stock standard 
• Standard diluent 
• Detection reagent A 
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• Assay diluent A 
• Detection reagent B 
• Assay diluent B 
• Tetramethylbenzadine (TMB) substrate 
• Stop solution 
Additional equipment used included: 
• Microplate reader with 450 ± 10nm filter – SpectraMax® Plus 384 and SoftMax® 
Pro 6.4 (Molecular Devices Corp., California, USA)  
• Multi-channel, high precision pipettes with disposable tips (Gilson Inc, 
Wisconsin, USA) 
• Table top centrifuge suitable for 2 ml tubes 
• Incubator at 37°C 
• CASY® cell counter and analyser (Roche, Germany) 
Additional Solutions 
• Trypsin (Gibco, Life Technologies, UK) 
• CASYton solution (Roche, Germany) 
• Dimethyl sulfoxide (DMSO) (ThermoFisher Scientific, Massachusetts, USA) 
• Distilled water for use as wash buffer 
• 0.01mmol/l Phosphate Buffered Saline (PBS), pH 7.4 (ThermoFisher 
Scientific, Massachusetts, USA) 
116 
 
  
2.3.11.2 Experimental Procedures 
Cell culture 
Mesothelioma cell lines HP1 and H2595 and H226 were grown in culture medium 
solution, (Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 
Penicillin and Streptomycin (10,000 micrograms/ml) and heat-activated Foetal 
Bovine Serum (FBS)). Cells were grown in 75cm2 flasks with 20mls culture 
medium incubated at 37ºC and 10% CO2.  
To split cells, culture media was removed by me and cells were dissociated with 
3ml trypsin and the flask returned to the incubator for 10 minutes until the cells 
had become detached from the flask. 10ml of culture media was then re-added 
to the flask. 200µl of media and the cells in suspension were removed from the 
flask into a universal container. 9.8ml of CASYton solution was added to the 
container before being placed into a cell counter. Based on the cell count per 
ml, I calculated the volume of culture media with the cell suspension required to 
be added to a 75cm2 flask. A volume of fresh culture media was then added by 
me to make the total volume up to 20ml, prior to re-incubation at 37ºC and 10% 
CO2.  
Once an adequate supply of cells had been established, one flask from each cell 
line was used for further experimentation. Once cells in each flask reached 80% 
confluence (assessed by me under the supervision of Carol McCormick), culture 
medium was replaced with 2ml serum-free medium (consisting of DMEM and 
Penicillin/Streptomycin) and re-incubated for 24 hours. Cell-conditioned medium 
was then collected into a universal container and spun at 1200rpm for 5 minutes 
at 21ºC (i.e. room temperature) for 5 minutes. The supernatant was collected by 
me into eppendorfs and frozen at -80 ºC. 
Fibulin-3 Assay 
The assay used to measure Fibulin-3 levels is a sandwich Enzyme-linked 
Immunosorbent Assay (ELISA). The assay was performed by me, under the direct 
supervision of Carol McCormick, as per manufacturer’s instructions. A 96-well 
microplate is pre-coated with a FIbulin-3-specific capture antibody (by the 
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manufacturer) to which samples (antigen) were added prior to incubation for 
one hour at 37ºC. The microplate was then washed using distilled water to 
remove any unbound antigen before a second, independent antibody specific to 
Fibulin-3, which is conjugated to Horseradish Peroxidase (HRP) was then added. 
The microplate was again incubated for 30 minutes at 37ºC before being washed 
with distilled water to again remove any unbound conjugated antibody-antigen 
complexes. TMB substrate was then added to the microplate. The substrate was 
hydrolysed in proportion to the amount of conjugated antibody-antigen 
complexes present in the each well of the microplate, with a resultant colour 
change (blue). Stop solution (Sulphuric acid) was then added after a 15 – 20 
minute incubation period to terminate the enzyme-substrate reaction, resulting 
in a further colour change (yellow). The optical density of this colour change was 
measured spectrophotometrically at a wavelength of 450nm ± 10nm, using 
SpectraMax® Plus 384 spectrophotometer (Molecular Devices Corp., California, 
USA).  
 
Standard Curve 
A 7-point standard curve was produced using the Stock Standard and Standard 
Diluent provided in with the FBLN3 kit by me under the direct supervision of 
Carol McCormick. The concentration at each point of the standard curve was 
100ng/µl, 50 ng/µl, 25 ng/µl, 12.5 ng/µl, 6.25 ng/µl, 3.12 ng/µl, 1.56 ng/µl.  
To assess the validity of the standard curve, back calculated concentrations 
were compared with the known concentration of the standard solution at all 7 
dilutions. In order to be valid, the back calculated concentration needed to be 
within 20% of the known concentration (25% for the lower two concentrations). 
I then assessed the reproducibility of the standard curve by repeating this in 
duplicate on nine separate plates.  
Establishing Positive Control Samples 
I measured Fibulin-3 levels using supernatant collected from conditioned media 
from the Mesothelioma cell lines H226, H2595 and HP1 at 3 concentrations 
(undiluted, 1:1 dilution and 1:4 dilution). PBS was used as the diluent.  
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Establishing Negative Control Samples 
I measured Fibulin-3 levels using supernatant collected from conditioned media 
from benign mesothelial cell line LP9 at 3 concentrations (undiluted, 1:1 dilution 
and 1:4 dilution). PBS was used as the diluent. PBS and distilled water were run 
alongside as a quality control sample.  
2.4  RESULTS 
2.4.1 Site recruitment 
The TMG was approached by 13 hospital sites following study promotion with an 
interest in becoming a participating centre. Following review of each site’s 
estimated new number of patients diagnosed with MPM, recruitment target and 
access to facilities such as LAT, a mesothelioma MDT and research nurses, 7/13 
(54%) of these sites were selected as DIAPHRAGM recruiting centres. An 
additional 11 hospital sites (not including the 4 WoS centres) were approached 
directly by the TMG to participate in DIAPHRAGM. The mean time taken to open 
a recruiting centre was 22 (SD 11) weeks. Site set up was completed in a 
significantly shorter period of time in the Wos centres in comparison to the non-
WoS centres (median 81 days versus 154 days, p=0.0029). Projected recruitment 
numbers per site ranged between 2 – 75 patients, see Table 2.5.  
2.4.2 Patient recruitment  
Median time from site opening to recruitment of the first study participant was 
31.5 (IQR 11.5 – 66.5) days. 26% (n=5) centres achieved their initial projected 
recruitment target, with WoS centres recruiting 125% of their original projected 
recruitment and University Hospital of South Manchester achieving 124% of their 
original projected recruitment. The remaining centres achieved between 10 – 
67.5% of their recruitment target, see Table 2.6. The overall rate of recruitment 
to the SPM and AEC cohort is summarised in Figure 2.4 and Figure 2.5 
respectively. 
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Table 2.5 DIAPHRAGM recruiting centres and initial projected recruitment numbers provided by each site Principal Investigator 
 
     
Recruiting Centre Opening process initiated 
Opened for 
recruitment  
Initial projected total 
recruitment   
Glasgow Royal Infirmary, Glasgow 11/10/2013 31/12/2013 75  
Gartnavel General Hospital, Glasgow 11/10/2013 31/12/2013 75  
Southern General Hospital, Glasgow 11/10/2013 31/12/2013 75  
Victoria Infirmary, Glasgow 11/10/2013 31/12/2013 75  
Aberdeen Royal Infirmary, Aberdeen 20/12/2013 23/05/2014 30  
Southmead Hospital, Bristol 20/12/2013 18/06/2014 50  
St. James’s University Hospital, Leeds 28/02/2014 03/07/2014 50  
University Hospital Galway, Galway 20/12/2013 22/09/2014 40  
Northern General Hospital, Sheffield 20/12/2013 17/10/2014 10  
Glenfield Hospital, Leicester 28/05/2014 19/01/2015 20  
Basildon University Hospital, Basildon 17/09/2014 19/01/2015 10  
Royal Preston Hospital, Lancashire 17/09/2014 16/03/2015 30  
Royal Gwent Hospital, Newport 17/09/2014 08/04/2015 30  
Forth Valley Royal Hospital, Larbert 23/04/2014 22/04/2015 40  
Royal Alexandra Hospital, Paisley 20/01/2015 21/05/2015 30  
Inverclyde Royal Hospital, Greenock 20/01/2015 21/05/2015 40  
Aintree University Hospital, Liverpool 08/04/2015 03/06/2015 5  
Huddersfield Royal Infirmary, Huddersfield 04/02/2015 10/06/2015 5  
University Hospital South Manchester, Manchester 24/02/2015 10/06/2015 50  
Kings Mill Hospital, Sutton-in-Ashfield 09/04/2015 22/07/2015 10  
John Radcliffe Hospital, Oxford 17/11/2015 19/04/2016 15  
Derriford Hospital, Plymouth 23/03/2016 12/10/2016 2  
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Figure 2.4 Summary of recruitment to the Suspected Pleural Malignancy (SPM) 
cohort of the DIAPHRAGM study 
 
Figure 2.5 Summary of recruitment to the Asbestos-exposed control (AEC) cohort 
of the DIAPHRAGM study 
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Table 2.6 Details of recruitment to the Suspected Pleural Malignancy cohort by site in the 
DIAPHRAGM study 
  
     
Recruiting Centre Initial projected total recruitment  
Actual number of 
patients recruited 
Recruitment target 
achieved  
WoS centres, Glasgow 300 376 Yes  
Aberdeen Royal Infirmary, Aberdeen 30 7 No  
Southmead Hospital, Bristol 50 24 No  
St. James’s University Hospital, Leeds 50 13 No  
University Hospital Galway, Galway 40 20 No  
Northern General Hospital, Sheffield 10 5 No  
Glenfield Hospital, Leicester 20 2 No  
Basildon University Hospital, Basildon 10 8 No  
Royal Preston Hospital, Lancashire 30 2 No  
Royal Gwent Hospital, Newport 30 20 No  
Forth Valley Royal Hospital, Larbert 40 27 No  
Royal Alexandra Hospital, Paisley 30 18 No  
Inverclyde Royal Hospital, Greenock 40 12 No  
Aintree University Hospital, Liverpool 5 20 Yes  
Huddersfield Royal Infirmary, Huddersfield 5 5 Yes  
University Hospital South Manchester, Manchester 50 62 Yes  
Kings Mill Hospital, Sutton-in-Ashfield 10 6 No  
John Radcliffe Hospital, Oxford 15 10 No  
Derriford Hospital, Plymouth 2 2 Yes  
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Patient recruitment - Mesothelioma case accrual 
The mesothelioma rate following 24 months of recruitment was lower than 
initially estimated at 13% (original estimate 20%). The implication of this was 
that the target number of MPM cases (n=120) would not be achieved by planned 
study closure. This was identified by the TMG and a successful application was 
made to the Chief Scientist Office Scotland for a 12-month, no-cost, study 
extension to allow recruitment to complete. Selected centres (Southmead 
Hospital, University Hospital South Manchester and Oxford) were asked to focus 
recruitment efforts on patients requiring local anaesthetic thoracoscopy in an 
effort to enrich the mesothelioma population within the SPM cohort. This is 
because the prevalence of MPM in a population of patients undergoing LAT is 
higher than that of a population undergoing initial diagnostic pleural aspiration, 
as patients with underlying pathology diagnosed at pleural aspiration, e.g. 
secondary pleural malignancy diagnosed at pleural cytology, are removed from 
the cohort, leaving a more concentrated population. Centres were also 
encouraged to submit diagnostic update case report forms for any DIAPHRAGM 
patients who had an updated diagnosis of MPM at the time the diagnosis was 
made rather than waiting until the form was due at 12 months. These measures 
steadily improved the mesothelioma rate from 13% to 23% over the following 12 
months of recruitment (see Figure 2.6). This rate was kept under regular close 
review by the TMG. 
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Figure 2.6 Summary of recruitment of cases of Malignant Pleural Mesothelioma 
(MPM) within the Suspected Pleural Malignancy cohort of the DIAPHRAGM study 
2.4.3 Patient Population  
Suspected pleural malignancy cohort 
1143 patients were screened and 639 patients (107% of target) were recruited to 
the SPM cohort between December 2013 – December 2016. 44% (n=504) of 
screened patients were not recruited. 75% (n=380) were deemed ineligible, 7.5% 
(n=38) declined to participate due to being unhappy with the proposed protocol, 
12.5% (n=63) declined to participate for another reason and 5% (n=23) were not 
given the PIS for another reason (see Figure 2.7). 
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Figure 2.7 Study flowchart summarising recruitment to the Suspected Pleural 
Malignancy (SPM) cohort of the DIAPHRAGM study 
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Data cleaning is currently in the final stages of completion by the CRUK Clinical 
Trials Unit Glasgow, the following results are therefore preliminary. Of the 639 
patients recruited to the SPM cohort, mean age was 72 (SD 10) years, 75% 
(n=478) were male, 70% were current or ex-smokers and 56% (n=361) were 
asbestos-exposed. 28% (n=179) had a previous or current history of malignancy. 
85% (n=540) presented with breathlessness, 27% (n=171) with chest pain and 42% 
(n=270) as an acute admission. 
The preliminary results of final diagnoses of the SPM cohort are summarised in 
table 2.7. 165/639 (26%) of SPM patients had MPM and 209/639 (33%) had 
secondary pleural malignancy. 218/639 (34%) had benign pleural disease. 
Confirmation of final diagnosis is awaited in 47/639 (7%) at the time of writing.  
Provisional clinical staging data was available in 160/165 (97%) of MPM cases at 
the time of writing. Stage distribution for these patients was: I (32.5%, n=52), II 
(10%, n=16), III (38.75%, n=62) and IV (18.75%, n=30).
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Table 2.7 Preliminary results of final pleural diagnoses for patients recruited to the SPM cohort of the DIAPHRAGM study. Final diagnosis 
is awaited in 47/639 (7%). 
Pleural Malignancy (n=374, 59%) Benign Disease (n=218, 34%)   
Mesothelioma (n=165, 44%) BAPE (n=71, 33%)   
  Epithelioid (n=91, 55.2%) Parapneumonic effusion (n=20, 9%)   
  Sarcomatoid (n=20, 12%) Chronic empyema (n=7, 3%)   
  Biphasic (n=18, 11%) Reactive assoc. with Lung Cancer (n=11, 5%)   
  Desmoplastic (n=2, 1.2%) Fibrothorax/Haemothorax (n=9, 4%)   
  Lymphohistiocytoid (n=1, 0.6%) Heart failure (n=35, 16%)   
  Mesothelioma NOS/subtype TBC (n=33, 20%) Tuberculous Pleurisy (n=8, 4%)   
  Pulmonary Thromboembolism (n=4, 2%)   
Secondary Malignancies (n=209, 56%) Drug-related (n=2, 1%)   
  Lung Cancer (n=109, 52%) Post-cardiothoracic surgery (n=4, 2%)   
  Breast Cancer (n=17, 8%) Rheumatoid pleurisy/Inflammatory serositis (n=9, 4%)   
  Gastrointestinal cancer (n=15, 7%) Renal failure (n=3, 1%)   
  Haematological Cancer (n=15, 7%) Hepatic hydrothorax (n=4, 2%)   
  Gynaecological cancer (n=9, 4%) Other (n=6, 3%)   
  Renal (n=9, 4.5%) Benign effusion, cause unclear (n=25, 11%)   
  Other (n=8, 4%)     
  Adenocarcinoma, primary TBC (n=10, 5%)     
  Squamous cell carcinoma, primary TBC (n=4, 2%)     
  Adenosquamous carcinoma, primary TBC (n=1, 0.5%)        
  Unknown primary (n=12, 6%)     
BAPE; Benign Asbestos-related Pleural Effusion, TBC; to be 
confirmed           
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Asbestos-exposed control cohort 
113 asbestos-exposed control subjects were recruited (104% of target). 2 
patients were withdrawn after study registration due to concern and subsequent 
confirmation of the presence of pleural effusion at the initial study visit. A 
further 2 patient’s samples were mislabelled and therefore also withdrawn, see 
Figure 2.8. 15% (n=16) were recruited via the CAA database and 85% (n=93) were 
recruited from respiratory out-patient clinics.  
Mean age was 71 (SD 6) years and 94% (n=102) were male. 37% (n=40) had 
occupational exposure to asbestos via working in shipyards, reflecting the 
historic shipbuilding industry along the River Clyde in Glasgow. The remainder 
were exposed to asbestos through work in the maintenance industry (42%), e.g. 
electrician, joiner, plumbing, painter and decorator, insulation or heating 
engineer, boilermaker; construction work (6%); asbestos stripping (2%); the 
motoring industry (4%) or the merchant navy (3%). 6% (n=6) were exposed to 
asbestos indirectly via their father or spouse.        
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Figure 2.8 Study flowchart summarising recruitment to the Asbestos-exposed 
Control (AEC) cohort of the DIAPHRAGM study
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Cross-sectional MRI sub-study cohort 
Patients recruited to the MRI sub-study are described in detail in Chapter 3: 
Early Contrast Enhancement. 
2.4.4 Fibulin-3 validation  
2.4.4.1 Standard Curve 
The standard curve failed on two occasions (see Figure 2.9). On one occasion, 
the back calculated concentrations were too low (plate 6) and on the other 
there was a failure across all the whole plate, resulting in no interpretable 
values (plate 9). In all other occasions, the standard curve met acceptance 
criteria outlined in section 2.3.11.2. 
 
Figure 2.9 Standard curves measuring Fibulin-3 levels across 9 plates 
2.4.4.2 Positive Control Samples 
The serum-free conditioned medium from all three mesothelioma cell lines HP1, 
H2595 and H226 all had consistently measurable Fibulin-3 levels, see Table 2.8
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Table 2.8 Fibulin-3 levels measured in conditioned medium collected from three 
different Mesothelioma cell lines 
Cell	line	
Mean	Fibulin-3	result	
(ng/ml)	
SD																						
(ng/ml)	
	
 
HP1		 		 		 	
				Undiluted	 171.392	 10.916	 	
				1:1	dilution	 166.224	 20.046	 	
				1:4	dilution	 131.918	 26.217	 	
H2595	 		 		 	
				Undiluted	 161.475	 45.238	 	
				1:1	dilution	 136.63	 29.712	 	
				1:4	dilution	 63.042	 10.154	 	
H226	 		 		 	
				Undiluted	 148.744	 30.146	 	
				1:1	dilution	 99.4	 1.156	 	
				1:4	dilution	 45.234	 3.057	 	
    
SD;	Standard	Deviation	 	  
 
2.4.4.3 Negative Control Samples   
The serum-free conditioned medium from the benign mesothelial cell line LP9 
and from the Phosphate Buffered Solution had consistently low Fibulin-3 levels, 
see Table 2.9. 
Table 2.9 Fibulin-3 levels measured in conditioned medium collected from 
benign mesothelial cell line (LP9), Phosphate Buffered Solution (PBS) and 
distilled water (H2O) 
Cell	line	
Mean	Fibulin-3	result	
(ng/ml)	
SD																						
(ng/ml)	
LP9	 		 		
				Undiluted	 4.689	 1.226	
				1:1	dilution	 1.78	 0.365	
				1:4	dilution	 0.641	 0.554	
PBS	 0.025	 0.01	
H2O	 0.013	 0.008	
SD;	Standard	Deviation	 	
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2.5  DISCUSSION 
2.5.1 Study Design 
DIAPHRAGM was a multi-centre study assessing the diagnostic and prognostic 
performance of two blood biomarkers, SOMAscan™ and Fibulin-3, recruiting 
patients with suspected pleural malignancy at time of presentation to secondary 
care centres. The prospective nature and overall study design was such that 
blood biomarker draw in the study replicates when these biomarkers would be 
drawn in clinical practice if they prove to have clinical utility and ensured that 
blood biomarker sampling and processing was consistent. In addition, body mass 
index, renal function, concomitant drugs and the effect of diagnostic pleural 
aspiration were all recorded, allowing the effect of these potential confounders 
to be established. 
Furthermore, patients were recruited from a mixture of district general 
hospitals, central teaching hospitals and tertiary referral centres, making the 
results more generalisable to the overall MPM population. Additionally, eligibility 
criteria were selected to maximise the potential participant population and 
provide a representative population encountered in normal clinical practice. 
Asbestos-related pleural plaques were not included as an inclusion criterion 
since these are absent in up to 25% of MPM cases, (46) and are also common in 
asbestos-exposed populations without MPM. (47) Patients with lung nodules or 
other visceral mass lesions were not excluded, assuming that pleural malignancy 
was suspected. This was because of the high prevalence of lung nodules in the 
target population (older patients, commonly smokers) and the high false positive 
rate of CT imaging in this regard.  
2.5.2  Challenges of recruiting in a multi-centre study 
DIAPHRAGM achieved 109% target recruitment to the SPM cohort and 104% target 
recruitment to the AEC cohort, but required a study extension period of 12 
months.  Successful recruitment of the target number of study participants was 
essential for the study to have valid and reliable outcomes. A multi-centre trial 
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design, involving tertiary specialist centres in addition to more general 
secondary care centres, as was the case in this study, increases the likelihood 
that results are reflective of the general population. Additionally, it allows for a 
wider population of potential study participants therefore increasing the 
likelihood that recruitment targets will be achieved more timeously. However, 
recruiting participants in a multi-centre study can be challenging and 
investigators often overestimate the pool of eligible participants (a factor 
sometimes referred to as Lasagna’s Law).(260) This is highlighted by the 
frequent finding of under-recruitment in many multi-centre clinical trials. In a 
study of 114 multicentre RCTs, McDonald et al reported that only 31% reached 
their original recruitment target, 34% revised recruitment targets (86% of which 
resulted in a lower target) and 53% of trials required a study extension. (261) 20% 
of trials included in this study were in the clinical area of cancer and 53% were 
in a hospital setting. More recently, in an updated review of multicentre 
randomised controlled trials, including 73 studies, of which 5% were in the 
clinical area of cancer and 40% were in a hospital setting, Sully et al reported 
55% of trials achieved target recruitment, with 47% requiring a study extension. 
(262)    
In the current study, time from site set up initiation to site opening for patient 
recruitment ranged from 56 days to 364 days (mean 157 (SD 80) days). Site set 
up was completed in a significantly shorter period of time in WoS centres, which 
were local to the TMG. The time taken from a site opening for recruitment to 
their first patient being recruited ranged from 0 days to 208 days (median 31 
days). Delays to recruitment commencement are not uncommon in multi-centre 
trials (reported to be occur in up to 41% of trials) and can result from a number 
of reasons including ethics, central and local trial procedures, such as Research 
and Development (R&D) approvals, contracts and paperwork completion. (261) 
Many members of the trials team in WoS centres were also members of the 
central TMG, including the chief investigator, and this may explain the more 
rapid site set up time in these centres.  
Additional challenges in multi-centre studies include competing studies, as many 
centres will be recruiting to several trials that the same cohort of patients may 
be eligible for; local staffing issues, such as staff shortages or changes and 
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differing clinical practices between centres. (261) The DIAPHRAGM study 
protocol aimed to address the issue of slightly differing clinical 
practices/pathways between centres by having some flexibility around the 
patient recruitment time-frame. Some centres will perform a diagnostic pleural 
aspiration at the initial clinic visit, in contrast other centres, who arrange for 
the patient to return for a diagnostic pleural aspiration at a later date. The 
study protocol allowed for patients to be recruited as long as they had sufficient 
time to consider the patient information sheet, with no requirement for a 
minimum period of 24 hours for consideration, as is required in many studies. 
This allowed patient recruitment at the initial clinic visit if required. 
Additionally, patients could be recruited after initial diagnostic pleural 
aspiration, which therefore also allowed tertiary centres, who were referred 
patients from other hospitals for further investigation such as thoracoscopy 
following an initial non-diagnostic pleural aspiration, to recruit these patients if 
eligible. The requirement for a follow-up study blood draw to be performed 3 
months after diagnosis in patients with MPM did however result in some eligible 
patients not being recruited at these tertiary centres, as follow-up was planned 
at the patient’s local secondary care hospital. This highlights the importance of 
close communication with centres who are likely to be a study recruiting centre 
when constructing a study protocol so that local clinical pathways and practices 
can be considered and addressed if possible.  
2.5.3 Challenges of recruiting a suspected pleural malignancy cohort 
Recruitment of a cohort of patients with suspected malignancy, who are often 
symptomatic with breathlessness or fatigue presents an additional challenge. 
Accrual to adult cancer trials has been reported to be as low as 5%, depending 
on the cancer primary and the treatment centre. (263) 639/763 (84%) of patients 
eligible for the SPM cohort in DIAPHRAGM were enrolled. Reasons for non-
participation of eligible patients in the study included lack of interest in the 
study, feeling too unwell to participate and feeling overwhelmed with 
information at the clinic visit. The proportion of eligible patients recruited in 
this study is superior to accrual described by Cooley et al, who recruited 230 
patients with lung cancer to a cross-sectional quality of life study, which was 
63% of all eligible patients. (264) Similar to that described herein, the most 
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common reasons provided when declining consent in this study included health 
limitations and lack of interest. Jenkins et al studied 240 patients with cancer 
eligible to participate in an RCT, assessing study participation and reasons for 
non-participation via a postal questionnaire. They reported a 72% acceptance 
rate for trial participation with the most common reasons for non-participation 
principally being associated with concerns regarding the randomisation process 
or not wanting to be randomised. (263) DIAPHRAGM was not a treatment 
intervention trial, nor did it require the need for randomisation, which is an 
additional likely reason for the higher rate of accrual in this study.   
LeBlanc et al have previously described barriers to patient recruitment to 
palliative care trials including patient factors, such as frailty, limited life 
expectancy, competing demands, not being interested in the trial, fatigue and 
the reminder of impending death. Additional barriers include patient burden 
when patients are in multiple studies and clinician gatekeeping, where the 
patients’ clinicians assume that clinical research would be too burdensome or 
upsetting to the patient. (265,266) While these barriers may be more prominent 
in recruitment of palliative patients, particularly to intervention trials, they 
undoubtedly also factor in recruiting patients with suspected cancer to studies 
such as DIAPHRAGM, particularly where initial invitation often coincided with 
initial presentation with suspected pleural malignancy. Gate-keeping can be a 
particularly difficult barrier in this context, as was experienced in the 
DIAPHRAGM study, where some clinicians were either hesitant to discuss a 
potential diagnosis of pleural malignancy early at presentation, or felt that 
providing additional study information would be too burdensome for patients at 
such an uncertain time in their diagnostic journey. The relationship between the 
clinician and the patient, including the degree of trust, and the communication 
of study information when first approaching a potential study participant is of 
paramount importance to the recruitment process. (267) In several of the 
recruiting centres in DIAPHRAGM, the patient’s clinician was also the local 
principal investigator for the study, with associated advantages of recruiting 
team having an existing patient-clinician relationship in addition to detailed 
knowledge of the study. In the earlier lung cancer study, an additional common 
reason reported for declining to participate was inconvenience. (264) Cox et al 
also describe the burden of trial participation on the patient in terms of time, 
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travel, interference with other commitments and discomfort from medical 
procedures as being important barriers to trial participation. (267) This was not 
observed frequently in the DIAPHRAGM study, perhaps due to the deliberate co-
ordination of study procedures with clinical visits, the short duration of study 
participation (a single visit) and the relatively low medical intervention burden 
of a single blood draw for the majority of patients. This may have resulted in the 
higher proportion of eligible patients recruited in our study.   
2.5.4 Strategies to improve study recruitment 
In a systematic review of 45 randomised controlled trials, Treweek et al 
described six principal categories of intervention adopted for trial recruitment: 
trial design (e.g. open versus blinded), obtaining consent, approaching 
participants, financial incentives, training for recruiters and trial co-ordination. 
(268) Interventions focused on consenting study participants included use of an 
‘opt-out’ approach, where all potential participants are approached as opposed 
to an ‘opt-in’ approach, where potential participants have to agree to be 
approached by the study team before being screened for eligibility. Sygna et al 
similarly described improved recruitment when adopting an opt-out approach in 
a randomised controlled trial recruiting cancer patients. (269) In the DIAPHRAGM 
study, the opt-out approaches included on-site screening and approaching all 
potentially eligible in-patients or patients attending clinic, with patients having 
the option to decline after a brief introduction to the study by the research 
team. Telephone or SMS message reminders as a follow-up to written invitation 
has also been found to improve trial recruitment. (268) In addition, face-to-face 
eligibility screening was found to increase recruitment, as was adopted in the 
DIAPHRAGM study for both SPM and AEC cohorts. The systematic review found 
conflicting results for the effect of additional education for recruiters on study 
recruitment, but consistent findings regarding little effect on recruitment for 
centres receiving on-site trial initiation visits versus none. (268) Concordantly, In 
the DIAPHRAGM study, there was no significant difference in study recruitment 
between centres who received a face-to-face site initiation visit and training 
versus those who received site initiation documentation and training via e-mail 
correspondence only. However, all sites did receive trial newsletters, which 
included individual feedback on recruitment progress and tips for successful 
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study recruitment from the trial management group. Personalised site feedback 
on recruitment has previously been reported to be an effective intervention in 
reducing time to meet recruitment targets in one randomised controlled trial 
(RCT), although this was not statistically significant. (270) Additionally, 
DIAPHRAGM was managed centrally by the CRUK Clinical Trials Unit Glasgow, 
who co-ordinated site set-up, answered queries from individual recruiting sites, 
confirmed participant eligibility, produced trial newsletters and provided 
updates to the CRUK trials website and the Mesothelioma UK newsletter. Sully et 
al reported that trials with CTU input appeared more likely to achieve successful 
recruitment (65% versus 48% for trials without CTU input, although this did not 
reach statistical significance). (262)  
 
Strategies adopted in the DIAPHRAGM study to maximise successful recruitment 
in the WoS centres included having a myself as a dedicated recruitment co-
ordinator for these sites and providing clinical teams with a pleural fluid 
aspiration service to incentivise clinicians to alert the research team of potential 
participants. Broad and simple eligibility criteria, resulting in 67% of screened 
patients being eligible, and reminder posters printed at each site also facilitated 
clinicians’ referral to the research team. Furthermore, pre-screening using the 
electronic Trakcare® system done by myself ensured that potentially eligible 
participants were not missed by clinical teams. I also regularly visited in-patient 
respiratory and acute medical receiving wards to identify potential participants.  
 
Similar strategies to improve recruitment have previously been identified as 
being commonly implemented in numerous multi-centre trials. (261) These 
strategies were also adopted in the earlier palliative care trial by LeBlanc et al, 
who had broad eligibility criteria, resulting in 79% of screened patients being 
eligible, and a dedicated recruitment nurse who relieved clinical nurses of the 
burden of identifying potential participants. (265) Coinciding study recruitment 
with a clinical visit, i.e. when the patient attended for their initial diagnostic 
pleural aspiration, was a further strategy adopted to facilitate recruitment. This 
was adopted to minimise the number of hospital visits, and therefore burden, for 
patients. Aligning study protocols with standard clinical practice and minimising 
burden on participants have both been recommended as potential strategies to 
improve study recruitment. (271)   
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For the asbestos-exposed control cohort, invitation letters were sent via 
Clydeside Action on Asbestos (CAA). Invitation via CAA was thought to be a 
useful source of potential study participants as the members included in their 
database were likely to be motivated (having independently approached CAA in 
the first instance) and have a definite history of asbestos exposure. However, 
recruitment via CAA was not as successful as initially anticipated, with only 
small numbers responding to the initial invitation letter and subsequently 
recruited (n=16). Personalised invitation letters, telephone reminders to non-
responders and financial incentives included with the trial invitation are all 
strategies which might have improved recruitment in this context, based on 
previously reported evidence. (268,272) However, adopting these strategies was 
not possible in the DIAPHRAGM study, as the CAA member database remained 
strictly confidential to the study team and CAA were unable to provide staffing 
resource for telephone reminders. Furthermore, study funding was limited, 
prohibiting the provision of financial incentive for potential study participants. 
However, reimbursement for travel costs or provision of transportation to the 
study centre was provided in order to minimise study participant burden. A 
significant improvement in the rate of recruitment to the asbestos-exposed 
control group was demonstrated when a protocol amendment allowed for 
patients attending respiratory out-patient clinics to be screened for the study. 
This is likely to be due to a combination of reduced patient burden, with 
potential participants no longer having to contact the study team independently 
to enquire about the study; consenting and completing study procedures on the 
same visit as the patient’s clinic attendance and the advantage of the clinician-
patient relationship, as discussed previously.  
 
2.5.5 Use of electronic health records for screening 
As a member of the clinical team, in addition to being responsible for 
recruitment in WoS centres, I was able to utilise the electronic health record 
(EHR) system (Trakcare®) to pre-screen potential participants attending 
respiratory outpatient clinics. The advantages of having access and utilising EHR 
to facilitate recruitment to clinical studies are well recognised. (273,274) These 
include the ability to efficiently pre-screen participants remotely, avoiding 
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unnecessary attendance at clinics or wards to recruit patients where there may 
not be any patients who are eligible and potentially reducing the number of 
potentially eligible participants who are missed by the recruiting team. As 
utilised in DIAPHRAGM, several previous studies have utilised EHR to identify 
potentially eligible participants. (275-277) Other trials have utilised EHR with an 
automated clinical trial alert system to prompt clinicians that their patient may 
be eligible for a clinical trial if eligibility criteria are met, with the option of 
subsequently alerting the trials team. This system has previously been reported 
to increase clinician referral rates and study enrolment. (278)   EHR can also be 
used as source data in clinical studies, as they typically include basic 
demographic data in addition to detail on co-morbidities and concomitant 
medications. (274) Clearly care must be taken in confirming accuracy of data 
identified in EHR with the study participant.  
Prior consent is often required for research teams to access clinical records, 
reducing the utility of using EHR for identifying potential participants in 
prospective clinical trials. (275) One advantage of the DIAPHRAGM study is that 
clinical teams were responsible for identifying and recruiting patients, allowing 
utilisation of EHR. Having inclusion criteria that were easily identifiable on EHR 
was an additional advantage in this study.  
2.5.6 Review of preliminary results 
The results reported herein summarises patient recruitment and preliminary 
demographic data of the study participants prior to completion of the data 
cleaning process. Biomarker analyses are in progress and these results are not 
yet available.  
Suspected Pleural Malignancy Cohort 
The mean age of patients in the SPM cohort was 72 years and 75% were male, 
this is similar to the age and sex distribution of patients included in the National 
Lung Cancer Audit pleural mesothelioma report 2016 (median age 75 years and 
83.4% male). (279) The majority of patients presented with chest pain and/or 
breathlessness, which is in keeping with previous reports of presenting symptoms 
in MPM. (39)  
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Final diagnoses were available for 93% (n=592) of the SPM cohort at the time of 
writing. The prevalence of PM in this study was 59%. Of the patients with a final 
diagnosis of PM, the primary cancer was MPM in 44%, lung in 29%, breast in 5%, 
gynaecological in 2%, gastrointestinal in 4%, haematological in 4%, renal in 2%. 
The remaining primaries were either unknown or awaiting confirmation from the 
local site. The British Thoracic Society (BTS) pleural disease guidelines, 
summarising 5 different studies incorporating 2040 patients with malignant 
pleural effusion, report lung and breast cancer to be the most common primary 
tumour sites in patients with malignant pleural effusion (approximately 37.5% 
and 17% respectively). (280) Haematological, gastrointestinal, genitourinary, 
‘other primary’ and unknown primary accounted for the remaining 11.5%, 7%, 
9%, 8% and 11% of malignant pleural effusions respectively. (280) This 
distribution of secondary pleural malignancies is similar to that reported in the 
DIAPHRAGM study. However, the earlier report was based on historical studies 
(published between 1975 – 1987) and is therefore likely to underestimate the 
prevalence of MPM, as these studies predate the use of local anaesthetic 
thoracoscopy and diagnoses were therefore predominantly based on cytological 
examination of pleural fluid samples. (281) (282) (283) (284,285) Additionally, 
the increasing incidence of MPM in the UK over the past 30 years (279) and the 
targeted recruitment of potential MPM patients referred for thoracoscopy after 
non-diagnostic pleural cytological examination in selected centres is likely to be 
responsible for the higher prevalence of MPM in our study cohort. Concordant 
with this is the higher proportion of MPM patients in the more recent multi-
centre study of MPE by Clive et al, which recruited from centres in the UK, the 
Netherlands and Australia (21.5%), (14) and that reported by Hallifax et al in a 
study of patients referred to a tertiary centre for LA thoracoscopy (54.5%). (82) 
Final staging data was available in 97% of MPM cases at the time of writing of 
this thesis. 68/160 (42.5%) presented with early stage disease (IMIG stage I/II). 
This is higher than that reported by the National Lung Cancer Audit pleural 
mesothelioma report 2016, which reported 17% of patients presenting with stage 
I/II disease. However, the reporting of stage in MPM has historically been poor, 
due to staging being relatively complex and only 42% of cases submitted to the 
audit had stage recorded. (279) Similarly, a recent review of the Western 
Australia Mesothelioma Registry, incorporating 2024 cases of MPM did not report 
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on stage distribution at all, (286) and a retrospective review of 337 MPM patients 
registered in the National Cancer Registry Ireland reported only 45% of patients 
having stage recorded (n=153), of which 33.4% (n=51) had stage I/II disease. 
(287) Another retrospective review of 101 patients diagnosed or referred for 
treatment at a single Dutch institution (Antwerp University Hospital) reported 
39% of patients had stage I/II disease (only 2/101 patients did not have stage 
recorded in this study). (288)   
2.5.7 Fibulin-3 Validation 
As previously discussed in Chapter 1: Introduction, there was significant 
variability in the both the reported diagnostic performance of Fibulin-3 
(sensitivity varying between 12.7% and 100%) and the reported levels measured 
in blood (mean levels ranging from 11.51ng/ml to 112.9ng/ml). (151,247,250-
253) While varying study design, incorporating variable sampling time-points 
could be one explanation for this variability, the validity and performance of the 
Fibulin-3 assay itself must also be considered. Pre-validation testing by the TPL 
highlighted concerns regarding assay consistency. In addition, the volume of 
positive control sample provided by the assay manufacturer was insufficient to 
complete assay validation testing. We therefore needed to source alternative 
positive controls to use as quality control samples, as described herein. 
Furthermore, at the time of writing further inconsistencies related to antibody 
printing on several of the 96-well plates in the FBLN3 kit have been reported by 
the Translational Pharmacology Laboratory. Exploration and testing of 
alternative Fibulin-3 assay kits are therefore in progress.  
2.6  CONCLUSION 
DIAPHRAGM was an adequately-powered, multi-centre study that successfully 
achieved target recruitment of patients to a suspected pleural malignancy 
cohort and asbestos-exposed control cohort. It represents the largest 
prospective biomarker study in MPM to date, recruiting over 700 patients, 
including over 160 patients with Malignant Pleural Mesotheloma. The prospective 
nature, study design and Fibulin-3 assay validation will allow the diagnostic 
performance of Fibulin-3, SomaSCAN™ and Mesothelin in Malignant Pleural 
Meosthelioma to be clearly defined. At the time of writing, Mesothelin assays are 
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complete for all baseline samples. SOMALogic® have measured 11 of the original 
13 proteins included in the original SOMAscan™ assay in all baseline MPM cases, 
83 non-MPM effusion cases and 83 AEC cases. Fibulin-3 assays are complete for 
approximately half of the baseline samples. Data cleaning is currently in its final 
stages and analysis of available biomarker results is due to commence shortly.
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3 Chapter 3: Early Contrast Enhancement (ECE)  
3.1 INTRODUCTION 
Clinically overt pleural metastases are associated with a median survival of only 
3 months in patients with Lung Cancer (14). In patients with macro-nodular 
pleural tumour this is easy to detect, with sensitivity and specificity exceeding 
90% in previous studies using Computed Tomography (CT) (77,289) and Magnetic 
Resonance Imaging (MRI). (77,99) Simple pleural effusion is, however, 
detectable in 25% of Lung Cancer patients at presentation, and affects 40% at 
some time during their journey. (15) This is associated with a significant survival 
disadvantage, even if the effusion is too small to safely aspirate, or pleural 
cytology appears reassuring. (15,290) This suggests that occult pleural 
metastases are present in at least a proportion of these patients. Unfortunately 
it is difficult to define, using existing techniques, which patients should be 
directed to thoracoscopic sampling as part of Lung Cancer staging. Subjective 
cross-sectional imaging, using CT or MRI, is poorly suited to the detection of 
typically sessile pleural tumours, distributed heterogeneously over a large 
surface area. This makes it impossible to reliably distinguish between low-
volume pleural metastases and a benign reactive effusion (e.g. due to lobar 
collapse). 
Similar challenges are encountered when assessing asbestos-exposed patients 
with a new pleural effusion, where the principal differential lies between Benign 
Asbestos-related Pleural Effusion (BAPE) and early-stage Malignant Pleural 
Mesothelioma (MPM). Misdiagnosis at this stage probably contributes to rates of 
emergency MPM presentation, via recurrent symptomatic pleural effusion, which 
exceed 50% in parts of the UK (43,291). This is associated with adverse survival 
(43,291), and limits opportunity for enrolment in clinical trials, which may 
ultimately improve MPM outcomes.  
These diagnostic difficulties are reflected in the poor diagnostic sensitivity 
(between 58% - 68%) of CT for detecting pleural malignancy in routine clinical 
practice. (82,83) As previously discussed, LAT is extremely sensitive, but cannot 
be performed in all patients and centres, and is still an invasive test. (71) 
Therefore, a novel, non-invasive method of selecting patients for invasive 
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sampling is urgently required. This should ideally be objective and sensitive, 
even in patients with subtle or absent morphologic features of malignancy, as is 
frequently the case, particularly in early stage MPM.   
3.1.1 Tumour Angiogenesis 
Tumour angiogenesis describes the formation of new blood vessels, which is 
necessary for tumour cell population expansion and tumour growth beyond 1 – 
2mm in diameter (292) and metastatic spread. (293) Increased microvessel 
density, a surrogate marker of tumour angiogenesis, has been shown to be 
associated with poorer patient outcomes in numerous cancers including breast 
(294,295), prostate (296), lung (297) and MPM. (37,298,299) The timing of 
tumour angiogenesis varies between tumour type, (300) but can occur early in 
tumour development in several cancers (301-303), including breast (304), 
bladder (305) and lung cancer. (306) 
3.1.2  Imaging of Angiogenesis 
There are several imaging techniques that can be used to assess angiogenesis, 
including number and spacing of blood vessels, blood volume, blood flow and 
vascular permeability (307), with resulting potential clinical utility in the non-
invasive diagnostic assessment of malignancy and in the assessment of response 
to anti-angiogenic therapies. These include DCE-MRI, PET, ultrasound, CT and 
single photon emission computed tomography (SPECT). 
Ultrasound 
Doppler US is readily accessible and allows assessment of the vascular anatomy 
and blood flow through tumour, however this technique is limited to assessment 
of larger vessels rather than intra-tumoural microvessels. The introduction of 
intravascular microbubble-enhanced doppler US allows assessment of vessels and 
blood flow down to 50 - 100µm in diameter. (308,309) This technique is however 
heavily operator-dependent with a limited field of view, does not provide 
information on vascular permeability and is not currently widely used.  
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Perfusion CT 
Perfusion CT (or Dynamic Contrast Enhanced-CT (DCE-CT)) involves the serial 
acquisition of the same volume of tissue over time following the administration 
of intravenous iodinated contrast agent. (310) This imaging technique allows 
assessment of tissue blood flow, blood volume mean transit time and vascular 
permeability. (311) Detection of increased or abnormal tissue perfusion can 
suggest malignancy even prior to the development of gross anatomical 
abnormality detectable morphologically. Previous studies have demonstrated 
potential utility in assessment of pulmonary nodules and MPM. (312-314) 
Perfusion CT has the advantage of widespread availability and there is also a 
direct linear relationship between iodine concentration and enhancement 
(measured in Hounsfield Units). (311) However, the multiplicity of protocols 
using different mathematical models (315) and high radiation burden have 
limited its widespread use in routine clinical practice to date. (110,316) 
PET 
15O-labelled tracers can be used in PET imaging. Inhalation of fixed doses of C15O 
results in biding of C15O to haemoglobin, forming C15O-Hb, which remains within 
the vasculature. 15O PET imaging can therefore be used to detect blood flow and 
vascular volume. (308) However, the tracer has a short half-life and requires 
patient inhalation. The technique is also limited by high cost, limited availability 
of equipment and poor anatomic resolution. (309) 18F-Fluciclatide is a novel PET 
tracer targeting integrins αvβ3 and αvβ5, currently being examined in imaging 
research in tumours such as breast cancer. (98) Integrins are a family of cell-
extracellular matrix adhesion molecules. Integrin αvβ3 in particular is known to 
play a key role in angiogenesis and expression of αvβ3 and αvβ5 is increased in 
activated tumour-associated endothelial cells. (317) (318)       
Dynamic contrast-enhanced MRI (DCE-MRI) 
MRI allows acquisition of high-fidelity anatomical and biological data in multiple 
phases of contrast enhancement, without use of ionizing radiation, making it an 
attractive research imaging tool. DCE-MRI is an MRI technique that can exploit 
the characteristic feature of high permeability of immature new vessels within 
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tumour. (319) Due to high vascular permeability, MRI contrast agents (most 
frequently a low-molecular weight Gadolinium chelate) demonstrate rapid 
‘wash-in’ and ‘wash-out’ as it passes through tumour vessels on T1-weighted 
imaging. The differential pattern of ‘wash-in’ and ‘wash-out’ can be 
mathematically fit into compartment models to produce estimates of tissue 
perfusion and permeability.  (319) 
DCE-MRI has been widely used in clinical trials to assess early response to anti-
angiogenic chemotherapeutic agents. As previously highlighted in Chapter 1, 
DCE-MRI involves the administration of an intravenous contrast agent, typically 
of low molecular weight such as gadolinium, followed by rapid image acquisition 
to allow temporal imaging of signal intensity changes within a volume of 
(tumour) tissue. Signal intensity changes result from changes in contrast 
concentration in the extravascular and extracellular space, which depends on 
tumour perfusion, tumour vascularity, tumour vascular permeability and the 
fractional volume of the extravascular and extracellular space. (308,309,320) 
Unlike perfusion CT, where the relationship between enhancement is directly 
linear to the concentration of iodine contrast within the tissue, signal intensity 
at T1-weighted DCE-MRI is also dependent on the native T1 relaxation rate of 
the tissue. (309) Acquisition of DCE-MRI data therefore requires sequences that 
allow for anatomic localisation of tumour followed by sequences that allow for 
calculation of the baseline T1 of the tissue before acquiring dynamic data post-
contrast. (320) DCE-MRI has previously been used as a diagnostic imaging 
biomarker in the evaluation of breast mass lesions, being able to differentiate 
benign from malignant breast masses. (113) Previous studies have demonstrated 
that assessment of contrast kinetics at DCE-MRI results in improved specificity of 
differentiation between benign and malignant breast masses over conventional 
MR imaging with morphological assessment. (112) A systematic review of studies 
assessing breast lesions using MRI found that DCE-MRI had an overall sensitivity 
of 82% and specificity of 74% for the detection of breast malignancy. (321) This 
improved to a sensitivity of 95% and specificity of 86% when morphologic data 
was combined with perfusion data obtained at DCE-MRI. (321)  
DCE-MRI has also been shown to be of diagnostic utility in the assessment of 
prostate lesions, (116) with differing contrast kinetic parameters allowing 
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differentiation between benign and malignant prostate lesions. (322,323) Similar 
to the early contrast enhancement pattern of pleural malignancy reported here, 
previous authors have demonstrated an initial increase in contrast enhancement 
followed by a decrease being typical of a malignant prostate lesion. (324) DCE-
MRI has also been used as a predictive biomarker of response to anti-angiogenic 
chemotherapeutic agents such as bevacizumab in a number of cancers, including 
mesothelioma, (117) lung cancer (325), glioma (326) and breast cancer. (327)  
However, as discussed previously, DCE-MRI requires a mass lesion to define an 
adequate Region of Interest (ROI), and image acquisition is limited to a 
relatively small number of slices so the entire hemithorax, and therefore pleura, 
cannot be assessed. This limits its clinical utility in the early detection of MPM, 
which typically has a sessile, heterogeneous growth pattern and rarely presents 
as a mass lesion in early stage disease. Giesel et al performed DCE-MRI in 19 
patients with confirmed MPM and reported different contrast kinetic parameters 
between tumour tissue and normal tissue, (117) however, 10/19 (53%) of these 
patients had bulky stage IV disease, which adds little value over morphological 
assessment. 
This chapter describes a novel MR imaging biomarker of pleural malignancy, 
Early Contrast Enhancement (ECE), which can be applied to patients with pleural 
effusion and minimal pleural thickening. 
3.2  AIM AND OBJECTIVES 
The aim of this study was to define a contrast-enhanced MR imaging method to 
detect pleural malignancy with high diagnostic sensitivity and specificity, 
exploiting pathognomonic, non-anatomical features of pleural malignancy that 
would be present in all patients, including those with pleural effusion and 
minimal pleural thickening.  
We hypothesized that MRI methodology targeted to increases in constituent 
blood vessel density, and therefore tumour angiogenesis, could accurately 
identify pleural malignancy, even in early stage disease.   
Study objectives and outcome measures are presented in Table 3.1.  
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Table 3.1 Study Objectives and Outcome Measures of the Early Contrast 
Enhancement Study 
STUDY OBJECTIVE OUTCOME MEASURES 
 
Primary 
 
To determine whether 
perfusion-based, ce-MRI can 
differentiate pleural malignancy 
from benign pleural disease with 
comparable or superior 
sensitivity and specificity to 
subjective CT or MRI morphology 
assessment 
 
 
 
Diagnostic classification based on 
• MRI contrast enhancement pattern  
• CT morphology assessment 
• MRI morphology assessment 
 
Diagnostic assessment including pleural   
biopsy results 
 
Secondary 
 
To determine whether there is a 
correlation between contrast 
enhancement pattern at MRI and 
tumour vascularity 
 
To determine the reproducibility 
of ECE, CT and MRI morphology 
 
 
• Mean Signal Intensity Gradient at ce-MRI 
• Tumour MVD based on Factor VIII 
immunostaining in FFPE pleural biopsies 
 
 
• Inter-observer agreement (Cohen’s Kappa) 
• Intra-observer agreement for ECE only 
(Cohen’s Kappa) 
Exploratory 
 
To determine whether there is 
an association between: 
 
1. ce-MRI parameters and 
Survival 
 
2. Tumour vascularity and 
Survival 
 
 
 
 
 
 
• MSIG at ce-MRI 
• Overall Survival (months) 
 
• Tumour MVD (Factor VIII immunostaining 
in FFPE pleural biopsies) 
• Overall Survival (months) 
 
ce-MRI; Contrast-enhanced Magnetic Resonance Imaging, CT; Computed 
Tomography, ECE; Early Contrast Enhancement, FFPE; Formalin-Fixed Paraffin-
Embedded, MVD; Micro-vessel Density, MSIG; Mean Signal Intensity Gradient  
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3.3  METHODS 
3.3.1 Ethical Approval 
Ethical approval for this study was provided by the West of Scotland Research 
and Ethics Service (reference 12/WS/0219 and 13/WS/0240). NHS Greater 
Glasgow and Clyde acted as the study sponsor. 
3.3.2  Study Population  
Patients included in this chapter were recruited from a pilot study conducted to 
establish MR imaging acquisition and analysis protocols, and as part of the 
DIAPHRAGM MRI sub-study (further details of which are included in chapter 2).  
Patients presenting with suspected pleural malignancy, as defined by a pleural 
effusion or pleural-based mass lesion, to the Southern General Hospital (now the 
Queen Elizabeth University Hospital), Gartnavel General Hospital, Victoria 
Infirmary and Glasgow Royal Infirmary between January 2013 and October 2016 
were invited to participate. Patients were identified at respiratory outpatient 
clinics and in acute admission units or respiratory inpatient wards. All patients 
were reviewed by myself or Dr Kevin Blyth (Consultant Respiratory Physician) 
who reviewed the need for pleural biopsy (either image-guided or 
thoracoscopically), based on clinical need and patient wishes, and their 
eligibility for the study. Eligibility criteria were as follows: 
Inclusion criteria  
• Suspected pleural malignancy requiring investigation by thoracoscopy 
(medical or surgical) or image-guided pleural biopsy 
• Sufficient fitness for pleural biopsy 
• Informed written consent 
Exclusion criteria 
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• Pregnancy 
• Known allergy to gadolinium contrast 
• Significant renal impairment (eGFR <30ml/min) 
• Known MRI contraindication (e.g. cardiac pacemaker, metallic foreign body) 
All patients underwent comprehensive diagnostic assessment for an unexplained 
pleural effusion as described in chapter 1. This included routine blood tests, 
chest radiograph, thoracic ultrasound, pleural fluid analysis and contrast-
enhanced CT imaging, followed by LAT, VATS or image-guided pleural biopsy.  
3.3.3 Clinical Assessment  
Local anaesthetic thoracoscopy 
All patient assessments and procedures were performed by myself and Dr Kevin 
Blyth. Assessment for LAT included a review of appropriateness and fitness for 
LAT as per BTS guidelines, (71) and a repeat thoracic ultrasound to ensure that 
the patient had an accessible pleural space lying in a lateral decubitus position, 
i.e. sufficient pleural fluid volume or if pleural fluid volume was insufficient or 
absent then the presence of normal lung ‘sliding’. Lung sliding on thoracic 
ultrasound describes the normal appearance of the visceral pleura moving 
relative to the parietal pleura and chest wall (328) and is an indication that a 
pneumothorax can be induced at LAT. 
Patients were admitted to the Queen Elizabeth University Hospital the evening 
before or the morning of LAT, with the procedure being performed in the 
afternoon. Patients were given fasting instructions and pre-medication (20mg 
oral morphine solution and 1.2mg oral atropine (if the patient was aged <75 
years and had no contra-indications on 12-lead electrocardiograph)) was given 
approximately 1 hour prior to LAT. LAT was performed in a dedicated endoscopy 
suite (and in a sterile theatre prior to June 2015). The patient was positioned 
appropriately in bed before being attached to 3-lead cardiac monitoring, blood 
pressure monitoring and a pulse oximeter. The procedure was performed under 
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conscious sedation (using intravenous midazolam +/- alfentanil) and strict 
aseptic technique. A repeat thoracic ultrasound was performed with the patient 
on the procedure table in every case. After appropriate infiltration of local 
anaesthetic (1% lidocaine with adrenaline 1:200,000), a pneumothorax was 
induced using a Boutin needle followed by blunt dissection to the pleural space. 
A single 7mm port was then inserted and any residual pleural fluid aspirated. A 
rigid thoracoscope was then inserted via the port to allow thorough inspection of 
the pleural cavity. Biopsies were taken of any obvious tumour affecting the 
costal pleura or in the absence of obvious tumour, multiple biopsies of 
representative costal pleura were taken. Talc poudrage was performed on a 
case-by-case basis before a 24-French intercostal chest drain was inserted and 
secured with sutures. Residual pneumothorax was evacuated using thoracic 
suction before the patient was returned to the ward to convalesce. A post-
procedure chest radiograph was taken and the chest drain removed when 
deemed appropriate (in cases where talc poudrage was not undertaken this was 
generally when the lung was shown to be re-inflated on the chest radiograph). 
Following discharge post-LAT, all patients were followed-up at a dedicated 
specialist pleural clinic.  
Diagnostic Protocol 
Final diagnoses were based on histology results and MDT consensus where 
available. In the event of suspected false negative pleural biopsy in patients 
with suspected MPM, repeat biopsy results were reviewed. A diagnostic review at 
12 months was undertaken in all patients, which included review of any interval 
imaging or repeat biopsy where performed.   
3.3.4  Sample Size and Assumptions 
An a priori sample size calculation was not possible given the novel nature of the 
primary contrast-enhanced MRI outcome measure. A target sample size of 60 was 
deemed to be large enough for these methods to be developed and tested. 
Assuming a 50% incidence of MPM in the study cohort (based on our unit’s MPM 
incidence at LAT), 30 MPM patients would also allow a moderate correlation 
(r=0.5) between the relevant secondary outcome measures to be detected with 
80% power at a 5% two-sided level of statistical significance.  
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3.3.5  Imaging acquisition 
3.3.5.1  Contrast enhanced-CT Acquisition 
Contrast-enhanced CT imaging was acquired prior to pleural biopsy or other 
significant pleural intervention (except pleural aspiration) in all patients.  CT 
examinations were performed in the course of routine clinical work-up at one of 
three Clinical Radiology Departments with expertise in thoracic imaging, using 
standard techniques and were not protocolised. CT scans were acquired on a 
variety of machines (GE Medical Systems BrightSpeed, LightSpeed or Optima 660; 
Toshiba Aquilion). In all patients, multi-slice helical CT images reconstructed 
with a maximum contiguous slice thickness of 2 mm were acquired at baseline 
and following administration of intravenous iodinated contrast material, 
typically 100 ml of 300 mg/ml of Optiray™ (Mallinckrodt Pharmaceuticals, 
Ireland) according to standard local clinical protocols. In 53/58 (91%) patients, 
post-contrast imaging acquisition was in the venous phase, between 60 and 70 
seconds following contrast injection. In 5/58 (9%) patients, post-contrast imaging 
acquisition was in the pulmonary arterial phase (bolus-tracked CTPA).  
3.3.5.2  Pleural MRI Acquisition 
All MRI scans in this thesis were performed by the Glasgow Clinical Research 
Imaging Facility radiographers and myself under their guidance. Scans were 
performed at the BHF Glasgow Cardiovascular Imaging Facility between January 
2013 and August 2015, and at the Queen Elizabeth University Hospital between 
August 2015 and October 2016. Scans were performed using a 3-T Siemens 
Magnetom Verio® (Siemens, Erlangen, Germany) between January 2013 and 
August 2015, and using a 3-T Siemens Magnetom Prisma® (Siemens, Erlangen, 
Germany) between August 2015 and October 2016. Full resuscitation equipment, 
including a defibrillator and emergency drugs were available within close and 
easily accessible proximity to the patient at all times, as was a fully qualified 
Advanced Life Support provider (myself). All patients had pleural MRI performed 
prior to pleural biopsy or other significant pleural intervention (except pleural 
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aspiration). All study participants were provided with access to study 
transportation to and from the MR imaging facility. 
Patient preparation and positioning 
All patients were asked to complete a safety questionnaire before entry into the 
MR scanning room (see Appendix 12). A plain orbital radiograph was taken if 
there was any history of previous injury involving metal fragments with potential 
involvement of the eyes, and reviewed by a consultant radiologist (Dr David 
Stobo) to exclude retained metal fragments. Patients were asked to remove any 
metal clothing or accessories, such as watches or belts, and were provided with 
a patient gown to change in to. A 20 or 22-gauge cannula was inserted into the 
patient’s antecubital fossa, wrist or hand for intravenous contrast 
administration. Patients were then positioned head first and supine on the MR 
examination table and a phased array chest coil placed and secured on their 
chest with straps. They were then supplied with ear plugs and headphones, 
allowing them to hear instructions during the scan and to listen to music in 
between instructions, and an emergency buzzer. After describing breathing 
instructions that would be given throughout the course of the scan acquisition, 
the patient’s bed was moved inside the bore of the magnet. Communication via 
the headphones and the emergency buzzer were both tested prior to initiating 
image acquisition.  
MR Image Acquisition 
Imaging protocols were developed in the first 6 patients, all of whom had non-
contrast-enhanced scans and are not included in the final analyses. Initially, 
images were acquired in three separate axial blocks. This methodology was 
adapted from cardiovascular magnetic resonance imaging protocols performed 
pulmonary hypertension studies previously conducted by Dr Blyth. (329)  
However, the objective of these prior studies was to assess the right ventricle 
rather than the entire thorax, which was required in the present study. The 
three axial blocks acquired in these initial patients needed to be ‘stitched’ 
together, which inevitably resulted in the potential for image overlap and/or 
discontinuity. Additionally, the resulting images were not isotropic and 3-
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dimensional (3D) volumetric assessment was therefore not possible, see Figure 
3.1.  
 
Figure 3.1 Example of a non-contrast enhanced MRI scan, acquired in separate 
axial blocks (Panel A) and their corresponding sagittal (Panel B) and coronal 
(Panel C) images, early in the process of developing imaging protocols for the 
Early Contrast Enhancement study 
A new 3D isotropic imaging protocol was therefore developed by Dr Foster and 
Dr Blyth in the remaining 60 patients (see Figure 3.2). T1-weighted, fat-
saturated, 3D spoiled gradient echo sequences (repetition time 2.8 - 3.23ms, 
echo time 1 - 1.08ms, field of view 400 – 440mm, matrix 224 x 100, flip angle 9°, 
slice thickness 1.8 – 1.9mm, no inter-slice gap), were acquired during a short 
breath-hold at end-inspiration. Number of slices acquired ranged between 104 – 
144 slices (median 120 (IQR 120 – 128). Breath-hold duration varied between 16 – 
22 seconds, depending on the size of the patient’s thorax. If the patient 
reported difficulty with the breath-hold or initial MR images had evidence of 
significant breathing artefact, then slice thickness was increased to reduce the 
breath-hold time. The field of view was adjusted if required to ensure all image 
acquisitions remained isotropic despite any adjustments in slice thickness. All 
Images were acquired isotropically in the coronal plane at baseline and at 
numerous set time points after intravenous gadobutrol contrast (Gadovist (0.1 
mmol/kg), Bayer Healthcare Pharmaceuticals, Berlin, Germany) was 
administered, at an injection rate of 2 ml/second.  
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In the majority of patients (53/60), images were acquired at baseline, 40 
seconds, 80 seconds, 4.5 minutes, 9 minutes and 13.5 minutes after intravenous 
contrast administration. In one patient, there was incomplete contrast 
enhancement, possibly due to contrast extravasation and was therefore 
excluded from further analysis. In 6/60 patients, the 40 second and 80 second 
post-contrast images were omitted and TrueFISP sequences were performed in 
the first 120 seconds post-contrast, as described in previous DCE-MRI studies in 
MPM patients. (117) After review of the contrast enhancement patterns in the 
first 27 patients, the imaging protocol was altered to include additional images 
acquired at 3 minutes post-contrast (acquired in 33/60 patients) in order to 
allow more detailed analysis of contrast enhancement at earlier time points.   
Imaging protocols for each patient are summarised in Table 3.2.
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Figure 3.2 Isotropically-acquired, contrast-enhanced MR images acquired over time pre-contrast (Panel A) and 40 seconds (Panel B), 80 
seconds (Panel C), 4.5 minutes (Panel D), 9 minutes (Panel E) and 13.5 minutes (Panel F) post-administration of intravenous Gadobutrol
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Table 3.2 Magnetic Resonance Imaging (MRI) protocols used in 66 patients with suspected pleural malignancy 
 
Case MRI Contrast Orientation FOV Repetition Flip Echo Matrix Slice No. of Baseline 40s post- 80s post- 180s post- 270s post- 540s post- 810s post-
No. Scanner Agent of VIBE (mm) Time Angle Time Thickness Slices contrast contrast contrast contrast contrast contrast
acquisition (ms) () (ms) (mm) acquired acquired acquired acquired acquired acquired
1 3T Verio None Axial/Coro 380/450 3.92 9 1.39 320x70 3 36 
2 3T Verio None Axial 380 3.92 9 1.39 320x100 3 28 
3 3T Verio None Axial/Coro 380 4.31 9 1.33 320x70 1.7 28 
4 3T Verio None
Axial/Coro
/Sagg
420/380/
380 4.31 9 1.33 224x100 1.7 28 
5 3T Verio None
Axial/Coro
/Sagg
420/380/
380 4.31 9 1.33 224x100 1.7 28 
6 3T Verio None Axial 420 4.31 9 1.33 224x100 1.9 28x5 
7 3T Verio Gadobutrol Coronal 400 3.21 9 1.08 224x100 1.8 120      
8 3T Verio Gadobutrol Coronal 400 3.21 9 1.08 224x100 1.9 120      
9 3T Verio Gadobutrol Coronal 425 3.23 9 1.06 224x100 1.9 128      
10 3T Verio Gadobutrol Coronal 400 3.06 9 1.07 224x100 1.8 128      
11 3T Verio Gadobutrol Coronal 400 3.06 9 1.08 224x100 1.8 120    
12 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 128      
13 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 112    
14 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 128    
15 3T Verio Gadobutrol Coronal 400 3.2 9 1.1 224x100 1.9 128    
16 3T Verio Gadobutrol Coronal 380 3.23 9 1.04 192x100 2 128    
17 3T Verio Gadobutrol Coronal 420 3.23 9 1.07 224x100 1.9 120      
18 3T Verio Gadobutrol Coronal 440 3.23 9 1.05 224x100 1.96 104      
19 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 120      
20 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 144    
21 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 128    
22 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 144      
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23 3T Verio Gadobutrol Coronal 415 3.23 9 1.07 224x100 1.85 128      
24 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 128      
25 3T Verio Gadobutrol Coronal 385 3.23 9 1.06 224x100 1.94 104      
26 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 120      
27 3T Verio Gadobutrol Coronal 420 3.23 9 1.07 224x100 1.8 120      
28 3T Verio Gadobutrol Coronal 437 3.23 9 1.05 224x100 1.95 104      
29 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 120      
30 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 120      
31 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 112      
32 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 120      
33 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 120      
34 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 112       
35 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 120       
36 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 120       
37 3T Verio Gadobutrol Coronal 400 3.23 9 1.08 224x100 1.8 120       
38 3T Prisma Gadobutrol Coronal 400 2.83 9 1.03 224x100 1.8 120       
39 3T Prisma Gadobutrol Coronal 400 2.83 9 1.03 224x100 1.8 120       
40 3T Prisma Gadobutrol Coronal 400 2.83 9 1.03 224x100 1.8 128       
41 3T Prisma Gadobutrol Coronal 400 2.83 9 1.03 224x100 1.8 128       
42 3T Prisma Gadobutrol Coronal 400 2.83 9 1.03 224x100 1.8 120       
43 3T Prisma Gadobutrol Coronal 400 2.83 9 1.03 224x100 1.8 128       
44 3T Prisma None Coronal 420 2.83 9 0.99 224x100 2.2 112 
45 3T Prisma Gadobutrol Coronal 400 2.83 9 1.03 224x100 1.8 120       
46 3T Prisma Gadobutrol Coronal 400 2.83 9 1.03 224x100 1.8 112       
47 3T Prisma Gadobutrol Coronal 400 2.83 9 1.03 224x100 1.8 120       
48 3T Prisma Gadobutrol Coronal 400 2.83 9 1.03 224x100 1.8 120       
49 3T Prisma Gadobutrol Coronal 440 2.8 9 1 224x100 2 120       
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50 3T Prisma Gadobutrol Coronal 400 2.8 9 1 224x100 1.8 120       
51 3T Prisma Gadobutrol Coronal 420 2.8 9 1 224x100 1.9 128       
52 3T Prisma Gadobutrol Coronal 400 2.8 9 1 224x100 1.8 120       
53 3T Prisma Gadobutrol Coronal 420 2.8 9 1 224x100 1.9 120       
54 3T Prisma Gadobutrol Coronal 400 2.8 9 1 224x100 1.8 120       
55 3T Prisma Gadobutrol Coronal 400 2.8 9 1 224x100 1.8 112       
56 3T Prisma Gadobutrol Coronal 400 2.8 9 1 224x100 1.8 112       
57 3T Prisma Gadobutrol Coronal 400 2.8 9 1 224x100 1.8 120       
58 3T Prisma Gadobutrol Coronal 400 2.8 9 1 224x100 1.8 128       
59 3T Prisma Gadobutrol Coronal 400 2.8 9 1 224x100 1.8 120       
60 3T Prisma Gadobutrol Coronal 400 2.8 9 1 224x100 1.8 112       
61 3T Prisma Gadobutrol Coronal 400 2.8 9 1 224x100 1.8 120       
62 3T Prisma Gadobutrol Coronal 420 2.8 9 1 224x100 1.9 120       
63 3T Prisma Gadobutrol Coronal 400 2.8 9 1 224x100 1.8 112       
64 3T Prisma Gadobutrol Coronal 400 2.8 9 1 224x100 1.8 120       
65 3T Prisma Gadobutrol Coronal 400 2.8 9 1 224x100 1.8 120       
66 3T Prisma Gadobutrol Coronal 400 2.8 9 1 224x100 1.8 120       
MRI;	Magnetic	Resonance	Imaging,	Coro;	Coronal,	Sagg;	Saggital,	FOV;	Field	of	View,	3T;	3-Tesla
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3.3.6  Imaging Analysis 
3.3.6.1 CT Analysis 
CT scans were anonymised and analysed in a blinded fashion by two experienced 
consultant thoracic radiologists (Dr Gordon Cowell (GWC) and Dr David Stobo 
(DBS), using VuePACS version 11.4 (Carestream Health Inc., Rochester, NY). Each 
made a subjective diagnosis of pleural malignancy or benignity based on the 
presence or absence of established morphological features of PM (81). Briefly, 
this was nodular pleural thickening, pleural thickening >1cm, mediastinal pleural 
thickening, enhancing pleural lesions, fissural nodularity, pleural mass or 
infiltration of mediastinal structures, chest wall or diaphragm. A third, 
independent, thoracic radiologist (Dr Colin Noble (CN)) provided a third opinion 
to resolve any discordant cases.  
3.3.6.2 MRI Analysis: Morphology 
MRI scans were anonymised and analysed for morphological features of pleural 
malignancy in a blinded fashion by the same consultant thoracic radiologists who 
performed the CT analyses. The presence or absence of established 
morphological features of PM, (76) including nodular or mediastinal pleural 
thickening, fissural nodularity, pleural thickening >1cm and chest wall or 
diaphragmatic invasion, was used to classify patients. Dr Colin Noble again 
provided a third thoracic radiology opinion, providing a casting classification in 
discordant cases. All radiologists were blinded to the perfusion MRI and other 
clinical data.  
3.3.6.3 MRI Analysis: Perfusion Data 
Perfusion analyses were performed by myself (ST) and Dr Kevin Blyth (KGB) 
(consultant respiratory physician) using OsiriX for Mac v5.8, 32-bit (Pixmeo, 
Bernex, Switzerland).  I was designated the ‘primary’ operator and my results 
were used for diagnostic analyses. KGB was designated the secondary operator, 
whose results were used to assess inter-observer agreement only. Intra-observer 
agreement was assessed by the primary operator repeating a random selection 
of analyses after a 2-month interval. All images were anonymised, assigned a 
random study number and analysed in batches. Both operators were blinded to 
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clinical and histological data. Each reviewed the entire MRI exam at each time 
point. Each defined up to 15 Regions of Interest (ROI), using a track-ball mouse 
and cursor, on what they felt were representative areas of disease affecting the 
pleura. 
The pleura was defined as the visible structure running parallel with, and medial 
to, the rib-cage and immediately contiguous with either aerated lung, pleural 
fluid or air (depending on the presence of a fully expanded lung, pleural effusion 
or pneumothorax, respectively at the imaged location). Care was taken to 
constrain the boundaries of the ROI to the parietal pleura, where possible, 
accepting that in cases where there was no pleural fluid or air separating 
parietal and visceral pleura this could not be guaranteed. Once the required 
number of ROI (minimum of 5 in patients with macro-nodular disease and 15 in 
patients with non-nodular disease) was defined on the 4.5-minute post-contrast 
scan, these were electronically copied and pasted onto all other scans. Each 
scan was then visually assessed and each operator was asked to make minor 
adjustments to the position of each ROI to account for inconsistencies in the 
patient’s breath-hold and chest wall position, where required. 
In patients with macro-nodular pleural disease, the positioning of the Pleural 
ROIs was based entirely on the operator’s suspicion of pleural tumour at that 
site (which in turn was based on the presence of a nodular mass lesion or an area 
of thickened pleural thickening exceeding 10 mm, see Figure 3.3 for an example.  
If large mass lesions or areas of contiguous pleural thickening were present, care 
was taken to ensure that ROIs within a single area were separated by at least 1 
slice. Each operator was asked to place up to 15 ROIs on areas of suspected 
parietal pleural tumour in these case. 
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Figure 3.3 Example of ROI placed on macro-nodular pleural disease at contrast-
enhanced MRI
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In the absence of macro-nodular pleural disease or pleural thickening greater 
than 10mm, it was not possible to visually select the most suitable location for 
ROI definition. Therefore, an alternative and consistent method of 
comprehensively sampling the imaging characteristics of the parietal pleura in 
these cases was defined. This involved placement of 15 ROIs at anatomically 
similar locations in each patient. These 15 ROIs were distributed across 3 coronal 
pleural slices which were defined as follows (also see Figure 3.4): 
1. Midpoint slice: slice with the largest continuous length of parietal pleura 
measured cranio-caudally. 9 ROIs were evenly distributed from cupula to 
costophrenic recess.  
2. Anterior slice: slice half-way from the midpoint slice to the most anterior 
slice where parietal pleura is identifiable. 3 ROIs were evenly distributed. 
3. Posterior slice: slice half-way from the midpoint slice to the most posterior 
slice where parietal pleura is identifiable. 3 ROIs were evenly distributed. 
The ROI sampling methodology was chosen to mirror thoracoscopic sampling, 
where biopsies are taken of obvious costal pleural tumour where present and in 
the absence of obvious pleural tumour, random biopsies of representative 
parietal pleura are taken.  
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Figure 3.4 Example of ROI placed on representative pleura in the absence of 
macro-nodular disease at contrast-enhanced MRI 
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Signal intensity (SI) was measured by the software within each ROI at each time 
point, allowing ROI SI/time plots to be generated (see Figure 3.5 for examples). 
A Mean SI/time plot was also generated for each patient, based on the mean SI 
measured in all ROI at each time point (see Figure 3.6). All signal intensities 
were corrected for background signal noise using SI measured in a ROI placed in 
extra-corporeal air (see Figure 3.7). The time point that SI peaked in each ROI 
and that Mean SI peaked in each patient was recorded. This allowed 
computation of ROI SI gradient (ROISIG) for each ROI, and Mean SI gradient 
(MSIG) for each patient. SI gradient was calculated using the formula: 
!"#$	&'	()* 	+*	,'#-."$/	 = 1"#2	+* − 4#5"6.$"	+* /	/.!"	/&	1"#2	+* 
MSIG was used to summarize ECE characteristics of each patient. ROISIG was 
used in a post-hoc analysis to define the characteristics of each ROI. 
 
 
Figure 3.5  Examples of signal intensity (SI)/time curves measured from up to 15 
ROI placed on representative pleura at contrast-enhanced MRI
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Figure 3.6 Example of mean signal intensity (SI)/time curves summarising ROI 
SI/time curves for individual patients at contrast-enhanced MRI 
 
 
Figure 3.7 Contrast-enhanced, T1-weighted coronal MR image with a ROI placed 
on extra-corporeal air, used to correct for background signal noise
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Early Contrast Enhancement (ECE)  
To define a contrast enhancement pattern typical of malignancy the ROI and 
Mean SI/time curves recorded in the first 6 patients with nodular pleural disease 
typical of malignancy were reviewed by myself and Dr Blyth, who were blinded 
to the radiologist’s morphological diagnoses. This pattern was termed Early 
Contrast Enhancement (ECE). The presence or absence of ECE in each patient’s 
ROI SI/time curves was used to classify the patient as malignant or benign 
respectively. This diagnostic criterion was chosen to mirror interpretation of 
pleural biopsy results, where all pleural biopsy samples are reviewed by a 
pathologist and identification of the presence of malignant features in any one 
pleural biopsy will result in a diagnosis of pleural malignancy, even if all other 
submitted biopsy samples demonstrate benign features only.  
3.3.6.4 Post-hoc Analyses regarding ROI Signal Intensity Gradient (ROISIG) 
Evidence of heterogeneous contrast enhancement in some patients with pleural 
malignancy prompted a post-hoc analysis to assess the contribution of benign 
(ECE-negative) ROI to the discriminant performance of ECE. We interpreted this 
as evidence of non-contiguous disease, commonly observed at thoracoscopy. 
Receiver Operator Characteristic (ROC) curves were plotted based on ROISIG for 
1) all ROI in malignant cases relative to patients with benign disease and 2) only 
ECE-positive ROI in patients with malignancy relative to ROIs in benign cases.  
 
3.3.6.5 Combining MRI morphology with ECE 
To assess the diagnostic performance of combined MRI morphology and ECE 
assessment, a two-step approach was adopted. 
1. MRI morphology was examined first. If the patient has morphological features 
of PM as previously described then the patient was classified as malignant, 
regardless of their ECE findings 
2. If MRI morphology was found to be benign, then ECE results were examined. If 
ECE was present, then the patient was classified as malignant 
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3.3.7  Assessment of Tissue Microvessel Density 
Paraffin-embedded pleural tissue biopsies obtained at thoracoscopy were 
examined by a Consultant Lung Pathologist (Dr. Craig Dick) to confirm that the 
tissue was representative of the histological diagnosis. Sections were cut on a 
digital microtome (4µm thickness) and stained with CD34 and Factor VIII 
immunostains (Leica Biosystems, UK, 1:50 and 1:200 dilution, respectively), see 
Figure 3.8 (Panels A and B respectively). Slides were digitized using Hamamatsu 
NDP (Hamamatsu, Welwyn Garden City). Microvessel density with lumen in the 
entire tissue specimen was measured using quantitative image analysis software 
(Leica Biosystems, U.K.), see Figure 3.8 (Panels C and D respectively), by either 
a pathologist (Dr. Catherine Humphreys) or a pathology research technician (Ms. 
Clare Orange). 
 
Figure 3.8 Paraffin-embedded representative pleural biopsies stained with CD34 
(Panel A) and Factor VIII (Panel B) immunostain (highlighting vessels as brown). 
Computer software was used to detect the immunostain (Panels C and D) to 
calculate Microvessel Density (highlighting vessels in different colours depending 
on vessel size and presence/absence of a vessel lumen) 
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3.3.8  Statistical Analysis  
Data distribution was assessed using histograms and D’Agostino-Pearson 
normality test. Normally distributed data are described by mean (+/- SD) and 
non-normally distributed data are described by median (inter-quartile range). 2 
x 2 contingency tables were used to calculate the sensitivity, specificity, 
negative and positive predictive values of ECE, CT morphology and MRI 
morphology for pleural malignancy. McNemar’s test was used to compare the 
sensitivity and specificity between ECE, CT morphology, MRI morphology and 
combined MRI morphology-ECE methodologies. Cohen’s Kappa statistic was used 
to assess inter- and intra-observer agreement. 
The discriminant performance of ECE was further assessed by plotting ROC 
curves for 1) only ECE-positive ROI and 2) all ROI in malignant cases, relative to 
patients with benign disease. MSIG was used to summarize the ECE 
characteristics of each patient. Any difference between MSIG and MVD in 
patients with PM relative to those with benign pleural disease was compared 
using unpaired t-test for normally distributed data and the Mann-Whitney test 
for non-normally distributed data. MVD was correlated against MSIG using 
Spearman’s rho test.  A p value ≤ 0.05 was considered statistically significant in 
all tests. P values were adjusted to account for false discovery rate with 
multiple testing using R v3.4.0 (The R Foundation). All other statistical analyses 
were performed using Graphpad Prism v7 (San Diego, USA) and IBM SPSS 
Statistics v22.0 (IBM, New York, USA) for Mac.  
3.4  RESULTS 
3.4.1 Patient Demographics 
118 patients were potentially eligible for the study, 66 were recruited to the 
study and 58 patients underwent contrast-enhanced MRI examination. 31/58 
were diagnosed with MPM, all of whom had surplus tissue available and suitable 
for tissue vascularity measurements (see Figure 3.9).  
51/58 (88%) were male and 39/58 (67%) asbestos-exposed. 9/58 (16%) had a 
history of previous malignancy and 13/58 (22%) had pleural plaque disease. Final 
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diagnoses are summarised in Table 3.3. 36/58 (62%) had a final diagnosis of PM. 
31/36 (86%) were diagnosed with MPM, of whom 65% (n=20) had epithelioid MPM, 
16% (n=5) sarcomatoid MPM, 13% (n=4) biphasic MPM and 6% (n=2) had MPM not 
otherwise specified (NOS). 5/36 (14%) were diagnosed with secondary pleural 
malignancy, of whom 60% (n=3) had metastatic breast cancer and 40% (n=2) had 
metastatic lung cancer.  
22/58 (38%) of patients had a final diagnosis of benign pleural disease. Benign 
pleural diagnoses included BAPE (50%, n=11), tuberculous pleurisy (14%, n=3), 
fibrothorax (9%, n=2), rheumatoid pleurisy (9%, n=2), reactive effusion 
associated with lung cancer (4.5%, n=1), post-lobectomy effusion (4.5%, n=1), 
secondary to pulmonary thromboembolism (4.5%, n=1) and drug-related (4.5%, 
n=1).  
Final diagnoses were based on histology from LAT in 46/58 (79%), VATS in 7/58 
(12%) and image-guided biopsy in 4/58 (7%). 1/58 (2%) were diagnosed based on 
radiology, MDT consensus and interval follow-up. All MPM cases were staged at 
regional MDT as I in 20/31 (64.5%), II in 0/31 (0%), III in 9/31 (29%) and IV in 2/31 
(6.5%). Median overall survival for patients with PM was 20 months. Mean follow-
up for patients with a benign pleural diagnosis was 20 (9) months. 
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Figure 3.9 Study flowchart of patients recruited to the MRI sub-study in the Early 
Contrast Enhancement study
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Table 3.3. Summary of pleural diagnoses in 58 patients with suspected 
malignancy recruited to the Early Contrast Enhancement study 
Pleural Malignancy (n=36, 62%) Benign Disease (n=22, 38%)   
          
Mesothelioma (n=31, 86%) BAPE (n=11, 50%)   
         
     Epithelioid (n=20, 65%) 
Reactive assoc. with Lung Cancer 
(n=1, 4.5%) 
     Sarcomatoid (n=5, 16%)       
     Biphasic (n=4, 13%) Fibrothorax (n=2, 9%)   
     Mesothelioma NOS (n=2, 6%)       
    Tuberculous Pleurisy (n=3, 14%,) 
Secondary Malignancies (n=5, 14%)       
    
Pulmonary Thromboembolism (n=1, 
4.5%) 
     Lung Cancer (n=2, 40%)       
     Breast Cancer (n=3, 60%) Drug-related (n=1, 4.5%)   
        
    Post-lobectomy (n=1, 4.5%)   
          
    Rheumatoid pleurisy (n=2, 9%) 
BAPE; Benign Asbestos-related Pleural Effusion     
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3.4.2  Imaging results 
In all patients, MRI was performed prior to pleural biopsy (median 1 (1 – 7) days) 
and after CT (median 20 (13 – 34) days). All imaging analyses were confined to 
the 59 patients who had contrast-enhanced MRI scans acquired. 49/58 (84%) 
patients had pleural thickening <10mm. Median pleural thickness for all patients 
5mm (IQR 4 – 7mm)), 47/58 (81%) lacked gross tumour nodules.  
3.4.2.1 CT Morphology 
Using CT morphology, 24/36 (67%) patients were correctly classified as PM (see 
Table 3.4). The majority of false negative cases had MPM (11/12 (92%)). All of 
these patients had early (IMIG Stage I) MPM. The single remaining false negative 
case had metastatic breast cancer. 
15/22 (68%) patients were correctly identified as having benign pleural disease 
(see Table 3.5). The false positive cases had BAPE (n=2), tuberculous (TB) 
pleurisy (n=2), haemothorax (n=1), rheumatoid pleurisy (n=1) and reactive 
effusion secondary to underlying lung cancer (n=1). 
3.4.2.2 MRI Morphology 
MR morphology correctly classified 28/36 (78%) patients with PM (see Table 3.4). 
The majority of false negative cases had MPM (7/8 (87.5%)). 86% (n=6) of these 
cases had early stage (IMIG Stage I) MPM. The single remaining false negative 
case had metastatic breast cancer.    
17/22 (77%) patients were correctly identified as having benign pleural disease 
(see Table 3.5). The false positive cases had BAPE (n=1), TB pleurisy (n=2), 
rheumatoid pleurisy (n=1) and reactive effusion secondary to underlying lung 
cancer (n=1).  
3.4.2.3 Early Contrast Enhancement  
The mean number of ROI defined was 14 (3) per patient. The average time taken 
to perform ROI placement and ECE calculations was 14 (3.5) minutes.  
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An early peak in SI (occurring at or before 4.5 minutes (270 seconds)) was 
identified in 6/6 mean SI/time curves and 58/62 ROI SI/time curves in the 
preliminary cohort of 6 patients with obvious nodular pleural disease (see Figure 
3.10 (Panels B and C) for examples). This curve shape was defined as being 
typical of malignancy and termed Early Contrast Enhancement (ECE). The ROI 
SI/time curves in the remaining patients were then reviewed. ECE was reported 
to be present, and the patient classified as Malignant, if at least one ROI SI/time 
curve demonstrated a peak in SI at, or before, 4.5 minutes, see Figure 3.10 
(Panels E and F) for examples). If ECE was not identified in any ROI SI/time 
curve the patient was classified as benign (see Figure 3.10 (Panels G and H) for 
examples).  
ECE was demonstrated in 92% (33/36) of patients with PM (see Table 3.4). All 
three false negatives had MPM, two were diagnosed with Sarcomatoid MPM (IMIG 
stage I and IV respectively) and one patient was diagnosed with Mesothelioma 
NOS (IMIG stage I) at pleural biopsy. Both false negative cases with Sarcomatoid 
MPM were accurately classified as malignant based on CT and MRI morphology.    
Two cases of Epithelioid MPM were initially diagnosed with BAPE at LAT but 
reclassified as Epithelioid MPM after developing progressive pleural thickening on 
interval CT follow-up and undergoing repeat pleural biopsies several months 
later. In both cases, the final diagnosis of malignancy was consistent with the 
initial positive ECE result. Both of these cases were classified as benign based on 
MRI morphology and one of the cases was classified as benign based on CT 
morphology.   
ECE was absent in 68% (15/22) patients with benign pleural disease (see Table 
3.5). The false positive cases had TB pleurisy (2/7), BAPE (2/7), rheumatoid 
pleurisy (1/7), PTE (1/7) and eosinophilic pleuritis secondary to drugs (1/7).  
3.4.2.4 Combined MRI Morphology and ECE Assessment 
Combined MRI morphology and ECE assessment correctly identified 35/36 (97%) 
patients with PM. The false negative case had MPM. It did however result in an 
increased number of false positives. There were 10/22 (45%) false positives 
following combined assessment, which included TB pleurisy (n=2), BAPE (n=3), 
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rheumatoid pleurisy (n=2), drug-related (n=1), PTE (n=1) and reactive effusion 
secondary to underlying lung cancer (n=1).  
 
 
Figure 3.10 Contrast-enhanced, coronal T1-weighted MR images and ROI signal 
intensity/time curves in patients with obvious macro-nodular disease (Panel A) 
demonstrating ECE (Panels B – C), in patients with effusion-dominant, low 
volume pleural disease (Panel D) but at least one ROI demonstrating ECE (Panels 
E – F) and where no single ROI demonstrated ECE (Panels G – H)
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Table 3.4 Demographics, diagnostics and imaging results in 58 patients with suspected pleural malignancy (PM) who underwent contrast-
enhanced MRI for ECE assessment, contrast-enhanced CT scanning and pleural biopsy. 36/58 were diagnosed with PM, 23/58 with benign 
pleural disease. False negative (*) and false positive (†) results are highlighted. 
Malignant Cases      
Case Age  Sex Diagnosis Disease CT  MRI 
MRI-
ECE 
No. (yrs)   Stage Morphology Morphology 
                
7 64 ♂ Epithelioid MPM I B* M M 
9 73 ♂ Metastatic lung IV M M M 
11 72 ♂ Epithelioid MPM I M M M 
14 81 ♂ Sarcomatoid MPM III M M M 
16 85 ♂ Epithelioid MPM I M M M 
17 64 ♂ Sarcomatoid MPM I B* M M 
19 72 ♂ Epithelioid MPM III M B* M 
20 78 ♂ Epithelioid MPM III M M M 
21 81 ♂ Biphasic MPM I M M M 
23 77 ♂ Epithelioid MPM III M M M 
24 66 ♂ Epithelioid MPM III M M M 
25 79 ♂ Sarcomatoid MPM I M M B* 
28 83 ♂ Epithelioid MPM III M M M 
29 76 ♀ Metastatic breast IV B* B* M 
30 74 ♂ Epithelioid MPM I M M M 
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31 70	 ♀ Metastatic breast IV M M M 
32 80 ♂ Sarcomatoid MPM IV M M M 
35 78 ♂ Epithelioid MPM I M M M 
37 66 ♀ Epithelioid MPM I B* B* M 
39 83 ♂ Biphasic MPM III M M M 
41 61 ♂ Sarcomatoid MPM IV M M B* 
42 72 ♂ Biphasic MPM III M M M 
43 82 ♂ Epithelioid MPM I B* M M 
46 76 ♂ Mesothelioma I B* B* B* 
47 85 ♂ Epithelioid MPM I B* B* M 
48 83 ♂ Biphasic MPM I M M M 
49 72 ♂ Epithelioid MPM I B* M M 
52 82 ♂ Epithelioid MPM I M M M 
54 56 ♂ Metastatic lung IV M M M 
55 85 ♀ Epithelioid MPM I B* M M 
56 84 ♀ Epithelioid MPM I B* B* M 
57 75 ♂ Epithelioid MPM I B* B* M 
58 82 ♂ Mesothelioma I B* B* M 
61 76 ♂ Epithelioid MPM III M M M 
63 63 ♂ Metastatic lung IV M M M 
65 67 ♂ Epithelioid MPM I M M M 
MRI; Magnetic Resonance Imaging, CT; Computed Tomography, ECE; Early Contrast  
Enhancement, MPM; Malignant Pleural Mesothelioma, B; Benign, M; Malignant, N/A; Not 
Appropriate 
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Table 3.5 Demographics, diagnostics and imaging results in 58 patients with suspected pleural malignancy (PM) who underwent contrast-
enhanced MRI for ECE assessment, contrast-enhanced CT scanning and pleural biopsy. 36/58 were diagnosed with PM, 23/58 with benign 
pleural disease. False negative (*) and false positive (†) results are highlighted. 
Benign Cases       
Case Age  Sex Diagnosis Disease CT  MRI MRI-ECE 
No. (yrs)     Stage Morphology Morphology   		
7 82 ♂ BAPE N/A B M† B  
9 85 ♂ BAPE N/A M† B B  
11 71 ♂ Rheumatoid pleurisy N/A M† M† B  
12 80 ♂ Haemothorax N/A B B B  
15 64 ♂ BAPE N/A B B B  
18 71 ♂ BAPE N/A B B B  
22 87 ♂ BAPE N/A B B B  
26 51 ♂ TB N/A M† M† M†  
27 76 ♂ BAPE N/A B B B  
33 79 ♂ Haemothorax N/A M† B B  
34 83 ♀ PTE N/A B B M†  
36 62 ♂ Post-lobectomy change N/A B B B  
38 69 ♂ Rheumatoid pleurisy N/A B B M†  
40 81 ♂ BAPE N/A B B M†  
45 76 ♂ TB  N/A M† M† M†  
50 72 ♂ BAPE N/A B B B  
51 72 ♂ BAPE N/A B B B  
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53 79 ♂ BAPE N/A M† B M†  
59 33 ♀ TB  N/A B B B  
60 72 ♂ Reactive effusion, 
underlying lung cancer 
N/A M† M† B 
 
62 80 ♂ Drug-related N/A B B M†  
65 63 ♂ BAPE N/A B B B  
MRI; Magnetic Resonance Imaging, CT; Computed Tomography, ECE; Early Contrast   
Enhancement, BAPE; Benign Asbestos Pleural Effusion, TB; Tuberculous pleurisy   
B; Benign, M; Malignant, N/A; Not Appropriate     
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3.4.3 Overall Diagnostic Performance 
The overall diagnostic performance of CT morphology, MRI morphology, ECE and 
combined MRI morphology and ECE are summarised in Table 3.6. Contingency 
tables used to generate this data are summarised in Table 3.7. 
CT Morphology 
Overall diagnostic performance of CT morphology was: sensitivity 56% (95% CI 37 
– 72%), specificity 77% (95% CI 60 – 89%), positive predictive value 68% (95% CI 47 
– 84%), negative predictive value 67% (95% CI 50 – 80%). 
MRI Morphology 
Overall diagnostic performance of MR morphology was sensitivity 68% (95% CI 48 
– 83%), specificity 85% (95% CI 69 – 93%), positive predictive value 77% (95% CI 57 
– 90%), negative predictive value 78% (95% CI 62 – 88%).   
ECE 
Overall diagnostic performance of ECE was: sensitivity 83% (95% CI 61 – 94%), 
specificity 83% (95% CI 68 - 91%), positive predictive value 68% (95% CI 47 – 84%), 
negative predictive value 92% (78 – 97%).  
Combined MRI Morphology and ECE Assessment 
Overall diagnostic performance of combined MRI morphology and ECE was: 
sensitivity 92% (95% CI 67 – 100%), specificity 78% (95% CI 64 – 87%), PPV 55% (95% 
CI 35 – 73%), NPV 97% (95% CI 86 – 100%). 
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Table 3.6 The diagnostic performance and reproducibility of CT morphology, MRI 
morphology and MRI-Early Contrast Enhancement (ECE) assessed in 58 patients 
with suspected Pleural Malignancy. Agreement was assessed using Cohen’s Kappa 
statistic. Diagnostic performance between groups is compared by McNemar’s 
test, adjusted for multiple comparisons. Statistically significant differences 
before and after adjustment are highlighted below 
 CT  
Morphology 
MRI 
Morphology 
MRI-ECE Combined MRI 
Morphology-ECE 
Sensitivity 
(95% CI) 
56% 
(37 – 72%) 
68% 
(48 – 83%) 
83%* 
(61 – 94%) 
92%** 
(67 – 100%) 
Specificity 
(95% CI) 
77% 
(60 – 89%) 
85% 
(69 – 93%) 
83% 
(68 – 91%) 
78% 
(64 – 87%) 
PPV  
(95% CI) 
68% 
(47 – 84%) 
77% 
(57 – 90%) 
68% 
(47 – 84%) 
55% 
(35 – 73%) 
NPV 
(95% CI) 
67% 
(50 – 80%) 
78% 
(62 – 88%) 
92% 
(78 – 97%) 
97% 
(86 – 100%) 
Inter-observer 
Agreement 
0.65 0.593 0.784 N/R 
Intra-observer 
Agreement 
N/R N/R 0.864 N/R 
*Unadjusted p value 0.022 but adjusted p value 0.066 (MRI-ECE vs. CT 
morphology) 
**Unadjusted p value 0.016 but adjusted p value 0.66 (Combined MRI morphology 
and ECE assessment vs. MRI morphology). For all other comparisons p >0.05 
CT; Computed Tomography, MRI; Magnetic Resonance Imaging, CI; Confidence 
Interval, PPV; Positive Predictive Value, NPV; Negative Predictive Value, N/R; 
Not Recorded
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Table 3.7 2 x 2 Contingency tables describing results of Computed Tomography 
(CT) Morphology, Magnetic Resonance Imaging (MRI) Morphology, Early Contrast 
Enhancement (ECE) at MRI and Combined MRI Morphology-ECE assessment in 
58/66 patients with suspected pleural malignancy 
	
 Final Pleural Diagnosis  
   Malignant  Benign   
CT morphology Malignant  24 7  
 Benign  12 15  
      
  Final Pleural Diagnosis  
  Malignant Benign  
MRI morphology Malignant  28 5  
 Benign  8 17  
        
  Final Pleural Diagnosis  
   Malignant  Benign   
MRI ECE Malignant  33 7  
 Benign  3 15  
       
  Final Pleural Diagnosis  
  Malignant  Benign   
Combined MRI 
morphology-ECE 
Malignant  35 10  
Benign  1 12  
     
CT; Computed Tomography, MRI; Magnetic Resonance Imaging, ECE; Early  
Contrast Enhancement 
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3.4.4 Post-hoc Analyses regarding ROI Signal Intensity Gradient 
A ROC curve plotted using only ROISIG data from ECE-positive ROI (n=273) 
demonstrated optimum sensitivity (90% (95% CI 86 – 94%)) and specificity (86% 
(95% CI 81 – 89%)) at a threshold of ROISIG >0.43 AU/sec (AUC 0.938, (95% CI 
0.918 – 0.957), p <0.0001, see Figure 3.11 (Panel A). 
Using all ROISIG data (n=482), regardless of the presence or absence of ECE, a 
ROISIG >0.29 AU/sec provided optimum, but reduced sensitivity (71% (95% CI 67 – 
75%)), specificity (68% (95% CI 63 – 73%)) and discriminatory performance (AUC 
0.776 (95% CI 0.744 – 0.808), p <0.0001, see Figure 3.11 (Panel B). 
 
Figure 3.11 Receiver Operating Characteristic (ROC) curves of Region of Interest 
Signal Intensity Gradient (ROISIG) measured in 58 patients with suspected 
pleural malignancy (PM) using contrast-enhanced MRI. In Panel A, only ROI 
demonstrating Early Contrast Enhancement (ECE) in patients with PM are 
included and in Panel B, all ROI are included, including those who failed to 
demonstrate ECE, resulting in reduced discriminative performance 
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3.4.5  Mean Signal Intensity Gradient (MSIG)  
Median MSIG was significantly higher in patients with PM (median 0.58 (0.27 – 
0.88) AU/s) than those with benign pleural disease (median 0.2 (0.06 – 0.29) 
AU/s, p <0.0001). 
3.4.6 Reproducibility 
CT Morphology 
There were 10 discordant classifications between the thoracic radiologists using 
CT morphology (17%), see Table 3.8. Overall inter-observer agreement for CT 
morphology was κ = 0.650.  
MRI Morphology 
There were 11 discordant classifications between the thoracic radiologists using 
MRI morphology (19%), see Table 3.9. Overall inter-observer agreement for MRI 
morphology was κ = 0.593. 
Early Contrast Enhancement 
19/58 cases were reviewed by KGB for inter-observer agreement. Of the cases 
reviewed, there were 2 discordant classifications between ST and KGB (11%), see 
Table 3.10. Overall inter-observer agreement for ECE was κ = 0.784. 
ECE was repeated by ST in 29/58 cases for intra-observer agreement. Of the 
cases repeated, there were 3 discordant classifications (10%), see Table 3.11. 
Overall inter-observer agreement for ECE was κ = 0.864.
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Table 3.8 Discordant cases at CT Morphology Assessment by two thoracic 
radiologists. False negatives (*) and false positives (†) are highlighted 
Patient Age  Sex Diagnosis Disease Observer 1 Observer 2 
No. (yrs)     Stage GWC DBS 
6 87 ♂ BAPE N/A M† B 
19 79 ♂ Haemothorax N/A M† B 
26 76 ♂ TB  N/A M† B 
27 82 ♂ Epithelioid MPM I B* M 
28 61 ♂ Sarcomatoid MPM IV M B* 
36 72 ♂ BAPE N/A B M† 
38 79 ♂ BAPE N/A B M† 
42 82 ♂ Mesothelioma I M B* 
51 64 ♂ Epithelioid MPM I M B* 
54 85 ♂ BAPE N/A M† B 
CT; Computed Tomography, MPM; Malignant Pleural Mesothelioma,  
BAPE; Benign Asbestos Pleural Effusion, TB; Tuberculous pleurisy,   
B; Benign, M; Malignant, N/A;Not 
Appropriate    
 
Table 3.9 Discordant cases at MRI Morphology Assessment by two thoracic 
radiologists. False negatives (*) and false positives (†) are highlighted 
Patient Age  Sex Diagnosis Disease Observer 1 Observer 2 
No. (yrs)     Stage GWC DBS 
4 72 ♂ Epithelioid MPM III B* M 
6 87 ♂ BAPE N/A B M† 
19 79 ♂ Haemothorax N/A M† B 
20 78 ♂ Epithelioid MPM I B* M 
22 69 ♂ Rheumatoid pleurisy N/A B M† 
28 61 ♂ Sarcomatoid MPM IV B* M 
30 85 ♂ Epithelioid MPM I M B* 
39 84 ♀ Epithelioid MPM I M B* 
41 75 ♂ Epithelioid MPM I B* M 
44 33 ♀ TB  N/A B M† 
MRI; Magnetic Resonance Imaging, MPM; Malignant Pleural 
Mesothelioma   
BAPE; Benign Asbestos Pleural Effusion, TB; Tuberculous pleurisy  
B; Benign, M; Malignant, N/A; Not 
Appropriate    
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Table 3.10 Discordant cases at MRI Early Contrast Enhancement by two 
respiratory physicians. False negatives (*) and false positives (†) are highlighted 
Patient Age  Sex Diagnosis Disease Observer 1 Observer 2 
No. (yrs)     Stage ST KGB 
5 78 ♂ Epithelioid MPM III M B* 
6 87 ♂ BAPE N/A B M† 
MRI; Magnetic Resonance Imaging, MPM; Malignant Pleural Mesothelioma 
BAPE; Benign Asbestos Pleural Effusion, B; Benign, M; 
Malignant,  
N/A; Not 
Appropriate     
 
Table 3.11 Discordant cases at MRI Early Contrast Enhancement at repeated 
(intra-observer) testing. False negatives (*) and false positives (†) are highlighted 
Patient Age  Sex Diagnosis Disease Review 1 Review 2 
No. (yrs)     Stage ST ST 
24 81 ♂ BAPE N/A B M† 
36 72 ♂ BAPE N/A B M† 
41 75 ♂ Epithelioid MPM I M B* 
MRI; Magnetic Resonance Imaging, MPM; Malignant Pleural Mesothelioma 
BAPE; Benign Asbestos Pleural Effusion, B; Benign, M; Malignant,  
N/A; Not 
Appropriate     
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3.4.7  Tissue Microvessel Density 
There was no difference in tissue MVD between patients with PM and those with 
benign pleural disease using CD34 immunostaining (8.614 x10-5 (8.393 x10-5) 
vessels/tissue pixel and 7.052 x10-5 (5.655 x10-5) vessels/tissue pixel 
respectively, p=0.53, or using Factor VIII immunostaining (5.882 x10-5 (4.877 x10-
5) vessels/tissue pixel and 7.357 x10-5 (5.349 x10-5) vessels/tissue pixel 
respectively, p=0.29.  
3.4.8  Relationship between MRI Perfusion Data and Tissue Microvessel 
Density in patients with MPM 
There was a modest but statistically significant positive correlation between 
MSIG and MVD with lumen using Factor VIII immunostain (r 0.4258, p=0.02) in 
patients with MPM (see Figure 3.12 (Panel A)). There was also a modest but 
statistically significant negative correlation between MSIG and MVD with lumen 
measured using CD34 immunostain (r -0.412, p=0.0365) in patients with MPM 
(see Figure 3.12 (Panel B)). 
 
Figure 3.12 Correlation between mean signal intensity gradient (MSIG) and 
tumour Microvessel Density measured using Factor VIII (Panel A) and CD34 (Panel 
B) immunostain 
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3.4.9 Relationship between Tissue MVD and survival in MPM 
Median tissue MVD with lumen in patients with MPM was 0.008761 using Factor 
VIII immunostain. MPM patients with a higher tissue MVD (>0.008761) with lumen 
had a significantly poorer overall survival in comparison to those with lower 
tissue MVD with lumen (0.008761) using Factor VIII immunostain (median overall 
survival 10 months vs. 20 months, HR 2.723 (95% CI 1.093 – 6.784), p=0.03), see 
Figure 3.13 (Panel A).  
Median tissue MVD with lumen in patients with MPM using CD34 immunostain was 
higher (0.05966). In contrast to the above findings using Factor VIII immunostain, 
MPM patients with a higher tissue MVD (>0.05966) had a trend towards better 
overall survival than those with a lower tissue MVD, although this was not 
statistically significant (median overall survival 16 months vs. 10 months 
respectively, HR 0.484 (95% CI 0.207 – 1.138), p=0.08), see Figure 3.13 (Panel B). 
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Figure 3.13 Kaplan-Meier curves demonstrating the relationship between tumour 
Microvessel Density (MVD) and median overall survival using Factor VIII (Panel A) 
and CD34 (Panel B) immunostain
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3.4.10  Relationship between MRI perfusion data and survival in MPM 
Median MSIG in patients with MPM was 0.533AU/s. Patients with PM and a high 
MSIG of >0.533AU/s had a significantly poorer median overall survival than those 
with a low MSIG of <0.533AU/s (median survival 12 months vs. 20 months, HR 
1.898 (95% CI 0.8349 – 4.316), p=0.047), see Figure 3.14.  
 
Figure 3.14 Kaplan-Meier curves demonstrating the relationship between patient 
mean signal intensity gradient (MSIG) and median overall survival 
3.5  DISCUSSION 
3.5.1  Early Contrast Enhancement 
The aim of this study was to develop a novel imaging biomarker of PM, targeted 
to non-anatomical, perfusion-based changes that occur in malignancy, even at 
an early stage of disease. We hypothesised that a perfusion-based biomarker 
could differentiate between PM and benign pleural disease with sufficient 
diagnostic accuracy to be of routine clinical value.  
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Early Contrast Enhancement at contrast-enhanced MRI is a novel biomarker of 
PM, which differentiates PM from benign pleural disease with high diagnostic 
performance: sensitivity 83% (95% CI 61 – 94%), specificity 82.5% (95% CI 68 - 
91%), PPV 68% (95% CI 47 – 84%), NPV 92% (78 – 97%).  
ECE was defined as a peak in signal intensity at or before 4.5 minutes (270 
seconds) post-intravenous gadolinium contrast administration. ECE was 
demonstrated in 33/36 (92%) patients with PM in this study. This is later than the 
‘optimum’ pleural image acquisition timing of approximately 60 seconds post-
contrast at CT reported by previous authors. (75,330-332) However, this practice 
is recommended when utilising CT as the imaging technique and is based on 
differing Hounsfield Units rather than signal intensity at MRI as described here.  
Gadolinium is a low molecular weight, extracellular contrast agent with low 
osmotic activity, which is largely renally-excreted. Following intravenous 
administration, the diffusion of Gadolinium from the intravascular space into the 
extravascular extracellular space (EES) dependent on blood perfusion, 
microvessel permeability, surface area and diameter, water diffusion and tissue 
oxygenation and metabolism. (309,333,334) As Gadolinium is unable to cross cell 
membranes, its volume of distribution is essentially the interstitial space. 
Contrast enhancement gradient in the initial period after intravenous injection 
(wash in) is therefore dependent on tissue perfusion, maximal contrast 
enhancement dependent on the total uptake of contrast medium within the 
interstitial space and contrast washout dependent on vascular permeability. 
(335,336) Biological characteristics of the interstitial space, including stromal 
cellularity, fibrosis, collagen content and tumour proliferation will all therefore 
influence contrast kinetics at Gadolinium-enhanced MRI. (336)  
In semi-quantitative DCE-MRI of breast cancer, peak contrast enhancement has 
been reported to occur in the first 2 – 3 minutes following contrast 
administration, (113,337) which is earlier than the time point reported for ECE 
in this study. However, similar to our study, Buckley et al performed DCE-MRI in 
40 patients with breast cancer, and reported that contrast enhancement at 4 
minutes had a modest but statistically significant correlation with MVD measured 
using Factor VIII immunostain. (338) Additionally, Partridge et al examined 
‘delayed contrast kinetics’ at 4.5 minutes and 7.5 minutes post-contrast 
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administration at DCE-MRI in 280 patients with breast lesions and reported a 
higher percentage of patients with breast malignancy displaying persistent or 
plateau contrast enhancement at 4.5 minutes in comparison to the later time 
point. (339) 
One possibility for the slightly later contrast enhancement time point of 4.5 
minutes reported herein is the histology of MPM. MPM tumour tissue also 
contains interspersed regions of non-malignant stroma, which consists of 
moderately cellular fibrous tissue. Epithelioid MPM commonly produces high 
amounts of hyaluronic acid and sarcomatoid MPM contains large amounts of 
collagenous tissue. (340) As highlighted earlier, stromal cellularity and fibrosis 
also affect contrast kinetics and may be responsible for the ‘delayed’ contrast 
enhancement time point demonstrated in this study. Late gadolinium 
enhancement (>10 minutes post-contrast administration) has been demonstrated 
in cardiac sarcoid (341,342) and cardiomyopathies (343,344), as a result of 
myocardial fibrosis and increased EES secondary to collagen deposits. (345)       
The pattern of contrast enhancement reported in the current study is consistent 
with findings reported in a small retrospective study of 10 patients with MPM 
undergoing MRI assessment prior to surgery. In this study, Patel et al 
demonstrated peak tumour enhancement at 280 seconds post intravenous 
gadolinium contrast administration. (346)  Our findings are also in agreement 
with those of Falaschi et al and Boraschi et al who reported pleural hyper-
intensity on T1-weighted gadolinium-enhanced MR imaging in patients with PM. 
(100,347) Although the exact post-contrast timing is not specified in these 
studies, it is likely to fall within the definition used here for ECE.  
3.5.2  ECE – An Imaging Biomarker of Pleural Malignancy 
ECE demonstrated higher diagnostic sensitivity (83%) and NPV (92%) than 
subjective CT morphology without perfusion analysis (56% and 67%, respectively) 
and MRI morphology (68% and 78%, respectively). After adjustment for multiple 
comparisons, these differences did not reach statistical significance. Combining 
MRI morphology with ECE resulted in slightly reduced specificity (78%) and PPV 
(55%) than with ECE alone (83% and 68%, respectively). ECE was associated with 
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superior inter-observer agreement (κ 0.784) relative to CT (κ 0.65) and MRI 
morphology (κ 0.593). 
The high diagnostic performance of ECE reported in this current study is 
consistent with that reported in previous studies of signal intensity-based, 
contrast-enhanced MRI assessment of suspected PM. Falaschi et al reported 
sensitivity of 100%, specificity of 60%, PPV 70% and NPV 100% in 34 patients, 
18/34 (53%) were diagnosed with PM (9/18 with MPM), based on increased signal 
intensity of pleural lesions at T1-weighted contrast-enhanced MRI. Similarly, 
Boraschi et al reported sensitivity of 100%, specificity 95%, PPV 92% and NPV 
100% in a small study of 30 asbestos-exposed patients, 11/30 (37%) of whom 
were diagnosed with MPM. In this latter study, morphological features of PM 
were combined with the finding of increased pleural signal intensity to classify 
patients and authors did not report the diagnostic performance of signal 
intensity-based assessment alone. Neither author reported the stage distribution 
of the patients with MPM included in their studies and it is therefore impossible 
to conclude the added value of signal intensity data to routine morphological 
assessment, which is often less complex in advanced stage disease, based on the 
reported findings in these two small studies.  
The excellent specificity of 95% reported in the study by Boraschi et al is 
superior to the specificity reported here (specificity 83%). This is likely to be as 
a result of the benign pleural disease population included in the earlier study. 
While all patients included in the study had suspected PM, all of the patients 
with benign disease (n=16) were diagnosed with pleural plaques, which is 
arguably an easier population to differentiate from PM than the population 
included in the present study, which included 10 patients (45%) with BAPE and 1 
patient with a reactive effusion secondary to underlying lung cancer (Table 3.7). 
Similar to our findings, Falaschi et al reported false positive contrast 
enhancement results in patients with tuberculous pleurisy. This may reflect 
neoangiogenesis in active TB pleural lesions, since previous studies demonstrate 
increased serum vascular endothelial growth factor (VEGF) levels in TB, and 
evidence of VEGF expression in macrophages surrounding tuberculous lesions. 
(348,349)  
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Combining MRI morphology assessment with ECE assessment resulted in 
increased sensitivity of 92% and NPV of 97% at the cost of reduced specificity 
(78%) and PPV (55%). Hierholzer et al reported improvements in both sensitivity 
and specificity when combining morphology with signal intensity changes at MRI 
over morphology assessment alone (sensitivity 100% vs. 96% and specificity 93% 
vs. 80%). (77) 
As discussed in chapter 1, DCE-MRI and DWI-MRI have both previously been used 
in studies assessing patients with suspected MPM, based on differences in 
perfusion and tissue cellularity respectively. Both techniques have been reported 
to have excellent diagnostic sensitivity and specificity comparable and in some 
studies superior to that of ECE reported here. Giesel et al performed DCE-MRI in 
19 patients with confirmed MPM and reported different contrast kinetic 
parameters between tumour tissue and normal tissue, (117) however, 10/19 
(53%) of these patients had bulky stage IV disease, which adds little value over 
morphological assessment. Coolen et al performed quantitative analysis of 
images taken at DWI-MRI in 31 patients with suspected PM, reporting on overall 
sensitivity of 71% and specificity 100% for PM. When combining this data with 
contrast enhancement patterns at DCE-MRI, diagnostic performance improved to 
a sensitivity of 93%, at the cost of a reduced specificity of 94%. (90) In a later 
study, Coolen et al reported on a novel biomarker of PM at DWI-MRI – pleural 
pointillism. (350) They defined this as the presence of multiple, heterogeneous 
areas of pleural hyper-intensity at high b value DWI-MRI. The visual-based 
analysis methodology of pleural pointillism was felt to be simpler than 
calculating ADC values as was previously used when assessing PM using DWI-MRI. 
Using this novel imaging biomarker in a study of 100 patients, pleural pointillism 
differentiated benign from malignant pleural lesions with a sensitivity of 93% and 
specificity of 79%. (350)   
However, as discussed previously, DWI-MRI is limited by image quality due to low 
signal-to-noise ratio with frequent image distortion. (106) DCE-MRI also has 
limitations, as it requires a mass lesion to define an adequate ROI, and image 
acquisition is limited to a finite number of slices so the entire hemithorax, and 
therefore pleura, cannot be assessed. This limits its clinical utility in the early 
detection of MPM, which typically has a sessile growth pattern and rarely 
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presents as a mass lesion in early stage disease. Similarly, quantitative perfusion 
parameters at DCE-CT have been shown to correlate with tumour MVD. (351-353) 
Previous studies have reported on the potential utility of perfusion CT in the 
differentiation of benign from malignant pulmonary nodules. (354) In addition, 
results from a pilot study assessing DCE-CT in 13 patients with MPM, imaging a 
5.5cm axial extent of the thorax, reported correlation of contrast uptake with 
tumour burden and differential contrast uptake in patients undergoing 
chemotherapy versus observation alone. (314)  However, the role of perfusion 
CT in the differentiation of PM from benign pleural disease has not been widely 
studied. A potential advantage of perfusion CT over MRI- ECE, described here, is 
the greater availability of CT scanners and a quicker acquisition time. However, 
current perfusion CT methods do not allow complete assessment of the entire 
pleura, as is reported here using MRI, since perfusion CT is currently limited to 
defined sections of the thorax. Furthermore, high radiation exposure has so far 
limited clinical deployment of perfusion CT on a routine basis. (110,316)  
PET-CT also offers potential advantages over the MRI methods reported here. In 
MPM, PET-CT out-performs both CT and MRI in assessment of nodal and distant 
metastases. (140) In addition, previous studies report elevated maximal 
standardised uptake values (SUVmax), in PM, relative to benign disease and high 
sensitivity and specificity (pooled sensitivity of 95% and specificity of 82%) in a 
meta-analysis (89), However, PET-CT specificity is reduced in TB pleuritis (91), 
as is reported here for MRI-ECE, and following talc pleurodesis (220,355,356). 
PET-CT sensitivity is also reduced in early stage MPM, and epithelioid sub-types. 
(89,92) This significantly limits the utility of PET-CT as an early diagnostic test, 
particularly in effusion-dominant cases of MPM, which are most commonly of 
epithelioid origin.  
 
The principal advantage of ECE assessment described herein is its applicability to 
patients with minor pleural thickening (and therefore early disease stage) and 
the ability to assess multiple areas of pleura rather than being confined to a 
limited number of slices. In this study, 49/58 (84%) patients had pleural 
thickening <10mm and 47/58 (81%) lacked gross tumour nodules. Median pleural 
thickness for all patients 5mm (IQR 4 – 7mm)) and the minimum pleural thickness 
was 2.33mm. Of the 58/66 patients who underwent contrast-enhanced MRI and 
subsequent ECE assessment, 31/58 (53%) had a diagnosis of MPM and the 
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majority of these patients (64.5% (n=20) had IMIG stage I disease. Despite this, 
ROI placement and assessment for ECE was possible in all cases and with 
superior sensitivity and comparable specificity to CT and MRI morphology for PM, 
and similar diagnostic performance reported by Falaschi et al and Boraschi et al. 
Importantly, the patients included in these earlier studies had pleural thickening 
>10mm, or significant but undefined pleural thickening. (99,100)  
In addition, the native T1 of the tissue of interest needs to be known or acquired 
in order to allow calculation of contrast kinetic parameters such as amplitude, 
kep and kel at DCE-MRI. In cardiac MR imaging, the native T1 of the myocardium 
changes with pathology, for example, there is an increased T1 with myocardial 
oedema following infarction or with cardiac amyloidosis or lupus and a decrease 
in T1 in conditions with lipid or iron overload. (357,358) It is therefore possible 
that the native T1 of pleura may differ between underlying pathologies. Given 
the significant heterogeneity of disease distribution in MPM, this could therefore 
result in significant difficulties in accurately calculating contrast kinetic 
parameters at DCE-MRI. An additional advantage of ECE, as described in this 
chapter, over DCE-MRI therefore, is that the methodology does not require 
knowledge of the native T1 of the pleura to allow for ECE assessment.  
3.5.3 CT and MRI Morphology in Pleural Malignancy 
The presence of morphological features at CT and MRI that were used to classify 
patients as having PM in this study, including the presence of a pleural rind, 
nodular pleural thickening, fissural pleural thickening, parietal pleural 
thickening >1m and evidence of invasion of the diaphragm or chest wall are 
consistent with those commonly reported in previous CT and MRI studies 
assessing patients with PM. (40,76,79,81) These studies have all demonstrated 
that these features are consistently more commonly visualised in PM than in 
benign pleural disease.   
3.5.3.1 Diagnostic Performance of CT Morphology 
The diagnostic performance of CT morphology reported in this study (sensitivity 
56%, specificity 77%) is concordant with findings of recently reported studies by 
Hallifax et al, who reported CT sensitivity of 68% in 370 patients referred for 
LAT, (82) and by Tsim et al, who reported CT sensitivity of 58% in 315 patients at 
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initial presentation with suspected PM. (83) Both of these studies utilised the 
reporting radiologist’s original report, without any study-specific CT reporting. 
This better replicates clinical practice than the current study, where all CT 
scans were assessed by expert thoracic specialist radiologists. CT scans that 
were reported by thoracic radiologists in the previous study by Tsim et al 
demonstrated a higher level of sensitivity (68%). (83) However, the patients 
included in this study were recruited at the time of presentation, rather than 
prior to pleural biopsy as in the current study. The current study population 
could therefore be considered to be a more difficult to diagnose population than 
the one described in the original study as patients had already undergone initial 
assessment and pleural cytology examination and still required further 
assessment with pleural biopsy.  
The specificity reported in the current study is similar to numerous previous CT 
imaging studies, including Metintas et al who reported up to 70% sensitivity and 
65 – 95% specificity in a retrospective review of 215 patients with benign and 
malignant pleural disease (81) and Hierholzer et al, who reported sensitivity of 
93% and specificity of 87% in a retrospective review of 42 patients. (77) 
However, the sensitivity reported here is lower than that reported in this 
previous study. One possible explanation is that one of the false negative cases 
of MPM (patient 17, see Table 3.6) had an arterial-phase CT performed, which is 
associated with a significantly reduced sensitivity in comparison to venous phase 
CT. (83) In addition, all CT scans performed in the current study were acquired 
as part of routine clinical work-up and were therefore performed under local 
imaging protocols. Many authors recommend delaying image acquisition to 60 
seconds post-contrast in order to allow optimum assessment of the pleura. 
(330,359) It is therefore possible that these earlier studies, which included CT 
scans acquired as per research protocols, would have utilised more optimum 
contrast timing than that used in herein.  
Similarly, a study by Traill et al demonstrated superior sensitivity (84%) and 
specificity (100%) in comparison to the present study. (360) However, the earlier 
study included a small number of patients with benign pleural disease (8/40 
(20%)) relative to the current study ((22/58 (38%)). The false positive cases in 
the current study included 2 patients with TB pleurisy who were both noted to 
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have irregular pleural thickening at CT, resulting in malignant classification. 
Circumferential and nodular pleural thickening have previously been noted to 
feature in as many as 30% of cases of pleural TB at CT. (361) While the earlier 
study by Traill et al did include one patient with TB pleurisy, no pleural 
abnormality was identified on their CT. (360) 
The discordance between ‘real-life’ clinical imaging acquisition and reporting 
and research imaging acquisition and reporting highlights that although CT (and 
MRI) morphology can be highly accurate, these are operator-dependent, 
subjective processes.  
3.5.3.2 Diagnostic Performance of MRI Morphology 
The diagnostic performance of MRI morphology demonstrated in this study 
(sensitivity 68%, specificity 85%, PPV 77%, NPV 78%) is similar to results reported 
in previous studies of MRI assessment of PM. While MRI is typically reserved for 
staging, particularly prior to surgical resection, in MPM rather than as a 
diagnostic tool, (359) previous studies have demonstrated diagnostic 
performance comparable to CT in the differentiation of PM from benign pleural 
disease. (77,79,362) Hierholzer et al reported high sensitivity of 96% and 
specificity of 80% for PM in a retrospective review of 42 patients. (77) Similarly, 
Coolen et al reported sensitivity of 81% and specificity of 73% when assessing MRI 
morphology (and principally the finding of mediastinal pleural thickening) for the 
detection of PM in a prospective study of 100 patients with suspected MPM. (109)  
However, similar to CT morphology assessment, MRI morphology is an operator-
dependent, subjective assessment. The diagnostic performance of MRI 
morphology in routine clinical practice is therefore potentially lower than that 
reported in previous and this current study. 
3.5.4 Reproducibility 
The more objective nature of ECE suggests that this novel biomarker could 
improve consistency in radiological reporting of PM that is frequently responsible 
for reduced diagnostic performance of more subjective morphological 
assessment in clinical practice. (83) ECE in this study demonstrated higher inter-
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observer agreement (κ = 0.784) than both CT (κ = 0.65) and MRI morphology (κ = 
0.593). However, while the presence or absence of ECE is an objective 
assessment, the ROI placement is clearly a subjective, operator-dependent 
process. There is therefore the potential for sampling ‘error’, particularly in 
patients with a heterogeneous disease process such as MPM. 273/482 (57%) ROI 
placed in patients with PM did not demonstrate ECE and all of the false negative 
cases (n=3) had a diagnosis of MPM without evidence of macronodular disease 
(Table 3.6). These false negatives may represent ROI being placed on areas of 
benign pleural tissue interspersed with pleural tumour. Analysis of individual ROI 
contrast enhancement behaviour demonstrated superior discriminatory power 
when confounding ROI exhibiting a benign enhancement pattern (i.e. ROI not 
demonstrating ECE) in patients with PM were excluded (ROISIG AUC improved 
from 0.776 (95% CI 0.744 – 0.808) to 0.938, (95% CI 0.918 – 0.957).  
3.5.5  The Biological Basis of Early Contrast Enhancement 
In patients with MPM, MVD with lumen, measured in pleural tissue stained with 
pan-endothelial cell marker Factor VIII, positively correlated with MSIG at 
contrast-enhanced MRI, a surrogate marker for ECE (r 0.426, p=0.02) in this 
study. A relationship between MSIG and MVD with lumen measured using pan-
endothelial cell marker CD34 was also identified, however in contrast to Factor 
VIII immunostain, this was a negative correlation (r -0.412, p=0.037). No 
relationship was identified in patients with benign pleural disease. Importantly, 
our MRI and tissue perfusion measurements were performed prior to any 
intervention that could have altered the pleural microcirculation, including 
pleural drainage, pleurodesis or chemotherapy. This suggests that ECE is a 
perfusion-based biomarker, which is present in patients with PM because of 
increased MVD within areas of pleural tumour. Similar to the findings in the 
current study, contrast kinetic parameters at MRI have been reported to 
correlate with MVD measured in glioma, (363) breast lesions, (338) prostate 
cancer (364) and mesothelioma. (118) Since ECE was defined based on 
observations in patients with macro-nodular tumour (MPM in 5/6, secondary PM 
in 1/6) it is possible that a different definition may perform better in patients 
with lower volume pleural tumour or in cancers of different types, in which 
different microvascular or other features predominate. However, the correlation 
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we observed between tissue MVD and MSIG in MPM (r=0.4258, p=0.02, n=28) 
appeared preserved, and indeed more powerful, when this analysis was confined 
to patients without macro-nodules (r=0.6594, p=0.003, n=18). 
Tumour angiogenesis is now well-established as a prognostic biomarker in human 
solid tumours, including breast cancer, (365) prostate cancer (366) and 
NSCLC.(367) Kumar-Singh et al reported significantly increased intra-tumoural 
MVD in malignant mesothelium relative to non-malignant mesothelium and found 
that higher intra-tumoural MVD was associated with significantly worse survival 
outcomes in a study of 25 cases of MPM. They also described heterogeneity in 
the degree of vascularity both within and between tumour samples. (299) 
Edwards et al also demonstrated worsening survival outcomes associated with 
increasing MVD in a larger study of 104 cases of MPM. (298) Similar to the 
findings in these earlier studies, increasing MVD measured using Factor VIII was 
associated with worsening survival in this current study (Figure 3.13(a)). 
However, in contrast, intra-tumoural MVD measured using CD34 in this study was 
not found to be prognostically significant (Figure 3.13(b)) and there was no 
significant difference in MVD between patients with PM and those with benign 
pleural disease. One possibility is the individual antibodies used to quantify MVD 
in this study. Intra-tumoural MVD, measured using pan-endothelial cell markers 
such as Factor VIII and CD34, is a valid measure of tumour angiogenic activity. 
(368,369) CD34 and Factor VIII antibodies used in the current study have 
previously been shown to demonstrate reproducible immunostaining of 
microvessels in both frozen and paraffin-embedded tissue sections. (369,370) 
However, while Factor VIII is known to be a highly specific antibody for detecting 
intratumoural microvessel density, CD34 has been shown to also stain peri-
vascular stromal cells and lymphatic vessels. The reduced specificity of CD34 as 
an endothelial cell marker may have contributed to the contradictory 
relationships demonstrated between Factor VIII and CD34 immunostains and the 
lack of prognostic significance of MVD measured using CD34 in this study.  
Kumar et al demonstrated a correlation between overall survival and MVD 
measured using CD105 but not CD34 immunostain in breast cancer. Similarly, 
Taneka et al demonstrated that MVD measured using CD105, but not CD34 in 
patients with NSCLC. While Edwards et al did demonstrate a correlation between 
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overall survival and MVD measured using CD34 in 104 patients with MPM, they did 
report positive staining of stromal elements, which had morphological features 
of myofibroblasts, in 17% of cases and this precluded MVD quantification in 11% 
of all cases. (298) 
Another possibility for the differing result in the current study is the significant 
heterogeneity previously reported in the distribution of neovascularization 
within individual MPM tumour samples, (299) which composes the vast majority 
of our patients with PM (86% (n=31)). This highlights an important difference in 
methodology between our study, where there was computerised quantification 
of MVD within an entire section of tumour, and the previously discussed studies 
where MVD was quantified within selected ‘hot-spots’ of tumour.  
Identification of vascular hot spots at low magnification followed by 
quantification of MVD within these hot spots at 200x field was first described by 
Weidner et al (365) who initially examined tumour vascularity in breast cancer.  
An alternative to this method is microvessel quantification using Chalkley 
counting. Similar to the method described by Weidner et al, the Chalkley 
method involves examining tumour sections at low magnification to identify a 
vascular hot spot, before an eyepiece graticule containing 25 randomly 
positioned dots is rotated at higher magnification so that the maximum number 
of dots are on the vessels within the hot spot. The number of overlying dots are 
then counted rather than individual microvessels. (368) However, these methods 
can be subject to significant inter-observer variability and the hot spots are 
unlikely to be representative of the entire tumour. Computer-aided analysis 
systems, such as the one described herein, are a valid alternative to manual 
vessel counting (371-373) and has the advantage of being more objective than 
manual vessel counting. in addition, it allows counting within entire tumour 
sections, rather than restriction to vascular hot spots, and allows further 
information regarding tumour vascularity, such as vessel perimetry, to be 
defined.   
However, none of these described methods allow for ‘sampling’ of the entire 
tumour as measurements can only be made within biopsy samples, which may 
not be representative of the entire disease. This is particularly important in MPM 
due to its heterogeneous disease distribution. It also highlights another 
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important potential advantage of using an imaging biomarker to quantify tumour 
angiogenesis, as it would allow sampling of the entire tumour, while being non-
invasive.  
Clearly tumour angiogenesis is a dynamic process and therefore the degree of 
tumour vascularity and intra-tumour MVD will change over time. Assessment of 
MVD in tumour specimens taken at pleural biopsy therefore only provides a 
‘snapshot’ of tumour angiogenesis as it was at the time of biopsy. Changes in 
tumour angiogenesis over time cannot be assessed using intra-tumoural MVD 
unless repeated biopsies are taken. However, signal intensity measurements (in 
the form of MSIG) at contrast-enhanced MRI in this current study were 
prognostically significant (median survival 11 months for high MSIG vs. 20 months 
for low MSIG, p=0.047), see Figure 3.14. This highlights its potential as a 
prognostic biomarker, particularly as it can be repeated serially as it is non-
invasive and does not require ionising radiation.   
3.5.6  Potential clinical implications 
While MRI is becoming increasingly available, the ability to assess patients with 
suspected MPM with thoracoscopy remains relatively limited to specialist 
centres. If validated in larger studies, ECE may improve the accuracy of pleural 
imaging in cases of suspected MPM. This may allow pathway rationalization, 
directing patients appropriately to specialist centres and early invasive 
sampling, including early thoracoscopy when MPM appears likely. The results of 
our ROISIG post-hoc analyses suggest that benign (ECE-negative) ROI in patients 
with PM negatively contribute to discriminant performance. This is consistent 
with a hypothesis that these data originate from areas of interspersed benign 
disease in patients with discontinuous malignant pleural lesions, which are 
commonly observed at thoracoscopy. Measurement of SI and assessing ECE 
behaviour across the entire pleura using a volumetric approach could be 
developed in future studies. Theoretically, this would allow the pleura to be 
treated as a ‘single ROI’. Pleural SIG, being a continuous variable like ROISIG, 
could then be applied at different thresholds depending on the clinical context. 
For example, a lower threshold (maximizing sensitivity) in a pleural staging 
population vs. a higher threshold (maximizing specificity) for screening of 
asbestos-exposed persons for early MPM. MRI’s ability to acquire data without 
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use of radiation would be significant additional advantage in a screening setting. 
However, the performance of ECE in lower prevalence populations is likely to be 
inferior to that described here, and this would require further detailed study. 
Additionally, MSIG calculated at ECE assessment may provide important 
prognostic information. The significant correlation between intra-tumoural MVD 
as a marker of tumour angiogenesis and MSIG at contrast-enhanced MRI 
highlights its potential as a future predictive biomarker of response to anti-
angiogenic chemotherapeutic agents. This would however require significant 
further study to assess its performance in this regard. 
 
3.5.7  Limitations of this study 
The principal limitation is the relatively small sample size, reflected in relatively 
wide confidence intervals around some measures of diagnostic performance. 
Nevertheless, we have assessed ECE in large number of individual ROI (n=814) 
using a technique which appears reproducible.  
A second limitation, as discussed earlier, is that although ECE is objectively 
defined, the user-defined ROI from which SI is measured are not. Our pre-
defined strategy for ROI definition was devised to minimize variation. In nodular 
cases with visible tumour, ROI definition mirrored thoracoscopic tissue sampling, 
i.e. sampling of all malignant-looking disease if available, and if not sampling of 
multiple, evenly distributed areas of pleura. The method chosen for non-
nodular, effusion-dominant, cases was designed to be consistent, with ROIs 
defined on similar positions of similar slices by different operators. Although we 
demonstrated moderate ECE reproducibility, which exceeded that for MRI/CT 
morphology, this element of the method is a source of potential disagreement. 
Measuring SI and assessing ECE behaviour of the entire pleura, using a volumetric 
approach, could theoretically overcome this, but would require significant 
further development.  
An additional limitation is that we did not perform perfusion CT assessment for 
comparison with ECE, as all CT imaging in this study was performed as part of 
routine clinical work-up. However, as previously discussed, perfusion CT has not 
yet been widely studied in PM and is not routinely used in the assessment of 
patients with suspected PM in most centres at present. 
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Another limitation is the duration of follow-up of patients diagnosed with benign 
pleural disease. Median follow-up for patients with benign pleural disease was 20 
(8 - 27) months. The prevalence of MPM reported here may therefore be an 
underestimate of the true MPM rate since it is routine practice to follow-up 
patients with BAPE for a minimum of 2 years, because of the potential false 
negative pleural biopsy rate of up to 12% reported in previous case series. (45) 
However, all cases of BAPE underwent clinical follow-up at a specialist pleural 
clinic, with re-biopsy if there was any evidence of progressive disease. 
Furthermore, it remains unclear whether MPM during this 2-year follow-up 
period represents a genuine false negative biopsy at original assessment or a 
new diagnosis of MPM.  
The final limitation of the methods described is the time taken to perform ECE 
analysis. Although not excessive it is slower than subjective morphology 
assessment.  Evolution of the technique, including increased computer 
automation should allow reduction in the time required in the future.  
3.6  CONCLUSION 
In this chapter, the methods for acquisition and measurement of a novel, and 
largely objective MRI biomarker of pleural malignancy – Early Contrast 
Enhancement (ECE) have been described. CT remains an important imaging tool 
in the assessment of suspected PM, however in clinical practice it is limited in its 
sensitivity for detection of early stage MPM and its specificity for differentiating 
reactive effusion from pleural metastatic disease in lung cancer, particularly 
when pleural thickening is minimal.  
Within the limitations of this study, ECE appears to be a sensitive, specific and 
reproducible, perfusion- based biomarker of PM. The methodology used to define 
ECE is applicable to patients with minimal pleural thickening, making this 
technique useful in patients with pleural effusion predominant, low volume 
metastatic pleural disease and early stage MPM. 
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4 Chapter 4: Volumetric Assessment of Malignant 
Pleural Mesothelioma 
4.1 INTRODUCTION 
Accurate staging in cancer practice is of vital importance for patient 
management and clinical research as it provides information regarding patient 
prognosis and suitability for radical treatment measures and clinical trials. It 
also allows researchers to group patients appropriately in order to accurately 
compare treatment outcomes and allows clinicians to monitor disease and 
therapeutic response. In addition, accurate cancer staging and stage groupings 
allow international comparisons regarding timing of patient presentation, 
treatment rates and overall cancer survival rates to be made. 
4.1.1 Staging of Malignant Pleural Mesothelioma 
Well-established staging systems exist for most cancers, including lung cancer, 
often based on large international datasets. One of the most widely used cancer 
staging systems is the ‘TNM’ system proposed by the American Joint Committee 
on Cancer (AJCC) and the International Union for Cancer Control (UICC). The 
TNM staging system is based on the extent of the primary tumour (T), the degree 
of lymph node involvement (N) and the presence or absence of metastasis (M), 
with patients being grouped into stage grouping based on their individual T, N 
and M. (374) However, staging in MPM is difficult due to its unusual, non-
spherical growth pattern, proximity to intercostal muscle and vessels and the 
limitations of current imaging techniques in accurately quantifying disease 
extent, particularly of the primary tumour (T).  
The first mesothelioma staging system was proposed by Butchart et al in 1976, 
(375) based on 29 patients undergoing pleuro-pneumonectomy: Stage I – tumour 
confined to ipsilateral pleura, lung and pericardium; stage II – tumour invading 
chest wall or mediastinum, disease involving contralateral pleura or lymph nodes 
within the chest; stage III – tumour infiltrating through the diaphragm with 
peritoneal involvement or lymph node involvement outside the chest; stage IV – 
distant blood-borne metastases. Similarly, Sugarbaker et al proposed a 
mesothelioma staging system based on 55 patients undergoing pleuro-
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pneumonectomy, which predominantly differentiated patients based on surgical 
resectability and lymph node involvement. (376)       
Subsequently, the International Mesothelioma Interest Group (IMIG) proposed a 
TNM-based staging system for MPM, (121) which was adopted by the American 
Joint Committee on Cancer (AJCC) and Union for International Cancer Control 
(UICC) in the 7th edition of their staging manuals. (377) This staging system was 
largely derived from evidence from small scale retrospective, surgical data. T 
staging was based on survival differences reported by Boutin et al based on the 
presence or absence of visceral pleural involvement (378) (T1a versus T1b); 
surgical resectability (T2 and T3 disease resectable by extra-pleural 
pneumonectomy +/- recection of focal chest wall disease versus unresectable T4 
disease). N descriptors were based on nodal staging for non-small cell lung 
cancer (NSCLC). M descriptors were identical to that used in early (5th) editions 
of lung cancer staging (M0 – no distant metastatic disease, M1 – metastatic 
disease outside of the ipsilateral hemithorax). (121)   
However, the IMIG proposed mesothelioma staging system had several 
limitations. The International Association for the Study of Lung Cancer (IASLC) in 
collaboration with IMIG reviewed the staging system against a large, 
retrospective database comprising 3101 patients from 15 international centres. 
Review of the staging in 1056 patients in whom both clinical and pathologic 
staging data was available, demonstrated significant rates of upstaging of 
patients thought clinically to have early (stage I/II) disease following 
pathological assessment. (125) Differentiation between some of the T-
descriptors is only feasible at surgery or thoracoscopy, e.g. T1a (disease limited 
to parietal pleura only) versus T1b (disease involving visceral pleura), and much 
more difficult to perform on imaging assessment alone. A lack of significant 
survival difference between T1a and T1b stages, even at pathological staging, 
has subsequently been demonstrated. (126)  
In addition, the nodal staging system for MPM is identical to that for NSCLC, 
despite the fact that the lymphatic drainage of the pleura is different to that of 
the lung. (122,379)  
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Abdel Rahman et al retrospectively reviewed lymph node involvement in 53 MPM 
patients undergoing EPP and systematic lymph node dissection or sampling. 
18/53 (34%) had evidence of lymph node involvement, of these 7/18 (39%) had 
mediastinal lymph node metastases without any evidence of hilar lymph node 
involvement. 7 patients included in this study did not have evidence of lung 
parenchymal involvement, and none of these patients had evidence of hilar 
nodal involvement. The authors therefore raise the possibility that nodal spread 
in MPM is different from that in lung cancer, spreading initially to mediastinal 
nodes, with hilar nodal involvement only occurring via invasion of the lung 
parenchyma. (124) This perhaps explains the lack of significant survival 
difference between cN1 versus cN2 disease (median overall survival 16.9 months 
vs. 17.4 months respectively, HR 1.06, p=0.78) on review of the large IASLC 
mesothelioma database. (127) 
As a result, updates to the IMIG/7th edition TNM mesothelioma staging system 
have recently been proposed, including collapsing the previous T1a and T1b 
descriptors into a single T1 stage. (126) N-descriptors have also been updated, 
more accurately reflecting the drainage pattern of the pleura, (122,124,379) 
with N1 disease now including any ipsilateral, intra-thoracic nodal involvement 
and N2 disease now including ipsilateral supraclavicular, or contralateral nodal 
involvement. (127)      
4.1.2 Imaging Modalities for the Staging of MPM 
4.1.2.1 CT in the Staging of MPM 
CT remains the most commonly used imaging modality for the detection and 
staging of MPM. Subtle invasion through chest wall or diaphragm may be missed 
utilising CT however, and this is therefore typically better assessed at MRI. (130) 
In addition, while distant metastases, including pulmonary metastases can 
usually be readily identified on CT, (132) the sensitivity and specificity of CT for 
detecting nodal metastases is poor, at 56% and 39% respectively (95% confidence 
intervals not reported). (130) Review of the IASLC database also demonstrated 
an underestimation of nodal involvement at clinical staging (22%, 226/1029 
clinically staged as having nodal metastatic disease versus 38% (321/851) 
following pathological staging). (127) Of note, only 56% of clinically staged 
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patients were reported to have had PET imaging, further highlighting the 
limitations of CT for nodal staging. Additional staging investigations such as PET-
CT and MRI are therefore often applied when patients are being considered for 
radical treatment such as surgical resection.  
 
4.1.2.2 PET-CT in the Staging of MPM 
Plathow et al assessed the accuracy of CT, PET-CT and MRI for the selection of 
patients with potentially-operable disease by acquiring all scans prior to surgery 
in 54 patients (52 of whom subsequently underwent surgery). They concluded 
that PET-CT offered the highest diagnostic accuracy, for example in stage III 
disease, diagnostic accuracy rates for CT, MRI and PET-CT were 75% (sensitivity 
75%, specificity 100%), 90% (sensitivity 91%, specificity 100%) and 100% 
(sensitivity 100%, specificity 100%), respectively, largely due to the superior 
performance of PET-CT in detecting nodal and distant metastases. (140) 
Integrated PET-CT has been shown to have better sensitivity than conventional 
CT for the detection of nodal metastases and extra-thoracic metastases. 
(139,141,142) However, the limitations of integrated PET-CT should also be 
appreciated in MPM. Poor spatial resolution translates into relatively poor 
sensitivity for extra-pleural invasion. One previous study reported a sensitivity of 
only 67% (at 93% specificity) for the detection of local invasive T4 disease (141) 
and MRI offers superior performance in this regard. Therefore, PET-CT has 
important limitations but some utility in the staging of patients who are being 
considered for radical therapies and/or trials, particularly in the detection of 
nodal and extra-thoracic disease.   
 
4.1.2.3 MRI in the Staging of MPM 
MRI is superior to CT in detecting invasion of chest wall, diaphragm and bony 
structures, which was best visualised on T1-weighted images, and important for 
both detection and staging of MPM. (79,144) Stewart et al performed contrast-
enhanced 1.5-Tesla MRI scans on 69 patients with apparently resectable MPM 
following contrast-enhanced CT scanning. MRI detected the presence of 
unresectable disease in 17/69 (22%) of these patients not previously 
demonstrated on CT. This included mediastinal involvement, diaphragmatic 
invasion, chest wall infiltration and contralateral pleural disease. (145) Currently 
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MRI is not routinely used for diagnostic assessment of MPM but has clinical utility 
in MPM staging and assessment of the presence of infiltrative disease that would 
preclude surgical resection. 
 
4.1.3 Volumetric Assessment of MPM 
Primary tumour volume has been previously demonstrated to be of prognostic 
significance (see Table 4.1). Pass et al first reported shorter median overall 
survival associated with higher pre-operative tumour volume measured using 
free-hand manual delineation of tumour at contrast-enhanced CT in patients 
with MPM undergoing cytoreductive surgery. (134) Similarly, Gill et al 
demonstrated poorer survival in epithelioid MPM with higher primary tumour 
volume estimated at CT in patients undergoing extrapleural pneumonectomy. 
(135) More recently, increased primary tumour burden estimated using maximal 
pleural thickness at CT has been demonstrated to be associated with worsening 
survival and increased nodal involvement in MPM. (126)  
Tumour volume assessment at 18F-FDG PET-CT, utilising SUV-based thresholding 
to define the volume of interest, has previously been studied as a prognostic 
biomarker (380) and as predictor of response to surgery and systemic treatment. 
A higher metabolic tumour volume was reported to be associated with tumour 
recurrence after extrapleural pneumonectomy or stable or progressive disease 
following chemotherapy. (381) 
While promising, many of these earlier studies assessing primary tumour burden 
in MPM have been limited by significant inter-observer variability and the 
laborious or complex nature of manual tumour delineation/segmentation. (382) 
Delineation of tumour from surrounding structures such as the mediastinum, 
atelectatic lung and intercostal muscle can be challenging, particularly as 
neighbouring structures are often of similar HU to pleura, as previously 
demonstrated by Chen et al. (383) MRI has superior sensitivity and inter-observer 
reproducibility than CT at assessing early chest wall and diaphragmatic 
involvement in MPM due to its excellent contrast and spatial resolution. 
(132,384) This makes MRI a potentially more attractive imaging modality in the 
assessment of primary tumour volume, as it would allow more accurate 
assessment of tumour extent and delineation from adjacent structures such as 
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intercostal muscle and diaphragm. In addition, biologic parameters such as 
signal intensity can be measured and potentially exploited for volumetric 
assessment at MRI. Plathow et al have previously performed tumour volume 
measurements at MRI in order to assess response to systemic treatment in 
patients with MPM by combining 2D segmented volumes generated semi-
automatically using HASTE sequences. (385) 
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Table 4.1. Summary of results of previous studies assessing the prognostic significance of imaging-derived tumour volume in patients 
with Malignant Pleural Mesothelioma 
Study 
Number 
of 
patients 
Imaging 
modality 
Median 
tumour 
volume 
(cm3) 
Inter-
observer 
variability 
Definition of high 
tumour volume 
(cm3) 
Median o.s. 
(low tumour 
volume) 
Median o.s. 
(high tumour 
volume) 
Statistical 
significance 
Pass et al (130) 47 CT 100 NR ≥100 22 months 11 months 0.03 
Liu et al (382) 30 CT 473 ICC 0.993 >618.49 21.5 months 10.2 months 0.07 
Gill et al (131) 88 CT 319 NR >500 24.4 months 12 months <0.001 
Gill/Rusch et 
al (132, 133) 129 CT NR 
Spearman 
Correlation 
0.822 
Divided into Tertiles: 
(1) 91.2; (2) 245.35;  
(3) 511.35 
(1) 37 months;  
(2) 18months (3) 8 months <0.0001 
o.s.; overall survival, NR; not recorded, ICC; intraclass correlation co-efficient 
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4.2 AIM AND OBJECTIVES 
The aim of this study was to develop methods for the acquisition and 
measurement of tumour volume, in patients with MPM, at contrast-enhanced 
MRI. We hypothesised that primary tumour volume measured at contrast-
enhanced MRI would correlate with overall disease stage and/or subsequent 
survival.   
Study objectives and outcome measures are summarised in Table 4.2.
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Table 4.2. Research Objectives and Outcome Measures for the MRI Volumetry study 
         
Research Objectives Outcome Measures 
Primary 
    
To determine a method for MPM primary tumour 
volumetry based on contrast-enhanced MRI that is:                                                                      
a) accurate                                                                           
b) reproducible                                                                     
c) practical  
Outcome of a scoring matrix for different methodologies 
comprised of:
a) Accuracy in measurement of an MRI phantom 
volume 
b) Accurate coverage of pleural tumour in patients, 
based on subjective visual assessment 
c) Intra-observer agreement by intra-class correlation 
co-efficient 
d) Time taken to complete volume analysis 
  
Secondary   
    
1. To determine the correlation between primary tumour 
volume and clinical T-stage 
1. Primary Tumour Volume at MRI and Clinical T-stage 
based on regional Mesothelioma MDT staging 
2. To determine the relationship between primary 
tumour volume and subsequent survival 
2. Primary Tumour Volume at MRI and Median Overall 
Survival 
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4.3 METHODS 
4.3.1 Ethical Approval 
Ethical approval for this study was provided by the West of Scotland Research 
and Ethics Service (reference 12/WS/0219 and 13/WS/0240). NHS Greater 
Glasgow and Clyde acted as the study sponsor. 
4.3.2 Study Population 
Patients recruited in this chapter were recruited from a pilot study conducted to 
establish MR imaging acquisition and analysis protocols, and as part of the 
DIAPHRAGM MRI sub-study (further details of which are included in chapter 2). 
Patients presenting with suspected pleural malignancy, as defined by a pleural 
effusion or pleural-based mass lesion, to the Southern General Hospital (now the 
Queen Elizabeth University Hospital), Gartnavel General Hospital, Victoria 
Infirmary and Glasgow Royal Infirmary between January 2013 and October 2016 
were invited to participate. Patients were identified at respiratory outpatient 
clinics and in acute admission units or respiratory inpatient wards. All patients 
were reviewed by myself or Dr Kevin Blyth (Consultant Respiratory Physician) 
who reviewed the need for pleural biopsy (either image-guided or 
thoracoscopically), based on clinical need and patient wishes, and their 
eligibility for the DIAPHRAGM MRI sub-study.  
Eligibility criteria for the DIAPHRAGM MRI sub-study are described in Chapter 3, 
section 3.3.2 (page 149 – 150). Only patients with complete contrast-enhanced 
MRI examinations and a final diagnosis of MPM were included in this volumetry 
study. 
4.3.3 Pleural Diagnostics and Staging 
All patients included in this chapter had pleural histology pursued by the 
following methods: LAT, VATS or image-guided pleural biopsy. All cases were 
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discussed at the West of Scotland Mesothelioma MDT, where pathological 
diagnosis and staging based on imaging, and where available, thoracoscopic 
findings, were confirmed. All patients were followed-up in the pleural clinic.  
4.3.4 MR Image Acquisition 
MRI acquisition methodology is described in detail in Chapter 3, section 5.2. 
Briefly, MRI scans were acquired using 3-T Siemens Magnetom Verio® (Siemens, 
Erlangen, Germany) between January 2013 and August 2015, and using a 3-T 
Siemens Magnetom Prisma® (Siemens, Erlangen, Germany) between August 2015 
and October 2016.  
T1-weighted, fat-saturated, 3D spoiled gradient echo sequences were acquired 
during a short breath-hold at end-inspiration (repetition time 2.8 - 3.23ms, echo 
time 1 - 1.08ms, field of view 400 – 440mm, matrix 224 x 100, flip angle 9°, slice 
thickness 1.8 – 1.9mm, no inter-slice gap). Number of slices acquired ranged 
between 104 – 144 slices (median 120 (IQR 120 – 128). Images were acquired at 
baseline pre-contrast and at 40 seconds, 80 seconds, 4.5 minutes, 9 minutes and 
13.5 minutes after intravenous gadobutrol contrast (Gadovist (0.1 mmol/kg), 
Bayer Healthcare Pharmaceuticals, Berlin, Germany) was administered, at an 
injection rate of 2 ml/second. All images were acquired in the coronal plane but 
were isotropic allowing tumour volume to be assessed in 3D.   
4.3.5 MRI Phantom 
An MRI phantom was developed in conjunction with the Department of Clinical 
Physics and Bioengineering, NHS Greater Glasgow and Clyde. It is composed of a 
Polymethyl methacrylate (PMMA) outer casing with a central solid cylinder of 
PMMA. A precise volume of water (1360cm3) was added, creating a shallow pool 
of fluid between the solid central cylinder of PMMA and the outer casing, broadly 
similar to the thin pleural space in humans, see Figure 4.1. The phantom was 
scanned multiple times, removing the phantom and then replacing it into the 
MRI scanner each time, using a 3-T Siemens Magnetom Prisma® (Siemens, 
Erlangen, Germany) scanner.  
217 
 
 
An acceptable error around the MRI-measured phantom volume was defined as a 
measured volume < +/- 5% of the true volume. 
 
Figure 4.1 MRI phantom. Panel A is a photograph of the MRI phantom containing 
a precise volume of fluid sitting in between the solid central PMMA cylinder and 
the outer casing. Panels B and C demonstrate MRI phantom imaged at T1-
weighted MRI in coronal (Panel B) and axial (Panel C) planes, where the thin 
layer of fluid (light grey) can be seen between the two layers of PMMA  
4.3.6 Image Analysis 
All images were anonymised and analysed in a blinded fashion by ST in batches. 
All pre- and post-contrast MR images were assessed for the time point at which 
maximum contrast enhancement and signal intensity separation between pleura 
and adjacent structures (intercostal muscle, pleural fluid and lung) occurred 
(see Figure 4.2). In the majority of patients (80% (n=25)), this occurred at 4.5 
minutes post intravenous contrast administration and this time point was 
therefore used for all further image analyses. 
Initial analysis methodology involved manual delineation of the pleura in every 
image slice using OsiriX for Mac (Pixmeo, Geneva, Switzerland), see Figure 4.3 
for an example. This methodology was discontinued due to the unacceptable 
amount of time taken to complete each analysis (approximately 65 minutes). 
Subsequently, a method using the ‘MIALite’ plug-in for OsiriX was trialled, which 
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utilised threshold-based segmentation of the pleura (see Figure 4.4 for an 
example). However, segmentation could only be ‘seeded’ from a circular ROI, 
and while a ‘blocking’ circular ROI could also be applied to limit segmentation to 
pleura, due to the circular nature of the ROI tool, there was significant inclusion 
of adjacent non-pleural structures or significant exclusion of pleura. This 
method was also felt to be too time-consuming to be applicable to future 
clinical practice (approximately 45 minutes per analysis). Finally, analysis using 
Myrian® software v2.0 (Intrasense®, Montpellier, France) was trialled, using four 
different analysis methodologies, all of which utilised semi-automated, 
threshold-based segmentation. MRI phantom volume was also defined using all 
four methodologies.  
 
Figure 4.2 Example of mean signal Intensity/time curves for ROI placed on 
pleura and adjacent structures in a patient with MPM. Peak contrast 
enhancement and separation of curves at 4.5 minutes post-contrast 
administration
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Figure 4.3 Manual delineation of pleural volume at contrast-enhanced MRI using OsiriX software
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Figure 4.4 Semi-automated volume segmentation in a patient with MPM at contrast-enhanced MRI, in coronal (Panel A), axial (Panel B) 
and sagittal (Panel C) planes, using the MIAlite plugin for OsiriX. Areas of similar signal intensity to the ‘seeding circles’ (not shown) are 
highlighted in red. The yellow ‘blocking circles’ are placed to prevent seeding in to adjacent structures. The final segmented volume is 
highlighted in green. 
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4.3.7 Segmentation using Myrian®  
Axial images were used for initial volumetric measurements due to familiarity 
with axial images from routine clinical practice and perceived easier delineation 
of anatomical structures, particularly at the extreme ends of the image series, 
and ease of free-hand ROI drawing. Once these measurements were complete, 
coronal and sagittal images were also reviewed for completeness.  
4.3.7.1 Use of a contour mask to constrain region growing 
For all four analysis methodologies subsequently described, a free-hand region of 
interest (ROI) ‘contour mask’ was defined prior to signal intensity threshold-
based segmentation to improve precision of the final segmented volume of 
interest. Creation of the contour mask allowed me to largely constrain 
subsequent signal intensity-based region growing to the pleura. Initially, image 
brightness was optimised for visualisation of the pleura before the ROI contour 
mask was defined, based on visual analysis and manual delineation of the pleura 
every 8 – 10 slices. Care was taken to delineate pleura from adjacent structures. 
The ROI contour mask was then extended through the entire image series semi-
automatically to create a complete contour mask (See Figure 4.5). Small 
adjustments to the semi-automated contour mask were then made if required. 
The ability to draw a free-hand contour mask with Myrian® software overcame 
the limitation of being restricted to blocking circles with the MIAlite plugin for 
OsiriX.
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Figure 4.5 Contour mask (grey) of pleural volume in axial (Panel A) and coronal 
(Panel B) planes, created semi-automatically using Myrian® software
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4.3.7.2 Segmentation based on signal intensity thresholds 
After creation of a contour mask, a semi-automated region-growing step 
followed, based on signal intensity threshold parameters. Four different signal 
intensity threshold parameters were defined, as described in the following 
sections. A semi-objective scoring matrix was used to define the optimum set of 
parameters to assess tumour volume.  
4.3.7.3 Segmentation Method 1 
The signal intensity threshold parameters for region growing in method 1 was 
defined from the median SI range from the 28/31 patients included in the 
volumetry study who were ECE positive, excluding SI data from ROI where ECE 
was negative (219/492 ROI excluded) (as described in Chapter 3). This SI range 
was +/- 81AU.  
Exclusion of ECE negative ROI to calculate the SI range was done due to the 
potential that these ROI were placed on interspersed areas of benign pleura in 
patients with MPM.  
The ‘3D wand’ tool available within Myrian® software was then used to measure 
signal intensity in up to 3 ROI manually placed on the pleura. Region-
constraining signal intensity threshold parameters were based on the SI 
measured by the 3D wand +/- 163AU. Segmentation of everything within the 
contour mask that had signal intensity within this SI threshold range was then 
performed automatically resulting in a segmented volume, see Figure 4.6. 
4.3.7.4 Segmentation Method 2 
The signal intensity threshold parameters for region growing in method 2 was 
defined using the signal intensity measured from all ROI (n=492) in MPM patients 
who were ECE positive (28/31). The median SI range for these patients was 
calculated as +/- 99AU. This SI range was tested as it was felt to be 
representative pleural sampling in an MPM population.  
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ECE negative ROI were not excluded as in method 1 so that a wide distribution of 
pleural ROI per patient remained included for the final median SI range 
calculation.  
The 3D wand tool was used as described in method 1, measuring SI in up to 3 ROI 
manually placed on pleura. The signal intensity threshold parameter was defined 
as the SI measured by the 3D wand +/- 99AU.  
Identical to method 1, subsequent region growing included all structures 
included within the contour mask with a signal intensity falling within this SI 
threshold parameter was performed automatically, see Figure 4.7. 
4.3.7.5 Segmentation Method 3 
The signal intensity threshold parameters for region growing in method 3 was 
based on the individual signal intensity range for each patient (31/31). Signal 
intensity was measured in 15 ROI for each patient, evenly distributed throughout 
the pleura as described in Chapter 3, section 3.3.6.3, page 162. The difference 
between the maximum measured SI and the minimum measured SI in these 15 
ROI was used as the SI threshold range. Each patient therefore had an individual 
signal intensity threshold parameter, based on what was felt to be 
representative pleural sampling.    
The 3D wand tool was then used to measure signal intensity in up to 3 ROI 
manually placed on the pleura as described for Segmentation Methods 1 and 2. 
Segmentation SI threshold parameters were based on the SI measured by the 3D 
wand +/- the SI range for that individual patient. Segmentation of everything 
within the contour mask that had signal intensity within this SI threshold was 
then performed automatically, resulting in a segmented volume, see Figure 4.8. 
4.3.7.6 Segmentation Method 4 
The SI threshold parameters used for segmentation in method 4 was based on 
the mean SI +/- 2 standard deviations (SD) measured in pleural ROI for each 
individual patient (31/31 patients included in the volumetry study). For patients 
with non-nodular pleural disease (20/31), the mean SI +/- 2 SD was based on SI 
measured in 15 ROI. For patients with nodular pleural disease (11/31), the mean 
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SI +/- 2 SD was based on SI measured in up to 15 ROI placed on nodular pleura 
plus an additional 6 ROI placed on areas of non-nodular pleura.  
The ROI SI range in non-nodular patients was normally distributed and +/- 2 SD 
therefore represented individualised 95% confidence intervals for SI threshold 
parameters. For the nodular patients, the ROI SI range was not normally 
distributed. +/- 2 SD therefore did not represent a 95% confidence interval for SI 
distribution in these patients. However, it was felt to be important to include 
additional SI measured from ROI placed on areas of non-nodular pleura to ensure 
inclusion of representative pleura in the final volume of interest.   
The ‘3D wand’ seeding step was not required for this method. Segmentation of 
all structures within the contour mask with a signal intensity falling within the 
segmentation SI threshold parameters were automatically segmented, (see 
Figure 4.9). 
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Figure 4.6 Semi-automated, threshold-based segmentation of pleural volume at 
contrast-enhanced MRI using Methodology 1 (SI of pleural ROI +/- 81AU). The 
segmented volume is highlighted in blue (Panels A (axial plane) and B (coronal 
plane). Panel C is a 2D image of the competed volumetric study from anterior, 
left lateral and posterior positions.   
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Figure 4.7 Semi-automated, threshold-based segmentation of pleural volume at 
contrast-enhanced MRI using Methodology 2 (SI of pleural ROI +/- 99AU). The 
segmented volume is highlighted in blue (Panels A (axial plane) and B (coronal 
plane). Panel C is a 2D image of the competed volumetric study from anterior, 
and left lateral positions.   
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Figure 4.8 Semi-automated, threshold-based segmentation of pleural volume at 
contrast-enhanced MRI using Methodology 3 (SI of pleural ROI +/- signal intensity 
range for individual patient). The segmented volume is highlighted in blue 
(Panels A (axial plane) and B (coronal plane). Panel C is a 2D image of the 
competed volumetric study from anterior and left lateral positions.   
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Figure 4.9 Semi-automated, threshold-based segmentation of pleural volume at 
contrast-enhanced MRI using Methodology 4 (mean signal intensity +/- 2SD for 
the individual patient). The segmented volume is highlighted in red (Panels A 
(axial plane) and B (coronal plane). Panel C is a 2D image of the competed 
volumetric study from anterior and left lateral positions.   
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4.3.8 Reproducibility 
Volume was measured in each of the 3 repeated MRI phantom scan series to 
estimate variance between measurements. Pleural volumes for 15/31 randomly 
selected cases were re-measured by ST, after a lapsed time period of 
approximately 3 months in order to assess intra-observer agreement for all 4 
segmentation methodologies.  
4.3.9 Defining Optimum Segmentation Methodology 
Optimum methodology was defined using a scoring matrix. Points for each 
method were awarded based on their performance across a number of factors. 
Points were awarded (minimum of 1 point for the methodology with the poorest 
performance up to a maximum of 4 points for the methodology with the best 
performance) for each of the following variables: 
• Accuracy of measured MRI phantom volume – points awarded in decreasing 
order based on the error of the estimated volume around the MRI phantom 
true volume, e.g. 4 points were awarded to the methodology resulting in the 
estimated volume with the smallest error around in the MRI phantom and 1 
point awarded to the methodology resulting in the largest error around the 
phantom. 
• Subjective visual assessment that the final segmented volume encompasses 
the majority of visible disease without excessive inclusion of adjacent 
structures – points awarded in decreasing order from best subjective visual 
assessment (4 points) to worst subjective visual assessment (1 point). 
• Time taken to complete segmentation – points awarded in decreasing order 
from shortest to longest time to complete volume measurements. 
• Reproducibility (based on intra-observer agreement) – points awarded in 
decreasing order from highest intra-observer Intraclass Correlation 
Coefficient (ICC) to lowest intra-observer ICC. 
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The methodology with the highest Optimum Methods Score based on the above 
parameters was defined as the optimum methodology and was used for all 
subsequent analyses. 
4.3.10 Inter-observer agreement 
In order to assess inter-observer agreement, pleural volumes for 15/31 randomly 
selected cases were also measured by an experienced thoracic radiologist (GC), 
using the optimum methodology only. GC was blinded to all image analysis 
results and patient outcomes.  
4.3.11 Statistical Analysis 
Data distribution was assessed using histograms and D’Agostino-Pearson 
normality test. Normally distributed data are described by mean (+/- SD) and 
non-normally distributed data are described by median (inter-quartile range).  
Intraclass correlation co-efficient (ICC) was used to assess intra-observer and 
inter-observer agreement. The relationship between pleural volumetry and 
clinical T-stage was examined Spearman’s rho test and Jonckheere’s trend test. 
Difference in mean MRI tumour volume between patients with T1/T2 disease 
versus T3/T4 disease was compared using unpaired Student’s t-test. Survival 
analyses were performed using Cox proportional hazards regression and Kaplan-
Meier methodology. Patient groups (high volume versus low volume) were 
dichotomised around increasing intervals of 100cm3 to determine the volume 
that resulted in the widest separation of the survival curves. A backwards 
stepwise Cox proportional hazards regression model was used to determine 
whether tumour volume (as a categorical variable – high versus low tumour 
volume) was an independent predictor of survival. The co-variates used in this 
analysis were Eastern Cooperative Oncology Group (ECOG) performance status 
(PS), patient age, sex, white cell count (WCC), serum albumin and haemoglobin. 
Age was treated as a continuous variable and the remaining co-variates were 
treated as categorical variables. These co-variates were selected as they had 
previously been identified as being of prognostic significance in MPM. (386,387) 
Co-variates were tested to exclude multi-collinearity before being included in 
multivariate analysis. 
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A p value ≤ 0.05 was considered statistically significant in all tests. All other 
statistical analyses were performed using Graphpad Prism v7 (San Diego, USA) 
and IBM SPSS Statistics v22.0 (IBM, New York, USA) for Mac.  
4.4 RESULTS 
4.4.1 Patient Population 
31 patients were included (Figure 4.10), all patients had pleural MRI performed 
prior to thoracoscopy or image-guided biopsy (median 1 (1 – 13) days) and prior 
to any significant pleural intervention other than diagnostic pleural aspiration. 
Mean patient age was 76 (7) years, 28/31 (90%) were male, 27/31 (87%) had a 
history of asbestos exposure and median overall survival was 14 months.  
21/31 (68%) had epithelioid subtype, 4/31 (13%) biphasic subtype, 5/31 (16%) 
sarcomatoid subtype and 1/31 (3%) had mesothelioma NOS. 20/31 (65%) had 
IMIG/TNM7 stage I disease, 0/31 stage II disease, 9/31 (29%) stage III disease and 
2/31 (6%) stage IV disease. 5/31 (16%) had evidence of nodal and/or distant 
metastatic disease. 6/31 (19%) patients completed four cycles of 
Platinum/Pemetrexed combination chemotherapy. 
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Figure 4.10 MRI Volumetry study flowchart 
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4.4.2 MRI Volume Analyses 
4.4.2.1 MRI Phantom 
MRI phantom volume using analysis methodology 1 was 1301cm3 (-59cm3, 4.3% 
error); using methodology 2 was 1311cm3 (-49cm3, 3.6% error); using 
methodology 3 was 875cm3 (-485cm3, 35.7% error) and using methodology 4 was 
1553cm3 (+193cm3, 14.2% error). 
4.4.2.2 Patient Volumetry 
Measured pleural volume for each patient using each analysis methodology is 
detailed in Table 4.3. Intra-class correlation coefficient for each of the four 
methodologies is summarised in Table 4.4. Inter-item correlation matrix for each 
of the four methodologies is summarised in Table 4.5. Intraclass correlation co-
efficient between the four methodologies was 0.745 (95% CI 0.616 – 0.851). 
Methods one and two had similar analysis times, requiring approximately 14 
minutes to complete the contour mask and then a further 1 - 2 minutes to select 
up the pleural ROI for threshold–based segmentation (i.e. a total analysis time of 
approximately 16 minutes).  
Methods three and four required the additional step of measuring SI within up to 
15 ROI to establish threshold criteria prior to segmentation, which took 
approximately 11 minutes. Method three required selection of a pleural ROI 
seed-point for segmentation, resulting in a total analysis time of approximately 
28 minutes. As method four does not require the user to select a pleural seed-
point ROI to perform segmentation, completion of volume analysis using method 
4 took approximately 27 minutes. 
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Table 4.3 	     
      
Pleural tumour volumes for 31 patients with Malignant Pleural Mesothelioma  
measured at contrast-enhanced Magnetic Resonance Imaging using four  
different semi-automated segmentation methodologies 
	
     
Patient	 Method	1	Volume	(cm3)	
Method	2	
Volume	(cm3)	
Method	3	
Volume	(cm3)	
Method	4	
Volume	(cm3)	 	
1	 380 444	 469	 234	 	
2	 213 259	 194	 430	 	
3	 212 265	 215	 269	 	
4	 499 614	 576	 304	 	
5	 270 453	 379	 247	 	
6	 241 375	 445	 394	 	
7	 367 336	 341	 436	 	
8	 450 185	 220	 235	 	
9	 313 317	 320	 236	 	
10	 128 229	 321	 149	 	
11	 106 281	 213	 312	 	
12	 156 363	 270	 445	 	
13	 337 380	 330	 155	 	
14	 164 223	 315	 225	 	
15	 219 339	 699	 358	 	
16	 134 222	 562	 316	 	
17	 373 461	 309	 383	 	
18	 98 113	 125	 133	 	
19	 109 214	 258	 185	 	
20	 455 654	 419	 338	 	
21	 228 457	 544	 341	 	
22	 313 591	 618	 595	 	
23	 352 346	 384	 420	 	
24	 211 280	 259	 255	 	
25	 501 488	 628	 472	 	
26	 269 317	 401	 252	 	
27	 135 349	 336	 370	 	
28	 272 292	 261	 354	 	
29	 505 517	 542	 454	 	
30	 442 560	 284	 351	 	
31	 471 556	 690	 342	 	
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Table 4.4    
Intra-observer agreement of four different methodologies tested in the volumetric assessment of 15/31 
patients with Malignant Pleural Mesothelioma 
 
 
    
  Intraclass Correlation Co-efficient 95% Confidence Interval  
ST (1) vs. ST (2) Method 1 0.869 0.654 - 0.954  
ST (1) vs. ST (2) Method 2 0.875 0.665 - 0.953  
ST (1) vs. ST (2) Method 3 0.849 0.551 - 0.949  
ST (1) vs. ST (2) Method 4 0.941 0.825 - 0.980  
    
    
Table 4.5     
     
Inter-item Correlation Matrix between four different methodologies 
tested in the volumetric assessment of 31 patients with Malignant Pleural 
Mesothelioma 
     
  Method 1 Method 2 Method 3 Method 4 
Method 1 1 0.893 0.726 0.694 
Method 2 0.893 1 0.8 0.762 
Method 3 0.726 0.8 1 0.683 
Method 4 0.694 0.762 0.683 1 
237 
 
 
4.4.3 Methodology Ranking  
Methodology ranking is summarised in Table 4.6. As analysis time was identical 
for methods one, two and three, these methods were all awarded the same 
number of points. Based on total scoring, Methodology 2 was defined as the 
optimum methodology for volumetric assessment of the pleura. Volumetry 
results using analysis methodology 2 are therefore used for the remainder of 
analyses included in this chapter.   
Table 4.6  
Scoring matrix to define optimum methodology between four different 
methodologies in the volumetric assessment of patients with Malignant Pleural 
Mesothelioma. Scoring is in descending order of best performance to worst 
performance for four different variables: (1) Error around volume measurements 
of an MRI Phantom; (2) Subjective visual assessment of inclusion of pleural 
without excessive inclusion of adjacent structures; (3) Analysis time; (4) Intra-
observer intra-class correlation co-efficient 
Method 
 
Accuracy: 
Phantom Error 
Accuracy: 
Visual  
Analysis  
Time 
Intra-
observer 
agreement 
Total 
Score 
Result Score Result Score Result Score Result Score 
1 -4.3% 3 NA 2 16 min 4 0.869  2 11 
2 -3.6% 4 NA 4 16 min 4 
 
0.875  3 15 
3 -16.6% 2 NA 3 28 min 2 0.849  1 8 
4 -35.7% 1 NA 1 27 min 3 0.941  4 9 
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4.4.4 Reproducibility 
The standard deviation around measurement of phantom volume at repeat 
scanning was +/- 18cm3 (+/- 1.4%). Regarding measurements of patient tumour 
volume, ICC for initial and repeated analysis by ST for intra-observer 
reproducibility was 0.875 (95% CI 0.665 – 0.953). ICC between ST and GC for 
inter-observer reproducibility was 0.962 (95% CI 0.893 – 0.987). In 87% (13/15) of 
cases, the absolute difference in volume between the 2 readers was ≤100cm3. 
Bland-Altman analysis demonstrated a bias of 6.896, see Figure 4.11. 
 
Figure 4.11 Bland-Altman analysis comparing volume measurements performed 
by ST and GC   
4.4.5 Relationship between primary tumour volume and clinical T-stage 
Mean MRI primary tumour volumes for T1 (n=20), T2 (n=1), T3 (n=9) and T4 (n=1) 
were 365.5cm3, 349 cm3, 395.8cm3 and 259cm3 respectively, see Figure 4.12. 
There was no significant difference in MRI primary tumour volume between 
patients with clinical T1 or T2 disease (tumour volume 364.7cm3) and those with 
T3 or T4 disease (tumour volume 382.1cm3), p=0.75. There was no significant 
correlation between measured primary tumour volume and clinical T-stage 
(Spearman’s rho = 0.02, p=0.897, Jonckheere’s trend test p=0.935). 
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Figure 4.12 Relationship between clinical T-stage and measured pleural tumour 
volume at contrast-enhanced MRI 
4.4.6 Relationship between disease volume and survival 
Median survival for all patients was 14 months. Median primary tumour volume 
was 346cm3 (IQR 265 – 461). There was a statistically significant reduction in 
median overall survival in patients with higher tumour volume, dichotomised 
around 200cm3 and 300cm3. The widest separation in survival curves occurred 
when patient groups were dichotomised around 300cm3. Patients with a high 
tumour volume (≥300cm3) had a significantly poorer median overall survival (8.5 
months versus 20 months, HR 3.14 (95% CI 1.33 – 7.4), p=0.0088, see Figure 4.13 
(Panel A)). This remained true when confining the analysis to 21/31 patients 
with epithelioid disease (median OS 9 months versus 25 months, HR 3.84 (95% CI 
1.27 – 11.56), p=0.017, see Figure 4.13 (Panel B)) and in 18/31 patients with 
epithelioid disease with no nodal or distant metastatic involvement (median OS 
8.5 months versus 25 months, HR 4.2 (95% CI 1.2 – 15.1), p=0.027, see Figure 
4.13 (Panel C)). In all patients, increasing tumour volume, by tertile (≤250cm3, 
250 – 400cm3, ≥400cm3), was associated with decreasing median OS, see Figure 
13(d); logrank for trend p=0.023).   
Haemoglobin and primary tumour volume were the only variables with statistical 
significance in the univariate Cox model (HR 2.035 (95% CI 1.154 – 3.589) for Hb 
<14g/dl, p=0.014, and HR 2.273 (95% CI 1.162 – 4.446) for primary tumour 
volume ≥300cm3, p=0.016), see Table 4.7. Both haemoglobin and primary tumour 
volume retained statistical significance in the multivariate Cox model, see Table 
4.8.   
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Figure 4.13 Kaplan-Meier curves demonstrating median overall survival based on 
MRI-estimated tumour volume in patients with MPM  
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Table 4.7        
Prognostic factors for 31 patients with Malignant Pleural Mesothelioma (MPM) 
analysed in a univariate Cox proportional hazards model 
 
 
        
Variable n Hazard ratio 95% Confidence Intervals 
p 
value 
 
 
Sex        
Female  3      
Male  28 4.044 0.952 - 17.188 0.058  
Age  31 1.006 0.950 - 1.065 0.829  
ECOG Performance Status      
0/1  24      
2/3  7 1.943 0.966 - 3.911 0.063  
Haemoglobin       
≥14g/dl  17      
<14g/dl  14 2.035 1.154 - 3.589 0.014  
White Cell Count       
<8.2 x109/l 15      
≥8.2 x 109/l 16 0.668 0.380 - 1.174 0.161  
Serum albumin       
≥35g/l  17      
<35g/l  14 1.678 0.946 - 2.975 0.077  
Histological Subtype       
Epithelioid  21      
Biphasic  4 2.128 0.510 - 8.879 0.3  
Not specified  1 1.367 0.497 - 3.756 0.545  
Sarcomatoid  5 0.886 0.257 - 3.057 0.847  
Disease Stage       
I/II  20      
III/IV  11 1.511 0.854 - 2.673 0.156  
Tumour Volume       
<300cm3  11      
≥300cm3  20 2.273 1.162 - 4.446 0.016  
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Table 4.8       
Prognostic factors for 31 patients with Malignant Pleural Mesothelioma (MPM) 
analysed in a backwards stepwise multivariate Cox proportional hazards 
model 
 
 
       
Variable   Hazard Ratio 95% Confidence Interval p value  
Haemoglobin  2.515 1.384 - 4.569 0.002  
Tumour volume 2.114 1.046 - 4.270 0.037  
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4.5 DISCUSSION 
This chapter reports on novel methodology for semi-automated assessment of 
primary tumour volume in patients with MPM, utilising contrast-enhanced MRI 
and a semi-automated, signal intensity threshold-based segmentation 
methodology. Myrian® software (Intrasense®, Montpellier, France) was used for 
volume segmentation. This software has previously been used for MRI-based, 
semi-automated volumetric assessment of organ volumes in infants undergoing 
post mortem examination following sudden unexpected death. (388) In this 
previous study, T2-weighted True FISP sequences and T1-weighted volumetric 
interpolated breath-hold examination (VIBE) sequences were acquired at 1.5T 
MRI. Similar to the methods described herein, images were acquired iso-
volumetrically to allow image reconstruction and to facilitate organ delineation 
and contours of organs were outlined semi-automatically. Agreement between 
MRI volumes and actual organ volume at post-mortem varied depending on the 
organ under assessment; the authors reported good agreement for brain, liver 
and lungs in this study. (388) Frauenfelder et al also used Myrian® software to 
examine voxel-based tumour volumes in 30 patients with MPM undergoing CT as 
a potential alternative to modified RECIST for assessment of response to 
systemic therapy. (389) They reported a high intra-class correlation coefficient 
of 0.99 between three independent readers, with superior agreement in 
comparison to assessment by modified RECIST criteria.   
The optimum methodology in our study was defined using an objective scoring 
matrix, which integrated the accuracy of MRI phantom volume measurements, 
the time taken to complete the analysis, subjective best visual assessment and 
reproducibility. Sargent et al reported criteria which should be considered when 
using a novel imaging methodology as an outcome measure in cancer clinical 
trials. This included accuracy, variance, reproducibility, availability of the 
imaging technology and a standardised interpretation protocol. (390) In our 
study, using the optimum methodology, the time taken to complete volume 
assessment was approximately 16 minutes per study, the standard deviation 
around the MRI phantom measurement was +/- 1.4%, accuracy was within 5% and 
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there was good inter-observer reproducibility (ICC 0.964 (95% CI 0.898 – 0.987)). 
MRI as an imaging technology is becoming more widely available and is 
accessible in most centres. In addition, the method described involves a 
standardised signal intensity threshold range for all patients, eliminating one 
potential source of variability between measurements. The inter-observer 
agreement in this study was excellent (ICC 0.964). Our reproducibility is similar 
to the earlier study reported by Frauenfelder et al (389) and that reported by 
Rusch et al in a multi-centre study of CT volumetry in MPM. Although Rusch et al 
did not report intraclass correlation co-efficients in this study, they reported 
good correlation (Spearman’s rho = 0.822) between readers and an absolute 
difference in CT volume of ≤200cm3 in 80% of cases, (138) similar to that 
reported in our study (absolute difference in MRI volume of ≤100cm3 in 87% of 
cases). However, only 129/164 cases were included for examination by both 
reference radiologists and despite good correlation of CT volume estimates 
overall, there were discrepancies in volume estimates of >60cm3 in 35 cases and 
>170cm3 in 16 cases between readers. Of the 16 cases with major differences in 
volume estimate, 8/16 (50%) were as a result of limited distinction between 
tumour and adjacent tissues, including cases with moderate or large volume 
loculated effusion. (137) The superior contrast resolution of contrast-enhanced 
MRI and therefore better delineation of pleural tumour to adjacent tissues and 
pleural fluid, as discussed herein, is a potential advantage of MRI in this regard. 
Other reported reasons for discrepancy between volume measurements in the 
earlier study included data entry errors, perception errors, resulting from 
difference in the perception of the location of the tumour between readers and 
user error in software tool knowledge. (137) 
A possible source of error in volume measurements in our study was the 
potential for unintentional exclusion of disease at the extreme apex and 
costophrenic recess or unintentional inclusion of adjacent structures, such as 
intercostal muscle. Our use of isotropic image acquisition should however limit 
this, as it allows for volumetric assessment in axial, coronal and sagittal planes, 
taking advantage of precise three-dimensional reconstruction of images and 
potentially limiting partial volume effect at the extreme apex or costophrenic 
recess. In addition, the MRI acquisition parameters in our study included a 1.8 – 
1.9mm slice thickness with no inter-slice gap, which is lower than that 
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previously in previous CT volumetry studies by Liu et al (5 – 7.5mm slice 
thickness, inter-slice gap thickness not reported) (391) and Gill et al (5mm slice 
thickness with a 5mm inter-slice gap). (135) Previous studies have demonstrated 
that increasing slice thickness can result in an under-estimation of true volume 
in CT volumetric assessment of the liver. (392)  
In addition, our use of signal intensity thresholds and the contrast timing of 4.5 
minutes was with the intention of exploiting differing biologic properties of 
pleural tumour from its surrounding structures, thus limiting their inclusion into 
the segmented volume. The ability to utilise differences in signal intensity to 
differentiate MPM tumour from surrounding structures based on their biologic 
properties is an additional advantage of the MRI methodology used here over 
previously described CT-derived methods, where this has been reported to be a 
significant challenge to overcome. (137)   
4.5.1 Prognostic significance of tumour volume 
Patients with a higher primary tumour volume (≥300cm3) had significantly poorer 
survival in the current study. This remained true when confining the analysis to 
patients with epithelioid disease only, an important consideration as histological 
subtype has previously been demonstrated to be of prognostic significance, (387) 
with non-epithelioid histology consistently being associated with poorer overall 
survival. (393) Furthermore, worsening median O.S. with high tumour volume 
was demonstrated when excluding patients with epithelioid MPM with 
prognostically important extra-pleural disease, i.e. those with nodal or distant 
metastases. The separation in survival curves was in fact wider, with a median 
O.S. difference of 16.5 months when non-epithelioid and metastatic disease was 
excluded versus a median O.S. difference of 11.5 months when all patients were 
included.  
Tumour volume was dichotomised around 300cm3 as this cut-off resulted in the 
widest separation in survival curves between low and high tumour volumes. This 
was similar to the methodology of two previous MPM volumetry studies by Gill et 
al and Liu et al, who examined survival curves dichotomised around tumour 
volume at increasing increments, finally dichotomising around the tumour 
volume that provided the widest separation in survival curves (500cm3 and 
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618.49cm3 respectively), rather than around the median tumour volume. On 
multi-variate analysis, tumour volume and haemoglobin were both independent 
predictors of survival in the patients with MPM in this study. Tumour volume, 
haemoglobin, age, sex, histological subtype, WCC, serum albumin and ECOG PS 
were all included in the multi-variate analysis despite not all variables being 
statistically significant on univariate analysis due to previous evidence that they 
are of prognostic significance in larger cohort and population-based studies. 
(386,387,393)  
Our results are in concordance with those of several preceding studies, which 
utilised CT as the primary imaging modality for assessing primary tumour 
volume. Pass et al initially identified the prognostic significance of CT-derived 
tumour volume in 47 patients with MPM undergoing cytoreductive surgery +/- 
post-operative photodynamic therapy. (134) Patients with a higher pre-operative 
tumour volume (≥100cm3) had a significantly poorer median overall survival than 
those with a lower tumour volume (<100cm3) – 11 months versus 22 months 
respectively, p=0.03. However, this cohort included patients undergoing two 
different operations- pleurectomy/decortication (P/D) and extrapleural 
pneumonectomy (EPP), which have subsequently been shown to be associated 
themselves with different subsequent survival. (394) In this study, patients 
undergoing EPP had a significantly higher pre-operative tumour volume than 
those undergoing P/D (418cm3 versus 88cm3 respectively, p <0.0001) and the 
potential independent adverse prognostic impact of EPP itself (395) may 
confound the volumetric differences observed. Additionally, there was a high 
rate of nodal involvement in this study (68%). This is important as nodal 
involvement itself is associated with poorer overall survival in MPM. (127) It is 
therefore an additional important potential confounding variable here, 
particularly as higher tumour volumes were also associated with increased rates 
of nodal involvement in this study. This study was further limited by the 
laborious method of deriving tumour volume, which required manual delineation 
of the pleura in each CT slice, and the time taken to complete volume 
measurements was not reported. Furthermore, the authors did not include 
assessment of inter-observer variability of these subjectively-defined 
measurements.  
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Liu et al performed semi-automated primary tumour volume measurements 
using contrast-enhanced CT in 30 patients with MPM prior to chemotherapy +/- 
EPP and post-operative hemi-thoracic radiation. (391) Their method for 
segmenting pleural tumour from surrounding structures involved initially 
separating the chest wall and ribs from the lung and pleura using an 
interpolation technique. The authors unfortunately do not detail the steps or 
time taken to perform this technique. Once this step is complete, sequential 
thresholding was used to exclude lung, liver and spleen. The user then manually 
corrected any obvious segmentation error. Using this method, the authors 
reported good inter-observer agreement (concordance correlation coefficient 
0.993 (95% CI 0.988 – 0.998) but did not report on time to assess each scan. 
Concordant with our findings, patients with a higher baseline primary tumour 
volume (>618.49cm3) had a trend towards poorer median overall survival (10.2 
months versus 21.5 months for patients with baseline tumour volume 
<618.49cm3, p=0.07). This tumour volume was chosen to dichotomise patients as 
it yielded the greatest statistical difference in survival between groups. There 
was no significant survival difference when patients where dichotomized around 
the median tumour volume (473cm3) and neither histological subtype nor nodal 
involvement were not taken into consideration in this earlier study. Importantly, 
approximately 50% of patients included had prior talc pleurodesis, a likely 
significant confounder when assessing pleural tumour volume.  
Gill et al also reported similar findings to those described herein, again 
reporting poorer survival with high CT-derived primary tumour volume with 88 
patients with epithelioid MPM undergoing EPP. (135) The volume segmentation 
method described in this earlier study involved automated software exclusion of 
pleural effusion, atelectatic lung, chest wall and adjacent solid organs followed 
by manual addition of identified areas of discontinuous and/or extrapleural 
tumour. The basis for software exclusion of adjacent structures, e.g. whether 
this was based on differing shape or spatial location of structures or differing 
Hounsfield Units, was not detailed and analysis time and inter-observer 
variability using this method were not reported. Median tumour volume was 
319cm3. The authors reported a significant reduction in median overall survival 
associated with a higher tumour volume (>500cm3, median overall survival 12 
months versus 24.4 months, p <0.0001). Similar to the present study, patients 
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were dichotomised at intervals of 100cm3 to determine the optimum tumour 
volume cut-off yielding the greatest difference in survival between groups. 
Tumour volume remained an independent predictor of patient survival in 
multivariate analysis (HR 2.02, 95% CI 1.18 – 3.47, p=0.01).  
Although we found the prognostic impact of increasing primary tumour volume 
to be statistically significant, due to small patient numbers (n=31) there was a 
wide 95% confidence interval around our hazard ratio (HR 2.73 (95% CI 1.162 - 
4.446). Nonetheless, tumour volume was a statistically significant prognostic 
variable on univariate analysis (p=0.016) and retained statistical significance on 
multivariate analysis (HR 2.114 (95% CI 1.046 – 4.270), p=0.037).  
Similar to our study, Plathow et al assessed tumour volume in patients with MPM 
using MRI. (385) Tumour volume was measured using a semi-automated region-
growing technique and shape-based interpolation rather than a signal intensity 
threshold-based method of segmentation as described herein. Volume 
estimations in this earlier study were used as a method to assess response to 
chemotherapy and the authors did not report on the relationship between 
tumour volume and overall survival. In addition, only a single reader measured 
tumour volume and the authors therefore did not report on the reproducibility 
of their method. While the authors report that their volume segmentation 
methodology had previously been demonstrated to be accurate regarding 
correlation between measured and true tumour volume, the previous study that 
they referenced examined volume measurements in intra-pulmonary nodules 
(396), which, being spherical and surrounded by lung are much simpler 
structures to volume than primary pleural tumour.  
PET-CT is an additional imaging modality that could be used for volumetric 
segmentation, exploiting increased 18FDG uptake by pleural tumour in 
comparison to adjacent lung, intercostal muscle and pleural fluid to potentially 
improving accuracy of semi-automated segmentation in comparison to CT alone. 
Nowak et al assessed tumour volume utilising 18FDG-PET in patients with MPM. 
(380) Tumour volume was measured using a 3-dimensional threshold-based 
growing algorithm from multiple ROI placed on pleural tumour. The threshold 
was based on mean FDG activity in the ROI in comparison to neighbouring pixels 
and the maximum normal background activity in the liver. Total Glycolytic 
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Volume (TGV) was calculated using total ROI volume and metabolic activity and 
was an independent predictor of prognosis on multivariate analysis. (380) 
However, 31% (n=28) of the patients in this study had prior pleurodesis, a 
potentially significant confounder given the well-documented intense metabolic 
activity associated with pleurodesis at PET-CT. (355,356) Furthermore, 18FDG-
PET in isolation is limited by poor spatial resolution, particularly in comparison 
to MRI used in the present study, and while all the patients in this study 
additionally underwent CT examination, the PET scans were not integrated with 
CT images and the radiologists computing TGV were in fact blinded to CT 
analyses. (380)  
Similarly, Lee et al used integrated PET-CT to measure pleural volume and 
metabolic activity (computing metabolic tumour volume (MTV) and total lesion 
glycolysis (TLG) parameters) in a small retrospective study of 13 patients with 
MPM undergoing extrapleural pneumonectomy +/- cisplatin/pemetrexted 
chemotherapy. They delineated an automated contour ROI, with thresholding 
based on mean SUV of the liver + 2SD. Patients with a high MTV and TLG and a 
significantly shorter time to tumour progression. However, this methodology for 
defining tumour volume is limited by the decision to use SUV of the liver to 
define the threshold for segmentation rather than that of the volume of 
interest, as is described in our methodology. Pleural lesions with intense FDG 
uptake may therefore be excluded, likewise, pleural tumour with low metabolic 
activity, e.g. early stage epithelioid tumours. Additionally, the authors did not 
report on the reproducibility of their method.  
Kitajima et al recently used PET-CT and gradient-based segmentation (397) in a 
retrospective review of 201 patients with MPM. They reported that a high TLG 
≥525g (calculated from MTV x SUVmean, where SUVmean is the mean SUV of the 
tumour) was an independent predictor of poor survival at multivariate analysis. 
(398) However, the authors did not report on the reproducibility of their TLG 
measurements in this study. Gradient-based segmentation requires additional 
image processing steps to improve image resolution and signal-to-noise ratio 
prior to image analysis, which introduces another potential source of variability 
between scans. (397)  
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4.5.2 Tumour volume and disease stage     
In this study, there was no significant correlation between clinical T-stage and 
primary tumour volume measured at MRI (r=0.02, p=0.897). This is perhaps not 
surprising as current T-staging describes the surfaces involved, the degree of 
extra-pleural invasion and potential resectability rather than tumour dimension 
measurements as is common in other tumours. (126) Our findings are concordant 
with that of Armato et al, who reported no significant difference in CT-derived 
tumour volume between patients with T1 or T2 disease and those with T3 or T4 
disease. (399)  
Conversely, Rush et al did report a correlation between CT-derived volume and 
pathologic T-stage in their multi-centre study, with increasing tumour volume 
being associated with increasing pathologic T-stage. (138) Importantly, there 
was considerable upstaging of clinical disease stage at the time of surgery in this 
study (62.8% clinical stage III/IV versus 86.9% pathologic stage III/IV disease). 
This again highlights the limitations of current clinical staging modalities and 
discrepancy between clinical and pathologic staging could be responsible for the 
contrasting findings between our study and this earlier study.  
In our study, increasing tumour volume, when grouping patients into tertiles 
(≤250cm3, 250 – 400cm3, ≥400cm3) was associated with a trend towards 
worsening median O.S. (not reached, 12 months and 8.5 months respectively), 
highlighting the potential role of imaging-based primary tumour volume as an 
alternative to clinical T-staging based on the extent of pleural surface 
involvement and extra-pleural invasion, as is currently the case. Rusch et al 
divided patients into quartiles based on CT-derived primary tumour volume, 
separation of Kaplan-Meier survival curves was demonstrated between all 
quartiles with the exception of quartile 2 and 3 (median O.S. 37 months, 18 
months, 18 months and 8 months for quartile 1, 2, 3 and 4 respectively). (138) 
The author’s therefore report that the best correlation between tumour volume 
and overall survival is demonstrated with three groups of volume measurements, 
similar to the analysis performed in our study.  
In an earlier study, Kircheva et al reported that pathologic tumour volume, 
measured following extended pleurectomy/decortication, was a better predictor 
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of survival than T-stage (at multivariate analysis, tumour volume increasing per 
ml HR 1.001, p=0.021; T2 versus T1 HR 5.622, p=0.028; T3 versus T1 HR 4.55, 
p=0.047; T4 versus T1 HR 5.156, p=0.033). (400) This perhaps reflects that 
tumour burden is more accurately represented by tumour volume than current 
clinical T-stage.  
Tumour thickness measurements is an alternative method for estimating disease 
burden. Nowak et al describe 3 single linear measurements at maximal tumour 
thickness from either chest wall or mediastinum, using axial CT images of 
patients with MPM. (126) Pleural tumour thickness measurements correlated 
with clinical T-stage and using the sum of the 3 measurements, increased 
tumour thickness was associated with poorer survival (median O.S. 13.2 months 
for the highest quartile group (>50.0mm) versus 23.4 months for the lowest 
quartile group (<16.0mm)), in addition to being associated with metastatic nodal 
involvement. (126) However, this method of tumour thickness measurement is 
likely to be subject to considerable inter-observer variability. In an earlier study 
by Armato et al, linear tumour thickness measurements perpendicular to either 
chest wall or mediastinum, were performed by six observers. Across all tumour 
thickness measurements, the 95% CI for inter-observer tumour thickness 
measurement differences was – 16.8 to 20.1%. The 95% CI were wider for 
measurements perpendicular to mediastinum, measurements of a fusiform mass 
or convex rind and with lower tumour thickness measurements (95% CI -25.6 to   
34.5% for tumour thickness measurements <5mm versus -6.8 to 7.3% for tumour 
thickness measurements >20mm). (401) In addition, using linear measurements 
obtained at a single image plane as opposed to 3D measurements as is performed 
in our study, is perhaps an over-simplification of the disease burden of this 
complex tumour.  
4.5.3 Implementation and Future Testing 
To be used in future clinical practice, the optimum methodology for examining 
tumour volume in this study requires the following steps: 
1. Create a contour mask using free-hand ROI delineation of the pleura every 8 – 
10 slices before automated propagation of the contour mask using Myrian® 
software 
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2. Make manual adjustments to the contour mask if required  
3. Input signal intensity threshold parameters as +/- 99AU 
4. Select up to three ROI on pleural tumour using the Myrian® 3D wand tool, 
following which the software will segment a volume based on the ROI signal 
intensity +/- threshold parameter of 99AU 
This optimum methodology is practically simple, semi-automated using 
computer-based volume software, and appears to have excellent reproducibility. 
This method is therefore worth testing further in larger, multi-centre studies. 
The signal intensity threshold parameter is based on results from the previous 
study described in Chapter 3: Early Contrast Enhancement. In this study, ROI 
were placed on pleura, distributed evenly cranio-caudally across three evenly 
spaced slices in an attempt to include sufficient representative pleural sampling. 
The threshold parameter (+/- 99AU) was the median SI range of all patients with 
MPM included in this study, excluding 3/31 patients who had ECE negative 
results. These patients were excluded as it was hypothesised that the ROI 
sampled in these patients represented false negative sampling of benign pleural 
interspersed between pleural tumour.  
Our ECE analyses were performed in a relatively small group (n=58), with 31/58 
having MPM, and have not yet been validated in a different population. 
Therefore, validation of our segmentation SI threshold parameters in another 
population with a repeat study where ROI signal intensity measurements and ECE 
assessment is performed prior to volumetric assessment would be preferable. If 
resulting SI threshold parameters were similar to our findings of +/- 99AU then it 
could perhaps be hypothesised that this threshold parameter is reasonably 
representative of the range in signal intensity in the majority of patients with 
MPM. If this hypothesis is true then centres elsewhere implementing this 
methodology would not need to repeat SI measurements in their own population, 
simply using +/- 99AU as the threshold range, which would be more time 
efficient.  
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4.5.4 Possible Clinical Implications 
High tumour volume was an independent predictor of poor survival in this study, 
suggesting that this method of tumour burden assessment could serve as an 
additional prognostic biomarker in patients with MPM. If the prognostic 
significance and reproducibility of volume measurements is reproduced in larger, 
multi-centre study, pleural tumour volume could be considered as an alternative 
to current, often difficult, clinical T-staging. The role of tumour volume versus 
tumour invasion and resectability, as is currently described in staging T 
descriptors, would require further assessment in a staging context.  
In addition, there is a potential role for the inclusion of tumour volume in 
prognostic models in MPM. Previously described prognostic models in MPM 
include the European Organisation for Research and Treatment of Cancer 
(EORTC) prognostic index, (402) the Cancer and Leukaemia Group B (CALGB) 
prognostic scoring system (403) and more recently, the prognostic model 
described by Brims et al. (386) The EORTC prognostic index comprises white cell 
count, ECOG performance status, histological subtype, patient sex and probable 
or possible histological diagnosis. (402) The CALGB model includes performance 
status, patient age, platelet count, the presence or absence of chest pain as a 
presenting symptom and lactate dehydrogenase level. (403) The Brims model 
included histological subtype, weight loss, performance status, haemoglobin and 
serum albumin. (386) In our study, only haemoglobin and tumour volume were 
statistically significant prognostic variable on univariate or multivariate Cox 
proportional hazards analysis. The small patient population is likely to be a 
significant contributing factor to the contrasting results here to that of previous 
studies. However, more recently, Kidd et al reported that routinely available 
clinical data are of fundamentally limited use, with clinical prediction models 
only improving survival prediction by 22% than would be expected by chance. 
(404) This highlights the limitations of prognostic markers that do not directly 
describe tumour extent and/or biology. Volumetric assessment of tumour burden 
may improve the performance of future prognostic models, as may additional 
emerging predictors such as tumour genomics.  
An additional potential future role of volumetry in MPM would be in response 
assessment following systemic therapy. Currently, modified RECIST (Response 
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Evaluation Criteria in Solid Tumours) criteria are used for response assessment. 
(405,406) Modified RECIST was developed to address the deficiencies of uni-
dimensional measurements employed in WHO and RECIST criteria for response 
assessment in a complex tumour such as MPM with its rind-like growth pattern. 
(407) Modified RECIST criteria incorporates the sum of six measurements of 
tumour thickness. Measurements are taken perpendicular to the chest wall or 
mediastinum in two positions at three separate levels on axial images. (405) 
Partial response and stable disease based on modified RECIST criteria have been 
shown to be predictive of better survival outcomes in MPM. (408) However, this 
method of response assessment is limited by inter-observer variability and bias 
associated with user selection of the sites at which tumour thickness is 
measured. (401,409) Results from earlier studies suggest that primary tumour 
volumetry may be a better method of response assessment than modified 
RECIST, particularly in terms of reproducibility. (383,389) A semi- or fully-
automated tool to measure ‘volumetric RECIST’, such as that described by Chen 
et al in a recent study of computer-assisted CT volumetric assessment of MPM 
patients, (383) would therefore be a major clinical advance.  
4.5.5 Study Limitations 
The principal limitation of this study is the use of a small study population 
(n=31) recruited from a single centre. The relationships reported between 
tumour volume and survival must therefore be interpreted in the context of 
wide confidence intervals around hazard ratios. Nevertheless, the method 
appears to have excellent inter-observer reproducibility and tumour volume 
remained a statistically significant prognostic variable on multivariate analysis. 
In addition, our finding that increased tumour volume is associated with poorer 
median overall survival is consistent with results from previous studies.  
Another limitation of this study is the method of deriving the signal intensity 
threshold subsequently used for segmentation. The threshold used in the final 
methodology was derived from mean SI measurements from patients with MPM 
as described in Chapter 3: Early Contrast Enhancement, which has not been 
externally validated.  
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Additionally, our MRI volumetric measurements were not correlated with post-
operative pathological volume, as conducted in the study by Armato et al. In this 
study, CT-based volume measurements modestly correlated (r = 0.66) with 
pathologic tumour volume following extended pleurectomy/decortication in 28 
patients with MPM. (399) None of the patients included in our study underwent 
surgical resection, as this treatment modality is currently not recommended in 
the U.K. for MPM. (143) We did validate our volume measurements with an MRI 
phantom, demonstrating little variance in our measurements and good accuracy. 
However, the MRI phantom in this study was a considerably more basic structure 
to volume in comparison to pleural tumour.  
The final limitation of this study is the relatively lengthy time required to 
complete volume measurements using the described methodology 
(approximately 16 minutes). The analysis time is significantly increased (to a 
total analysis time of approximately 30 minutes) if signal intensity 
measurements and ECE assessment are completed first. However, if our signal 
intensity threshold parameter is validated in future study, this additional step 
would not be required. Although the time taken to complete volume 
measurements is longer than the time it would normally take a radiologist to 
clinically stage a patient with MPM, it could still be completed within a time that 
is still likely to be feasible in clinical practice. Future technological advances 
will likely allow further automation of the methodology, shortening the time 
taken to complete volumetric assessment.  
4.6 CONCLUSION 
In this chapter, novel MRI methodology for the volumetric assessment of primary 
MPM tumour volume has been described. The methodology appears accurate 
based on validation against an MRI phantom volume, and reproducible within a 
patient population. High tumour volume was an independent predictor of poor 
survival and patients can potentially be grouped into volume tertiles associated 
with different survival outcomes. Volumetric assessment of MPM is a promising 
future prognostic biomarker in MPM, with potential utility in the staging of this 
challenging tumour.
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5 Chapter 5: Conclusions 
Malignant Pleural Mesothelioma is a complicated tumour, which can be 
challenging to diagnose. As a result, patients with suspected MPM often undergo 
a prolonged pathway from initial presentation to diagnosis. This results in 
patients being subjected to diagnostic uncertainty, multiple invasive procedures, 
frequent admissions due to breathlessness associated with recurrent pleural 
effusion and potential delays in the commencement of systemic treatment or 
clinical trial entry. Legal requirement for reporting suspected MPM to the 
procurator fiscal/coroner’s office and requirement for a post-mortem in the 
event of a histological diagnosis not being confirmed in life, due to MPM being 
classed as an industrial disease, is an additional source of anxiety and burden for 
family members. Furthermore, difficulties associated with staging and the sub-
optimal performance of prognostic models in MPM also results in a degree of 
clinician uncertainty regarding individual patient’s prognostication, making 
discussions surrounding the patient’s life expectancy and appropriateness of 
certain treatment options more challenging. The work in this thesis was 
undertaken to examine several blood and novel imaging biomarkers of MPM and 
their potential clinical utility in the diagnostic and prognostic assessment of 
patients with MPM in a real-world situation.  
5.1 Blood biomarkers in Malignant Pleural Mesothelioma  
A reliable diagnostic blood biomarker that offers high diagnostic sensitivity and 
specificity would be a major clinical advancement for MPM, directing 
appropriate patients to specialist centres for diagnostic work-up, including 
access to local anaesthetic thoracoscopy and specialist mesothelioma MDTs 
earlier in their patient journey. Unfortunately, despite promising early results 
for several potential blood biomarkers, including SOMAscan™, Fibulin-3, 
osteopontin, HMGB1 and mesothelin, no blood biomarker as shown reliably 
sufficient diagnostic performance to enter routine clinical practice. (143) 
Prior studies have been limited by their retrospective design, use of selected 
MPM cohorts (frequently utilising historical archived samples from surgical 
centres where patients have often undergone prior pleural biopsy, pleurodesis or 
systemic therapy), inappropriate controls, inconsistent assay methods and cut-
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off points and inconsistent sampling protocols, which often do not correlate with 
when these biomarkers would be used in clinical practice. Such methodological 
shortcomings and lack of external validation have limited interpretation of the 
true clinical utility of these biomarkers. (410) 
5.1.1 The DIAPHRAGM study 
DIAPHRAGM was a study that was rigorously designed to address many of the 
methodological limitations of these earlier studies. Firstly, DIAPHRAGM was a 
prospective study, recruiting patients from district general hospitals, larger 
academic centres and tertiary referral centres. Additionally, multiple centres 
across the UK and Ireland, all with a varying prevalence of MPM, were involved 
with recruitment. This means that biomarker results are likely to be relevant to 
the general MPM population in the UK. Secondly, patients were recruited to 
DIAPHRAGM at presentation with suspected MPM and the eligibility criteria were 
deliberately broad. The inclusion criteria did not include the requirement for 
history or evidence of asbestos exposure, such as pleural plaques, as these are 
absent in up to 25% of MPM cases. (46) Furthermore, patients with lung nodules 
or other visceral mass lesions were not excluded, assuming the investigator 
suspected new pleural malignancy. This was because of the high prevalence of 
lung nodules in the target population (older patients, commonly smokers) and 
the high false-positive rate of CT imaging in this regard. (411) The suspected 
pleural malignancy cohort in DIAPHRAGM is therefore reflective of an 
undifferentiated, real-world population. Our study cohort includes a generalised 
population of MPM, of typical histological subtype distribution, with varying 
stage distribution, which will allow interpretation of blood biomarker results in 
the context of both subtype and stage. In addition, the non-mesothelioma cohort 
includes a population of non-MPM pleural malignancy and benign pleural disease, 
with a significant proportion of these patients having BAPE, a population that 
often poses a real and significant challenge to differentiate from MPM. This 
ensures that our findings will be interpretable in the context of realistic 
differential diagnoses presenting to the clinicians with possible pleural 
malignancy or MPM. Furthermore, the timing of the blood biomarker sampling in 
this study (at initial presentation) replicates when these biomarkers would 
normally be taken (and of greatest diagnostic utility) in normal clinical practice. 
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In addition, the DIAPHRAGM protocol included a diagnostic review at 12 months 
of all cases where the baseline diagnosis was either benign or uncertain. Given 
that MPM can be difficult to diagnosis, even following pleural biopsy, and false 
negative histological sampling and requirement for repeated biopsy is not 
uncommon, this diagnostic review allowed for repeat biopsy results to be 
examined, ensuring that final classification of patients’ diagnoses was robust. 
The difficulty lay in the consideration of which of these patients were 
considered to have MPM at baseline (i.e. at time of biomarker sampling) with a 
false negative pleural biopsy versus having an evolving diagnosis of MPM during 
study follow-up. However, all recruiting centres had access to advanced pleural 
diagnostics, including medical or surgical thoracoscopy and a specialist 
mesothelioma MDT. Additionally, all MPM cases were discussed at a local cancer 
MDT and at least 50% of sites had confirmed that their MPM cases had been 
discussed at a regional specialist mesothelioma MDT at the time of writing. 
Finally, unlike previous studies, biomarker sampling and storage in this study 
were all performed according to a single protocol at all centres. Additional 
potential confounders such as renal function, body mass index and concomitant 
medications were all recorded. Importantly, all patients were recruited and had 
biomarker sampling prior to pleurodesis, intercostal chest drain insertion or 
pleural biopsy. The temporal relationship between biomarker draw and pleural 
aspiration was also recorded and we will therefore be able to assess the effect, 
if any, this has on biomarker levels. DIAPHRAGM is the largest, prospective 
multi-centre diagnostic biomarker study in the MPM literature to date. Due to 
the robust study design and successful recruitment of target study participants 
and MPM cases, DIAPHRAGM will determine the true clinical utility of 
SOMAscan™, Fibulin-3 and mesothelin in the diagnosis of MPM with precision 
around diagnostic performance estimates.  
5.2 Imaging biomarkers in Malignant Pleural Mesothelioma 
Imaging plays a major role in the assessment of patients with suspected MPM, in 
both diagnostic and staging contexts. Chest radiography and thoracic ultrasound 
are typically first line investigations. However, further imaging is required for 
the assessment of suspected MPM. Contrast-enhanced CT imaging is the 
recommended initial cross-sectional imaging modality for the examination of 
260 
 
 
patients with suspected MPM. (143) CT can readily identify several features of 
pleural malignancy, such as pleural enhancement or pleural nodularity, however, 
radiological interpretation can be difficult, particularly in early stage MPM, 
where pleural thickening is often minimal or absent. Similarly, PET-CT, while 
useful in staging of MPM, in particular the identification of nodal and extra-
thoracic disease, its use in the diagnostic assessment is limited by its 
availability, low sensitivity in early stage, epithelioid disease, and false positive 
FDG uptake in TB pleuritis, inflammatory disorders and prior talc pleurodesis. 
(143) MRI is an imaging modality that is becoming increasingly available in most 
centres in the UK. Its principal clinical utility in MPM at present is in the 
assessment of chest wall invasion or infiltration of the diaphragm, particularly 
when considering surgical resectability. (140) Previous studies have considered 
the diagnostic utility of MRI in the detection of pleural malignancy, particularly 
when combining anatomical with biologic data, such as dynamic contrast 
enhancement, with promising results. However, the clinical utility of these 
techniques have been limited by the requirement of bulky pleural tumour for 
their application, making it unsuitable for early diagnostics.  
5.2.1 Early Contrast Enhancement at MRI 
In chapter 2 of this thesis, a novel MRI biomarker of pleural malignancy was 
developed and its diagnostic performance and underlying biologic relevance 
were examined. I hypothesised that MRI examination targeted to increased 
microvessel density in malignant pleural tumour could accurately identify 
patients with pleural malignancy, including those patients with early stage MPM 
or minimal pleural thickening.  
Firstly, I demonstrated that whole MRI series of the entire thorax could be 
acquired in a single breath-hold, thereby minimising image distortion from 
breathing artefact, even in patients with large volume pleural effusion, with 
multiple acquisitions being possible over time post-contrast. Secondly, I 
demonstrated that pleural signal intensity could be measured, even in the 
absence of significant pleural thickening (84% of patients included had pleural 
thickening <10mm and median pleural thickness of all patients included in the 
study was 5mm). Thirdly, I demonstrated that Early Contrast Enhancement was a 
feature of pleural malignancy, with high sensitivity (83% (95% CI 61 – 94%)), 
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specificity (83% (95% CI 68 – 91%)) and NPV (92% (95% CI 78 – 97%)) for the 
differentiation of malignant from benign pleural disease. Furthermore, I 
demonstrated that the sensitivity and NPV of ECE could be further improved by 
combining MRI morphology findings with the functional data provided by ECE 
(sensitivity 92% (95% CI 67 – 100%), NPV 97% (95% CI 86 – 100%)). Pleural signal 
intensity measurements and subsequent classification of patients as malignant or 
benign based on ECE were reproducible (inter-observer agreement κ 0.784) and 
offered superior inter-observer agreement than subjective morphology 
assessment using CT (κ 0.65) or MRI (κ 0.593). Additionally, I demonstrated that 
MSIG (used to summarise ECE characteristics of each patient) correlated with 
tumour MVD in patients with PM (Spearman’s rho = 0.43, p=0.02), suggesting that 
early contrast enhancement in PM is at least partially a result of increased blood 
vessel density in pleural tumour, as a consequence of neoangiogenesis, which is 
known to occur early in tumourigenesis. Finally, I demonstrated that higher MSIG 
and tumour MVD were both associated with poorer median overall survival in 
patients with MPM, supporting my conclusion that ECE is a perfusion-based 
imaging biomarker.  
 
5.3 Staging of Malignant Pleural Mesothelioma 
Accurate staging of any cancer is important in order to provide patients with 
accurate individual prognostic information, select appropriate patients for 
different treatment approaches and to assess the survival benefit of emerging 
therapies in clinical trials. Clinical staging of MPM has proved challenging due its 
unusual rind-like growth pattern and attempts at developing clinical staging 
systems thus far have been limited by high inter-observer variability, (412) 
frequent up-staging at surgical staging (125) and variable prognostic accuracy in 
a real-world population. Volumetric assessment of MPM as a potential alternative 
to current staging systems has been garnering increasing interest in recent 
times. Several studies have demonstrated the prognostic significance of high 
tumour volume estimated using a number of imaging modalities and 
measurement techniques. These methods have been variably limited by analysis 
time and reproducibility. The optimum imaging modality and method of tumour 
volume assessment has yet to be adequately defined.  
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5.3.1 Volumetric Assessment of Malignant Pleural Mesothelioma 
In chapter 4, novel methodology for the volumetric assessment of patients with 
MPM was examined and the prognostic significance of tumour volume 
measurements using this methodology in patients with MPM was assessed. I 
hypothesised that tumour volume could be accurately and reproducibly assessed 
in patients with MPM using contrast-enhanced MRI.  
Firstly, I defined the best time point post-contrast to perform volumetric 
assessment in MPM patients by examining signal intensity/time curves of ROI 
placed on pleura and adjacent structures. I then attempted different methods 
for volume estimation. I excluded manual delineation of pleural contours using 
OsiriX as an acceptable method due to excessive time. Following this, I tried and 
subsequently excluded the use of the MIAlite plugin for OsiriX as an acceptable 
method due to excessive time and inclusion of inappropriate structures in the 
segmented volume due to the circular nature of the blocking and seeding circles. 
Finally, I used Myrian software, which allowed propagation of a free-hand ROI 
contour mask to constrain subsequent semi-automated, signal intensity 
threshold-based volume segmentation. I examined four different segmentation 
methodologies, each with different signal intensity threshold parameters. Each 
methodology was assessed and ranked in order of: accuracy with an MRI 
phantom, subjective visual assessment of the final segmented volume, time to 
complete volume measurements and reproducibility based on intra-observer 
agreement. The optimum methodology was defined as the method scoring 
highest based on a scoring matrix of the above variables. The optimum 
methodology had high accuracy (<5% error in MRI phantom measurement), good 
intra-observer reproducibility (ICC 0.875) and acceptable analysis time (16 
minutes). Secondly, I examined the reproducibility of the optimum method, 
demonstrating small variance around repeated measurements of the MRI 
phantom (+/- 1.4%) and excellent inter-observer reproducibility (ICC 0.962). 
Thirdly, I demonstrated that tumour volume at MRI did not correlate with 
clinical T-stage in patients with MPM (Spearman’s rho = 0.02, p=0.897, 
Jonckheere’s trend test p=0.935) This perhaps reflects the fact that current 
clinical staging systems in MPM principally describe invasion and surgical 
resectability rather than tumour bulk, in contrast to most other cancer staging 
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systems. Finally, I demonstrated that higher tumour volume (≥300cm3) at MRI 
was associated with significantly poorer survival (HR 2.273, p=0.016) and that 
tumour volume retained prognostic significance in a backwards stepwise multi-
variate Cox proportional hazards model (HR 2.114, p=0.037), concordant with 
previous volumetry papers in the MPM literature.   
5.4 Future Work 
Biomarker validation in a clinical population such as MPM is challenging. Any 
biomarker discovery studies require external validation in an appropriate 
population before entering routine clinical practice. Such validation studies have 
thus far been limited in MPM, reflected in the large number of potential 
biomarkers that have shown promise in translational studies but not entered 
clinical practice. In the course of completing DIAPHRAGM, a large, well-
phenotyped bioresource, which includes plasma, serum, DNA and, in a 
proportion, pleural fluid, has been developed. This will provide an invaluable 
resource for future biomarker validation (and discovery) studies, as all patients 
and samples included in the bioresource have undergone the rigorous diagnostic 
and sampling protocols that have been discussed herein.  
The reproducibility and simplicity of signal intensity measurements and ECE 
classification described herein would allow for additional centres to reproduce 
this technique. This is essential so that our results can be validated in a larger, 
multi-centre study and further understanding of the complex nature of MPM and 
its distribution within the pleural space can be gained. The potential 
implications of ECE entering clinical practice in the diagnostic assessment of 
patients with suspected MPM include pathway rationalisation, directing patients 
appropriately to specialist centres and early invasive sampling where MPM 
appears likely. Additionally, the lack of ionising radiation required for MRI 
acquisition and the ability of ECE assessment to be performed in cases with 
minimal pleural thickening means that it has the potential to be utilised in the 
future for screening of asbestos-exposed individuals for early MPM. Meso-
ORIGINS is a study which aims to examine genomic, transcriptomic and 
immunologic events in the development of MPM by performing sequential pleural 
biopsies in patients with BAPE over a period of two years. The proposed 
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surveillance programme includes circulating biomarker sampling in addition to 
repeated imaging surveillance in these patients. The proposed imaging 
surveillance will further explore the clinical utility and biologic basis of MRI Early 
Contrast Enhancement. The Meso-ORIGINS feasibility study, which will assess 
the feasibility of recruiting sufficient numbers of patients to the proposed study, 
has recently been funded by the June Hancock Mesothelioma Research Fund and 
will commence recruitment shortly. 
Although I examined the accuracy of MRI volumetric measurements using an MRI 
phantom, the accuracy of MRI measurements should also be examined using 
pathologic volume following surgical resection. MARS 2: a feasibility study 
comparing extended pleurectomy decortication versus no pleurectomy 
decortication in patients with MPM (NCT02040272) is currently open for 
recruitment, and patients are being recruited via the West of Scotland 
Mesothelioma MDT. Validating our MRI volume measurements in this population 
with resected pathologic volume is therefore possible.  
In addition, the MRI acquisition and volume segmentation methodology described 
herein is being replicated and progressed in the pre-EDIT study (NCT03319186). 
This study, which has commenced recruitment, is a randomised feasibility trial 
of pleural elastance-directed treatment of patients with symptomatic malignant 
pleural effusion. The study protocol incorporates assessment of pleural cavity 
volume pre- and post- large volume pleural aspiration, in order to validate 
pleural elastance measurements (∆ intra-pleural pressure (cmH20)/ ∆ volume of 
fluid removed (L)). 
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Appendix 3 DIAPHRAGM invitation letter to Clydeside 
Action on Asbestos members 
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Appendix 4 Asbestos-exposed Control Cohort Patient 
Information Sheet 
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Appendix 5 MRI Substudy Patient Information Sheet 
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Appendix 6 Baseline Information Case Report Form 
280 
 
 
281 
 
 
282 
 
 
283 
 
 
284 
 
 
285 
 
 
286 
 
 
287 
 
 
Appendix 7 MPM Follow-up Visit Case Report Form 
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Appendix 8 MPM Long-term Follow-up Case Report Form 
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Appendix 9 Diagnostic Review Case Report Form 
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Appendix 10 Asbestos-exposed Control Case Report Form 
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Appendix 11 Asbestos Exposure Questionnaire 
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Appendix 12 MRI Safety Questionnaire 
 
 
    Clinical	Research	Imaging	Facility	
MRI	Safety	Checklist	-	PATIENTS  
 
Patient	Name:	 	 	 	 	 Date	of	Birth:	 	 	 						Date	of	Scan:	
	
Address:		 	 	 	 	 Investigator:	 	 							 						Study	ID:	 	 	
	
	
	 	 	
CHI:		 	 	 	 	 	 Weight:	 	 	 					 					Height:	
	
Have	you	ever:	
Had	a	cardiac	pacemaker?																
Had	any	surgery	to	your	heart?								
• If	yes,	give	details……………………………………………….……………………………………………………………………………………..	
Had	any	surgery	on	your	head,	brain	or	eyes?		 																																													
• If	yes,	give	details……………………………………………….……………………………………………………………………………………..	
Had	any	surgery	involving	the	use	of	metal	implants,	plates,	or	clips?	
• If	yes,	give	details……………………………………………….……………………………………………………………………………………..	
Had	any	surgery	involving	the	use	of	electronic,	mechanical	or	magnetic	implants?	
• If	yes,	give	details……………………………………………….……………………………………………………………………………………..	
Had	any	other	surgery?	
• If	yes,	give	details……………………………………………………………………………………………………………………………………….	
Had	metal	fragments	in	your	eyes	or	any	other	part	of	the	body?														
																			
Do	you:	
Have	any	kidney	problems,	kidney	failure	or	ever	had	dialysis?	
Have	asthma,	eczema,	hayfever	or	any	known	allergies?	
Have	metal	dentures/dental	plate,	hearing	aid	or	wig?	
Wear	a	false	limb,	calliper	or	brace?	 	 	
Have	any	tattoos,	permanent	makeup	or	body	piercing?																				
Wear	any	type	of	skin	patch?		 	
	
Ladies:	
Could	you	be	pregnant?																																																																																																																																
• LMP	date:	……………………………………….	
Are	you	breast	feeding?								
Have	you	been	sterilised	or	have	an	IUD	fitted?		
	
	 																																		
YES	 NO		
YES	 NO		
	
YES	 NO		
	
YES	 NO		
	
YES	 NO		
	
YES	 NO		
	
YES	 NO		
	
	
YES	 NO		
YES	 NO		
YES	 NO		
YES	 NO		
YES	 NO	
YES	 NO	
	
YES										NO	
	
	
YES	 NO		
YES	 NO	
Before	entry	into	the	examination	room	all	metallic	objects	must	be	removed:		Metal	tools,	scissors,	keys,	watches,	pagers,	
credit	cards,	coins,	hair	clips,	hearing	aid	etc.	Have	all	objects	been	removed?	 																	 	 																																																																																		 
 
I	confirm	that	the	answers	to	the	above	safety	questions	are	correct	and	I	will	accept	a	contrast	agent	injection	if	required.	
	
Signature	of	patient	 __________________________															Date	___/___/___	
 
 
Signature	of	Authorised	Scanning	Staff	Member		
	
Refer	to	supervising	doctor	that	a	patient	is	safe	to	image	if:	
• An	implant	or	operation	is	not	included	in	safety	literature			 	
	
The	supervising	doctor	should	sign	here	if	they	now	
consider	the	scan	to	be	completely	safe.	
MRI	Drug	and	Contrast	Administration	Record	
	
 
 
 
 
 
 
eGFR												_____________	
	
Date	of	eGFR	____________																																																													If	eGFR	<59ml/min	consult	Supervising	Doctor	
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